var title_f5_8_5248="Algorithm for diagnosis of IPH";
var content_f5_8_5248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80333&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to idiopathic pulmonary hemosiderosis (IPH)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 616px; background-image: url(data:image/gif;base64,R0lGODlh+gFoAsQAAP///4CAgEBAQMDAwAAAAODg4PDw8NDQ0KCgoDAwMGBgYCAgIFBQULCwsHBwcJCQkBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD6AWgCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpdhCAGbnJ2en6ChoqOkpaanqKmqq6ytrq+fBZizJAIKsLi5uru8vb6/pwsDtMQCw8TIKcbJmMvMzyPO0JPS08nV1o/Y2bPb3Ive35Xh4ofk5ZHn6IPqQgUPAQgGAAIOAAgCByj1Lvw8DgJENBCQ71/AHwcYCEAw4sCAh/ocPpwHoMAAWQAeQmm3DhDHHwgIiCQQkGTGABhN/8RzYZKHpooEEqBkMYBAABQ1b97T6WMBhADH6I0MKGAkAYYBbIoQuTFoR0QfexQgAGHYgZsmB6AsEKABQJ0rMyqw5VChgAdLD46IF2BhQgbzBphFCyDeA1vzXiogybDAWAX6ANyt55fkTXwCGDQAsFfAYZ0NFNLV2mDsYsEEHaQEYAAg4HsEFvAUkVRn0QEHqNZVCoDpk6hP98De8YCAPRImkz4UKQDC0dYBa8p0HOBWUYYtR4hM4HtBAgIK6hr/vXwBdKEAni/QDEEmBAiMbQdIMEB7QAYOAlgvYB57AwLoba+GUJRA4fTkSTAfD6GAA6pqkcbaaa0RsBpxrjkxW/9seCyYQ2kl5EbAbje9h9V59olQgAEPMPDchREGpBtwnHX4IYkGmFRURkrVNp1c8AHFok5cCWAdhSKsyAAB8zC32jD/wciAjA3J9x5aya01IHQ7RpeUUQa+5hSDhDiIQ0hqySIhjjmRuOIIzD1QG4i4iTghiWGOSaKXBnaZ1C2bbKjAcwQ00GUB3SGwF47YfbniiLoZMKdIl81oaJICmhaTY/NAWGBTVJoz5RHWOaYQibp12aVJLmqVlDD/kamcmcOYFNoAoa6pYptKpZaAnQ4coMADqBJAK3x2wjfAaTUpht2Y7zHw44+z1kqXCBAIs6M+iMoKnT4EKqlTgk1YGan/HNbeUMCOoSFJqqZKtaQeVQ2ERFK4AWJ6pknmFkXmqoYC0ACdCXDlGwS3FQXeXt2dqS92ADjgG1zD6hbAvbc1pB1Da0YzlFBOOUotE9le+0bFFueBccZrbMxxHR5/fEbIIsdBcsljnIxyGyqv/EXLOhjw0AAUVSSLoPkMlDAOscpwwM4rIMBwEOl2PKnLdsCcwwCijXeb0IyhdcACBtSMw4K7vrDJEFG6oTTSWnx9Q9Yi3JLRRQvAKZpWImiUkGMCJRbYCIiZNoCdbS82EAOB4aOALFnLhdfZUK/lwFjH7K1PAZq4xQADN7cVQFwDCM0423XaIkLdGo5FZFsKWG2F/9hgX0F6DWRXBN4mBiRAKwLkTUXaTRAcwKG8cBVANQk0A8AAQ8YgIKzvCERmgO4GCC/zAhkFdIAsDziJ79B1CVDA1LgfTzXTNIvGYXRmF1fX9ANAMGRrDP2e0Tzq52d2evIWTcXppc9/tBSpt1bXTcuQHeXW2+kdA9TmlBqJhh7D6I/ufEdABhwjH1njkIdENJrZLYWBmxAG2foXEPAga39tU8v/bmLAABwgARb8ySa6Zrr71Q8O9JtB6tgDQg5eEIQShIABzjKzmuluMVtbxibgQQ9aTcQZxsia62RGQZVMq4g93OAwstY1A22tecqZ3Q/3R7atTWhmYXPhC70mxv8nkK11QOTfFA+iQ8bc5BjkCcDwjjeC8pRNjRVZwAJkIUcRHO8B9jAA86iYlyaW4IpWnKNFDmJDX8kFhFi84Sbs6EYDtBF+ZxHB3Fo4xqSV0QnlI8irLGhDwSwgMTfxUAJu44AECKBeJJgTKhEoggGOoJWvlFMCRpk1BJxyLJAkASJFgMt6SRGLByBIQa6YuhEyxpXng51CbmIAVQ4PCzHspII+qc0XUEQB1ONCNru5hHFybE6rDIM5yYmEdbJTCu58JxHiKc9t1pOMZ7DIRa4UzrUs5GjcXIIBNqkGet7zBwbFwa4wdsUSCI8z8pNfFH6Gz4MaDQ1XRAlKDCC5uFT/Bht+IQhYBidSrsTNV5CRW0UaR5e3PeAADHsH7xQSupW2paUKuUxX6oGzYTAuIzQVXcoCatEuJBQHiHSMX24ivrZcj3n6Gcb7KhQQBSiAZgaa1/GQkz3kcU+QBdCd7R5gyUbt7HmCic5X98ieDS3jN497KjKhF52REbWoWzjqDYb5wQ/yVZMoBKEKkwJJA/kqiwPM4EMYOQBAxpIheySBBF0ZSWPcZRNwc6b+ImgiiYJBr3i9AWhr8NcqFpZ3B/HizIYxzGoYiIcTkWJDATC1yJRgiYFjbHFmpiULbjYguPXsy+4aWmwS9wp/daSw/sqZS/KvpacVH23110fOLDJH/w+BamBsNCUe3SM4jGUaRZjl2zaVpJBoGG1xZ6BeGfhyAVzVpDL1wdx7JOBx1LTmaQXlSqwQ05XGZGxdoLm5wJLAl7YAL3bt+8rFaNa89/ilcL3Q3vXCoMJ2AKckMGzhFnB4Dgvc8HE7DM8Rk1icJj6xPVXMhg+z2AQu5l3NJqwDiiqjCFALaw9sPNwX97gLqeEJC4OQPxMMeQWz1dph+jk2Glchxj5ecBduAVX0+aN4ceVMR1fKtp06oKcVGQvfItkQybRmIHWtXk3fxj+lCpMrjBNp5+SskZDG1HNTrBwCBFfTu41FH7u6KYVTHOV2EhoJOkxAYM7EALTwNHpulP9ORsyHlfRBDnvXo+0gAyTW28GVIfAbCABqdzur9m5UKBEgQ9zH1JsIo5qrlipTp4dWSLdloOBZ62ayAOUoQ9m2jtUfFm3owVGT+cGbGwuERxBsSdKOEwYKYKMqKOyKtEU0J7TgJpLZNr4FdmtXnKwhkyhgFBfa3FxQwCkTANUoZc2Gpm1meQP2t98KczTO/KJGcshRakdpi5NMbavJtqsutloEwYUkuaWc10Ofe54OL0Ibs0PegDl6jb5bzCPlfVoBLEZ2+WOaJoUdROjCUStAEzYlb1HWgB28jQEgq3MLi96tWbKyEYf4w8PIBduKwLEkSUBNbZhMggBahPOeWj3/lr0WAjuzmrsUlirtwZ6CZLFs0DzMfc+3tXkJPS/3hdsVEQxM9TQY50bN+c4RqnYGfZPJ97br2o17T3Sm3Ilyn/vo2q53I/Tax3/vO8MFH4XAC97wKka83hVPYsav3fEWhvzDJV9cWwDj8pjPvOY3z/lSCIPwU9BE50dPelCItPSoR/2uQV/cJLP+9YpwPexnXwjZ0/72gLA97ne/B93z/vd28D3whx8H4RP/+GwwPvKXfwblM//5YnA+9Dkm+tRbf/Onv772Mb/66V8NTtsPv/jHT35PfN77PKB8odWPV/YDnu/ed/+L5X9Q+ice/tO3/4n1L0/+d9j/7ASA6yWA/91EDhpREfsEECiADwS1AwzIAskEdzCggG3wgGVAgNpEDq4BIS9xAiPyAx8IY/9GJDbwJRd2ZEXQJUh2Jg7zWfgHfRr4P0rRgWgGbrZiGQ6FEg+wIW1xWJFhC1YxFl9WMAwTD0xjExchI51BFqSBAHdRU7zzF8lUJ48TGIIzhLKSGHtmHSRYIgSBFkv4GXXROAjwFnkBFIPTgXphGFqWGJfxNtGSEVwYhDxlbR91ADrjR54RGDgzSWN4Fd/lhnb4Z3moDC/4fDGIWUqxIu8hE9YxH/WxGfoyIfvxHDAVI0OCJ96BQiPSEnzhG/+kFJXYHwXCbtdRRzEhOUXhHKEhL//w8R+Qk4oK8DugSD1F4QACkx0/wRxaEhPN8RzRURQKAIsAsyLtUYkE8Dzf0RYseA+1qIkHg0I1cS7JYh2rtouk+ByHEy6+YVjpsR7TqC969Bv7cIjMF4NGwT+vlSF/ciZBUgvelRqOsRcxl4oMURuL8R9XsS4HAS8zkhr2cCQokiQ7ghEF8CXP4Ts2MS6psR1kBTBFUlfXYyS2oi6lQhRRkpB+wio3IY/FYRO1gRTNCDD4GDDJ2CUrkhMA6Yq3olbhYmAG9EWLyJGGiH7p50IbOJPFaEVnEoIAUxPEISPMKB49OSGd2I8Y2TZIqBSbgpTw+JR9spBd1xsxAZFKyRP/4AIiR7mTXAkuQakVRekUXwIoMqmOM5KVWbkmmqgnZYkdKngCGNhJMZgo2BEqDfCIZCmWXfMde/YATugAlQMfqeFAPjEsvrGNGNkADqEUyQIjzOKUzAYdnrKRgqErlTEACmAn3yEUikkC39EA8zJqypKMFskmjQUfCokevsEivsKXjbVnuhKHnHkAg8k0uaaTXdKYy5IioIIuSulAvIKbrAGX5rh8c7kaZrlDoYGXYQmVtMUtCwCa1gEfeWEdijYsCPAd/xEQDeAbt9KRC5MW4ilM1gEBAxElYzmdkEMv+tCdFVlmvEFb4Vmaq1Ip8zA18JGQQgEeCSES0WmS/eIU/+6JFr4UE4AmnOAZGgyTneciKvzyHDiSksMJY8WJfFZyOdlpYMxgglywZzBSKDdpkztgJQfQjWMGDRy6BXsRGtSmA3E5Ri9qUTFaPzN6TzUKNpAnET20AjoWNOGkM7ajAhQ1UDZApCwwYT3TYhV6fJCnCeoWJz7KArOFPJ3RgKhFW3f3AjymAihYC0tqaCLqol8qBBHEE5ODZQSzb0IoM0EVTHWxNgjAR2jmRz0YED/lZ87gNyN1ohrCEHiaOILYJsegE3LBAJ/Xh+k1psBHeWSTH3bEDx0CQgnAEIpZa04yGrBzEW+VPqB2GArmVNhjPLITqXh4paDKPFr1U1b0RP9t1TrDkB/wYwY3ijSMehB6whjAcwyrmm0jIG5uekzO1Ea5dVqHZSCwU4YlkDXDdFgXNEzBZgxTswnAJKuK+nu1OgK140HOsKr5k3CzBawW5G6f+kTb2jYOcEB1ZEiv5RSr2qx2Ux4zY6UuGKY5cK2kga7LYFusQ4rH41348KsC5kz5IWrK+kTwkyK0NQ+ilq7RVVfk5Viys7DkYUmBIa8/Rq8lWK0/MEPeRQ+utEwV8rGMI2EAu2DOdEIDNK4XtENLJy8AtkkFu7Ky5F+C1LIBI3T5cUKv1KLzirEZW4FpNloUEWIi5rM/ywaRNXhQoHTXSQ0au3uz+k5RuzJTS07/VVsyVUtjW5oEgBorQqUCTysEVysyVdulV0oxeVQ1SaoCSMQyYXt7vcZR9dAXe/ZGj+NTCwo4H3UMfnNkcusAfhocbcpmnPEXViO3k5MRdxhmKhU/KPWmQBGnz5lJnKM74bM5toARO1VXA+FxDWe0NdBr8POv5ZOJbLVHx3SqXXVko6tgljpqY+U7aNGZIxA+TiIAuFYREYGqCbBV+pOpB4k2satqrUMrvwsXIoc+xDM1vstzoMtebxsDwqpgggEWtCJgy3oZBlJ09jC9WOSr0sYYirFrxbY6dnMPypZxuIFzzWZtNoJH+uNAOVJxcQIBxvu5zysDvSaukZRRaLhg/62lq0YWQliUcPyGvlWxvu6KXYfTW66Fcw0FcPC7riZrQVxBWc6bvxcWvTAwsNTLq/mQba56Wgd7ZB6MRf4aHAh3gLFaSxq3XNQEHp4rO9JFXlKUvA4RWGbjufrjWILkbDqGsBmswf3AwVq6ddQ7YDJRS/eVH8PEsoRVAih7Kb1EslM3YARhNUW3TOu2GEr3H4XbX/ZGS+ORGM80S/NSEmE8SiSHEgAmgSVGxBvsBRRxq0JQx2m2A9InKXL8Ar2GYLg7BID8tXvFs44wth+DyDBqxK+nyC/kyBYDyaUjyZFCybTKyKxnyS6jybHBySjjyR0BymSLyaAnyolMyoRnyv8co8riwMqRjMqHB8u858rcYHnld8u4nMucd359zALVp8vAPArZF8zEDArd18vlsMfIvMykZcjM/MxI5czQPM0zoMzUfM0oYM3YvM1rIc3c/M14B87iLKXePM7grM3mDM3onM6GUMzuLMxB+c7y7AlwDLpSOc/4nM/5PK3IbLbsnAJFJsf+/M8nENBEPNAEnaxOhrEIndAMu8wN7dBk1ssR7dAGrcEVndAXnb8ZrVAEhRo0ANIO0RD7ZBEWizryOtInIDOAc9JLgFY+0KN+5NIlIDMwsNHP29CC0hzHIgOIgigv4I//YRPvAdQzwBW6KlEpioqiEgXlQcgtcIDhTMD/PJowZuMCOG3PLfAclnIQLF3Tp4aADcjSySHVKUDW6VKVQlEzZl0CFrFrFnGVJqBPFLHUFmEhbj0RvRrWDQGzm2TSe71JDrF61uNHIK0hYa3ScadJ+7Q/cR1JX10CAhMgvYvVC02vCP0eWQIaIuGSdEKK3GIqztONJoGfVMEs98VCJfowK1IfNjESqDGdtdMrlDXU15EU9FIgTJEVRrEYKWouIgEi00gotEXaGEkn9rDaMcE+D8Ogy80eIzEasqJJotFo3zUe+mBVAGE1epQP0TMeQLRKtpQ1J9QW/ZQ/TmjZzIzQjuJHEpIrxkCPvXI8DgZcpGkS7DZQ10EVs2WJ/2xCWzFxERDaOlSTGldljwJZkEkBmBDaKSTy1lhilbwpM74J4SZhHY8pFMWzmsxB4YBJnQXQACkiLCEJIYotGEV4G1UDVZFRGcTU07N1AHcBSagLXDdTbA+tIde0AllttOwtH0x9lkxpE60jEhCAHCXhlFCS5EbmlF/SEk9uFMbAGk8C23mpgqVdKf4o102paefC5P+NHZ6Iu58Nm+mo3AuwSURykAvAN6GUGWZHENQzdqtUdu+a5MpkAkW20D3uswg9FQl8FVMRHSEBm29kE2HVWKtpEskinno0tA2Dre2WlGvyJY+O2KwREnRRNVfOGqsyD1sO4C4JIkUB6h006f9cqUcw8TcW8QC+MRXXdD0WsZ3C5BQcxTdVllbZPC1xYUg1PmrHPNH0oN4Q3QJVbhKN0R0UfuhAsSj7bSamGBAhQR+nFOkCEu0AA+VRMu02MuU6UeSuZJRhCegoZBL/ge0pWhRUCSLnXikmie7oaawx4ROLGe7gExq9sUKvRI7m+nNAMYziWzlfJhON1dP4IOAP8IPVoxUKBjugueO09QATKxDlLOwC7QJXEQ8U0QAab20+JSMc3xVNuDlAERbvEHN8xGSaoBUM0YFh0YEVAQ87iNQkEPIaNxNaATgxN4b+zvI7UdPwoBWsxTBB//JdgZpqqBNXsYMUL/KatAnykDz/22YClS31Q8PxTG/1oqMJnP5SfqoJMcUwGU9Q1YcRhR3Vlx2mHZ0NZewbICoEdnwFcU8TaS+ia28NXIHySPBSV8BRUK3ndW+Td5/Ofc7QMxCkajAliI/xf98Ci58DmeYDRlpHS8DXOU7RJJBMx7ArVjpaW9s2nzRksFExISNINK0CPFtkGZ3GTaswGHxIH4tegL/evFPtvnN+ek1LmX80g00Cj23YX/v7mjTWFdvYDRXZ69vYzkCbmS/Ymp/XmyQzbH1q3vDWJB3YKjE0Uo38yH91Yh1C0n9DGTE31p/5mwPxnpsfUkxMOnFVs1/s6XpVISVV3ygLxtA64DOMgcxs/7cAAkkDBInDKMCwKE5iAIRDDIHgFoAglAjJLAQDAeChKI0WwcMhYfMBorHj4qAb6BQKYnYbRTkgWOmAEWA4VAv0ItoKLHLCQBrgCCCcCavWITAcLJw9SEUlRBmYaAE0PTE6CUBFIRDclJ2lDUA4uMAQABjcLOaVWBVGNXBJBSgMwZwiCkUVMMAOweLm6u7y9vr+AgcLDxMXGxN/kglpDY2pHF2hADSk2BGeHjwQBQRExd0CKPgQjBi0ASCkyRa02cCAM2qTdAMk5BhAnCYjpAhRuzX4Fy5grSuwCgz4BE5WlAHQhBTIBwBCAQEjQAl08IAOokIHqg04BKrevXz2QP9JlJJsVkIVXMTFsANlj8WOsGp6TFAFnpQDAhi8qmdL1bGiRo8iTap0qdKVLnUQkeXCRjcBCbjA2RGpUB4HXrhFEQIObDJwtxh+Avu061d6lbTqaxi1Bj1uau3SYxilyRGFXKRCqopFHD81CRQYyLoDQcU1phrSCweh5tsdMbQSjfmo79N5Ma1qPbDicFApi07FCWQkV+GwQ5nCji17Nu3ahZzeYnIlZBSwPBL4WI2LwLtt9L69HDfr3L917ejdIv5ULcVc+/oNaO0AgXYED+ro1XHRb9gBvD3LCqmX1gPhhRIXhHyqQb7qUuzDSoaTfDjlDCRJwd4pp+kDwwEQAFj/SCpSZNaZbQ9CGKGED+JGFEQLNEDKFREhkEgAA7RXSAIPNMDANnMQsUKGC3jCYAANJICFJWZ49tSIJRKBAER5EKQPAjDKOIA53LE4JAIssrOiM3a0MkNnF2bohEH1JBdSAx6C2N6HLZwikkMgHsJjieiIMGYhCyAwgFdqKoThkS0GkqYDDqUpQiEumLekHQzUAMRj4sF4USivTViooYci+otTBQDIGCN4mIdODgcEYIABCOBRWmIPHOADK3g0NOIDr0SGTgA56MDNGJECwCgoAXAKBaYGcvMnCZii6qgB7b2y66izfOhoIRsV0I2rkj6aJhbCwtTqRmNcmmm0CYYz/0YDsL5CaQCmaGtrsSMQa2x7v5Iwy0YjFPDsKZjaBQumWGTjUa2rUMtTovfim69tTtWmllzAhKevUuwYVcALAjPVBC72Itywww/3wi9trM5CrS7CQmwUxccElLFRnC7coMcjk4yvxCWjnLLKuTC8sssvNwVzvgZgUQCqtAFyVM667GyMzcToGUzLMhNdNDAnS+GCAAtc0wvGiDpgK8tjRD3MVv4qdUAd//Ii8ilDc20M1kcbA7bRZ6N928UFXSoFzaUVEvApCDV0cyEDSN3TAHbTrQKqBwS1t96oqgX4Xrbq9nU13PTd0J9vM/IY5HsJCYopNC/o+MJuV/41F6LdjP85FzTzHTQjgtcIi2gePZYMQnnrYnbasxeNdBHxNcRCJ2p9cuBVmoFVggIomIEfKKKksEgg2Rxhp/DEB1CdLAQUn4MRSACghAA+yajFXzcAdwoDhB8mTShepbACGia44AOM2A/vwlMh2UDE+Yuo90mbbLx2vZ30W6YRVytfNaTgvxFwA0aoOEQf/tAFLijEDGhQwVVs5yDaYRBttgvFZCrVGXHwrjxRSEbw3NKbUm3HEFYAjp32Io8QogcLJIxMNoxTHoEoYATpyYxIavSJFNZDNH/Bwi1OYrAYwKA4QXwKEPewAlPwRwg0w5uDarjEIpbEh7iwIlji0J+MkKgaOdT/TKta8kReyC6DakSZBUHhkEOMpV2aQcsJtZg6HVxlB1YwAAHowRYbAk8wgSSTVwA5h7oI0l6qCCFo9LgQIhJhJZ94QAefUpao5HF78Iji3rjhg1v8UTPRwYwdpRDK4DkAHyQIwmLu0o3eHSYA/NlFGtdoy4xtUG3gAKEJpzRDO2LtP+uyiieUCEPfyLCO0rmFWoTQHYMochUmFKYyRHgLL5qjJzshAgSUSM2wcdJzSHxKN8lpNxiqxJjdwEc6ilBAdFQjhZ/YzwVZ5rVb4hOXumBFA8qQCTexKCRscoMDdPgADR2zVHFSE95YdIZ6kMhEwBTkL28kUR3tTYpoehM0/zPjQC0udE6PnA6faGSRBiCHSQ4hQkjNo4pw3o0IFiXCmrwgplqg0xARBaQCCHAPJ2TJSCyKyZqclMZa5jOpJtvFtT4UKl5N4lT08FWrIEXEMUBHT+l6URFMwalNdUoFWG3IsnKQ1VfFKqqXugdUkXUsU561XM7i6rEcdawajEFbOahrWueKLkkYS1Z2a5UPwCqrvnZLrL05hWEVywhJTCuJbaVHuAjbC6QqNbOGaqM4NbuLPXj2YZgNLWlpw9lCvLW0HmmaavE12tbCFimnjS1tM/ba2uJWGLPV7M8ySzOZ3Ta3wo3YcMdGslKFJYBaGYHWksYH5KYsuMOd7nBgJv+4xr3ubnlr3OFOiF0qksFuq0MEeFGLulwkjiV3G+wIq/uURPRTFQw5mMukS937tndl1IMDK6RxiQkmAn0xmEENwCeH33iKgCqQYBoC3FM3tOAPgRgEV/QgRBHuoAckMIE0DOaHbuSPEjeIS2dUJd8xeOdl9sUvdXcrsF+SESE/nGoMynGOdjqnlDK2RnvByJGRMEhQI82xWuIAxIBWIb8kvgU7zDOZHYhhFriL7j1ZbGX3qgzGsORMeC75LzqGkC+y9OUqtcKYpTHgT6NBzJDHkJa8NKM8m3SvJn4yAnjopcq21fOV+0zGlGlZPO39pmYINg3stOo57aUnA8bjTlj/wOcgDHhAmxNdozg0yx5zzk/YHJRnFfPZz1Z2sb4CXdQ2BSQNK+EBkHQwJxqF8NTTiNGYsTSuLW2tP1Yyx7UWIKNXd8MGBabgtVKkCjQtKSGQjCmDrAXdkq1Y1LQldb7iSlmpAusBZuXKqcKiKrIutgjYVsGpkhHZac1NXeTOjhy+TYIjSKJYUHjrtwrRrtS+VVgCYC+0Qy3t+1I7g3LbRTbUlGujhMe4s2lNff397+kGHINP68WuQKWUp20MZx4E9cM7HvGOgxyNDg95bT9O8pMzG+VXNrnKTx7tlieV5TAH+ctnfkuZ2/zfNc+5GvuIl58DPehCHzrRi270oyM9/+lKXzrTm+70p0Pd6V7geXGjbvWrYz3rQc+w1rvu9a8r3WJUH3tsFU72s6NdtWZPO9vbjs+1uz3uckcb3Odu97urrO543zvfHab3vgM+8If6u+ALb3jaEP7wil/8URLP+Mc/nC5ghzrXJw9100E+8yijiuU77/mtP1vzoveY42Fb+tGjfvChn+7pU+/6CLW+tLF/Pe1no5Y87a25vfhZ1Uwp9r0c3Bi6f9Dsa2/8pfDOLi71BXemVMfYjZyW0S9K8Y9vfaPkdCwCQExiklipSPGAAUDxjAG2gFwA+oBRNWjVFmRVovH1ZvtCtME1ysAnVOygHFtIZWJ4AANGOYK2Tf+CFVTf9RkgMfBOnjBRNyyIPAgAIfhGNzwATnVDjNhBqaxAAZiDaEAAjfiaAQjTDexKCngFI/TTB8YBO9hMaiCJD4RPA3xEsKVPFWzgHaAEDBTgAergLyQfWNwCBNhFMijAYdQRmG2LILACUcQROPhEQ9TCDk1E4AzRRvSGtkEApT1CIaREPsQRwbRGDu5gGO5TL/0LDSjgNNBAEbrZPAiUeagZVnwIF5jFXFhSyh1SHRXLVfCEJJVYN/wHaN2RGAoiUmRfVFyDFTSZFyHTNFAgPnBLyjmRKpQTrHSUDkDBhV2BwujAAfwMH+HDPdDCndUCOIDWCizS6g1iKgpDIYL/AgMkQAIAhZ3kQWJURR4RYDc0gVVg4GRICTzACGlUok/k30iVgJQYjFW4Tx4VgDBujwrwYmRgiDSp4jQeAxiejb0Y2vNR4zYGgzUajb00izZy4zjygje+HSqSYzqa4y2tYzrWHud9Xjx6Hg+4Yz3agjwuXeXhI9Jhnj36o7604z8K5BoF5EAa5OwU5EEqZNEk5EJemeTtY0RKpNbp40S6m0N6Fjxa5EZyZEcyHT1iZEaio0A2ZEg+TEkeH0qaJMKo5DuO5Eoi5Ev6Y0vCJL7Q5OvdZE0iSk6mHk/qZKH45OgFpfFBpEdiXUUa5dX148MN5TvyQFJCZVRyA0g2DLtI/+XRIeVVFh2/oV1T9plX5sL2aeVYap2vzR1YWhla3sRSUt3AdaVM4p1anoJbkh1dkp1c3hdeNpvc2eXY6SXrwaWE9CXPDSbPGVeecGUwDN8v9J5iBp8uNGZsgKAVICZqSY7kpBku/KXziQbuwU0wTB9k/klvnUJkNt8xLKYKKEVh5pxx+dyIFMVrsWbK+cJsFgMlxgA3wOYXlNMFNSEsbKZeYIoCIGFiEhdShMdpzuWSVF80JYVtwpxrco1U2Uz7TcL7EY78DQH9zYJ1okOG3dCqjEAqZOZ3KkAO3EIZbN87ZAeASEX+TYN4FsAWlKeOQAMjmMhFuE0PeVmiNQs4Bv9NcOqJWbSneiKGClADQ9hAZhKAjtQBAhRc/3kQAD7gXpgIITyg+KHnsoCn83nGWVFo/Ylft5EBJECBH23fXmHKVpDATzDBvLEWdLaca5pHo40QDzQZCPqACK5GCR7ACQqJF32gMFVOCGZHQfxHiRgAO1wKUKzAU3Dio0UPEImQjTEKkjKGFQQCIy7pJxiMBobHtahEjV7Ed5iJvagJcAZmhATMWGwChFpPCtjAMrbBBJpgDGDBpOmAIDiEDKpBkK4g4GBoKq2GD8KAkdrbK9XRCgDqlyZCssXBBsYEAjhpGzzRBtrpj+IDDuaajKqca3LD1CXDb5ZBJfbmk+CNHNb/QrEsjSBRBMGgADf42v1t4i3siisCUtwQkR9E2ave2BZ8go3GhDZMZak41QiFKheAVjkxTIMIaGepxa3+TgjlAYTm11mMwRai6nfo6nQYiw0IgoeSxaJOIXgkGxzGBK1qEhxWqynAhBftpdxJpyEkU2dgax1W027I4b5F4yJyAxU+YJ6EwhiIhUyNCjNBlz+Aliz8azd4RQ7M0xqyQmWugjOsRIwUwFsgSD3pgJo+TJuiK0TRDCCVhQOEq5fRUXs9EtZAIeP0qyBJ4y+tLJyl3LgyRMEuqsniIoZMmaei3LyaA8TeBw5i6LKxKCbKwiRSmkg8RM0ogVmxTbo0mKVG/xIM6EggXgFHPGqieVFNZOwFgkKbZAtXSIK5xQG3MmI9zafHOgzIPp90XG2YwcCCJINGTImNluojPSkjVKKqMC3M1lE5QcMjZY4F5itoTdLUdsYeGE7mLI2e+OzJueYOhA8Z/eKBQiEzxleVvuKBDuFPwKw0RIHS2EP5veKd5UgQtMVaJsJPGK7oBsINfEIoyO4kXEULzcJLUa4LPkY31Zke3QrbNozb1siRbB/JzppVWEElACNDMCNlDtGG/UTfdsPnmhRzSmAQ0MhIuQBxJtsztpfp/g/4wojy2u5anuWaktYrZKMutIIxJIJmqu+DRC7avAK8CoPshGO8xt1mNv9M7ALiLrAD7PACfMnvx7IlPgVB5Q6D2bQv/7qd/+bWs8Zd/YacBOMWBbudBYMcBteWBrcdB3ecB9MWCLOdCDPlU5LlCuMjVSKMWLJwDDedWcpdUcpw0WXlDRddAhuKVerwVKrwD+OFcf4k1jokCRdxNc4vOSJxEt/mEo9jEzvxMEjx3VXxFAPDFacvFmOQFssrFHMxxHhx/4JxGPtdGVPjGJvxAcOkGq/xKbgx28XxG4tjSM4xHd/x2eXxGu+xX6IxHdvkH6tiH4cxIRumIAPyTiLyIBoy2fmwEONwEEPy0f0eO3ZdDludIMLwJHMy1k2dZ/kcC+Oc4qGw2+2cy4z/cm2ksuGVctudsn6VzCoXXiuz3StnWSxrMg8Xni0DGi6LIS2nHS+zkS+HITCjnTATMy6Q5qrkCQH3guGQzS9r1c0wsxuWzTA0XyduwY+OmM7kjXI+cxqAs2wgM8lYkL8kQyhXsofeiTNzmjTDcWSks12ss+1MH1g0nwIQQiBYyjEw4WMmHsIqRcuU88icszwrmWa6KDtAg46ApKO8yPbxgiwLXsCgc0Iz1hawWR/5gB/gRGBxZy7MJ3iaB0PL6oeU30MXXIse6AAkKBbw1958kokc6NiQ53i6qLfOh50t2P3VFXq+9Coda76C8i7A4zx70ilk6pWMCBEd6o7KkA8Q/9o7F7OeHDWyJnUh6CkMZiwVWWlMMGrQ5oIFQgM3JAKl5cHeWKANtqqaMOCJ0CmZ7E1uxOkdwciS/ghQMKlAS8FdM4oKqiAx7tuWpvVgFbTHnHMrmEc6N7Md6FG7ilBVtapBwJh15DIcK3ZL4Kk1w8XwNACqrISaCECUwRQ2iEQJBSMSegFDACE3vJnK7isoTOC0loqwAkCswsHyBZN+UiEJUFr0hhBBh+bZHLRKYPTX6KxBJEkMDZIuUHTgWTRC/5m7KABpL5AVTA+qhkwdLWJ6xghnuxnuadEciixfR7YOUJp5jOwd6YUrEaMJCTdpFXd+2U7jRsWd/S1l1zGJVf91PBv3dN/N6L4Sp4KCBYaTS79HOdlgd9sPBDzizR7ieHtJ1X7nHbHCXjwUKCBErr7b4YjE9ijM1gZ3D9GmZs23ZlTGwZUvaJVvOFzF9Ta3ZcNzov53isNxHuGgCbSuKybTSE11HowoczPh7cIsCL4iBebXYoCS6nK46dIj6W74HTl5sL0iPbgij9vRYnRWUZvzZSfKOYjaYetTl8/4oaSLzg230Tw3bKx53xnz2Yk5xLT5Usz53r052cX5w9R5Uuz53d352OW5w/T5UQz63P051QV6wxR6USx6BR9BJ0N61H2yictwo7vdI0c6XmBypme1SFKkJGddIkNII9scqTv/salH5yKL+oSg+oyq+qrD3quHYav/JK3/rKzDum3YuuTieq4jXq8f4K63MbAboLCvpLF3MLH7Omwg+wgr+7Ij37OnpLRDOyFSu0tW+2UZ5abvoy6zWLF8HbdD3TobpEZyetS5MM0h4Q1Pukk2u1Ffuy0l+lHMO+29+xiiXL3HZppHcbyPzL0zhb77M79zI8CzMckJfNkQ/DYavPCGXMIXA8QLpb+THsVnkMQ38MKnMQaqd1FA8y+kpsbjQs8c/MM3SFO5MxkwgjivM2nuxWdeiwAS9bGXis8lmTFE5mVlhskNTWr6t8t5VCukAg8bmxGT7ZTkvB1kx1B1mrvXPP6R/0Cx/LVlpXRN57SjePRFRPQ7UZAjgPVY4SdO9ISJBBufjnRmuopLbwH25jtRuIeG0yciruiJ6rRD+1HBlTQLdANE5zT/YrzmYc0+1EIlnAoUbnU21MKPGsRXN+htA0gGSuprx4SjhoeD74pc24yWUm2LxrU0An3c6OcsaL4aAE6SkYehOv6efohZN/UVLHWJlrjT3wYdmP5e3oJn5wBkQxOv1ivWxFFMhBCxUsWZzIkSTQKw6vSfNXxS8ITc8IMA8Me4CjSrhquCwqwzAcdjsEJp/H3mBT7FrNqywVOUqUn1u/TC9j4Goqvkp0Vm282t+i4XPCxYI6/nIzxR6HNpnv8n/SsTCACDAARBsTRlAAgDsLavLDoL28K6SO7+DwwKh8Si8YhMKpfM5s60I/ikMIYKQZo5AgcDoEFyBRwAQ+JFhepGsMQBIH2QC9LBwgt4r9uDQQImoELHEwP3hOOUqLjI+MO2tlAAM3AQCDD46GbIZuIHo8DiAgNlKdP11QP02Mja6voKG3sYNQUpoEASkCAgYNCwq+liJsBwZlg4CSGQgCNlsCDgQIUArKJTnEDWIoBwAC1NqEY1iihrfr60CvPLy1DgHV2nzAxTl8uisMsQOgPFLsNOE40d6tAZPIgwIRI1ChsmYegwoqyCRSgmtCgxo8aND8tx3Ajxo8h0qY7/YDx4cqTKlQpDsmzp8aVMHylZ1pyJM6cTlzrN8ey58qZKoUCLGp111GfMpB+JinTKNKrMn1IVUa3qECpHrVi7arzqVQnYsAa5ajRLNq3BAAJMuH0LN67cuXTr2r2L125btRLt5P0LOLBbXHwLNxWMGC+vxIzrzjCcsEDjuosn00UAObNmImM3e2bU+bPo0WKXkj7dJDTq1ayRtX59RDXs2Zpl015t+7Zusrl3i+7tO3iiAZYZVy5e/LFwEcgRH29uWfnyzGyhW79O2bTu6ti7ezexd/pm4GnJ/9ZO2rx4oOq9th+PfvT79TjnV7UPGf/9+PSx6mf6H18BAshffwYh/9Ddc9ZJ4gqC2CkIHYMISZZgW9hhBguFD1p4HYYGGnHLd9gtIB0jIYpoHYkK+YUidITBwmKLyL34YRGiFHVjKzn2tGNZJemEVkU/5hTkcj3mdOQiSc605ERD4lTkEFE2NKVvTb50ZRNZrrSlK1Ve9CQjXyI05m1djnRmEml+tKaYYcpUJkFvvhTnbGce0IeEQ5xCUCNtgliiDwfoYYAeThSqyJ+KEGVAH4H+gOgOBejpRJ2TzFnGAHjw6QSnTFj62pkhJuChEA68MQ6mSChKRJYCQCAJWlQcoI0TrFaq6iQ3OJAAHkLQWggCpeIaS00DQKAAII9yhsOpw+Vao6gvGP9QBwMM9EPMGwgUMAABAWDGwgMMdlPCLb62uqyt6bYQQLKPgMGAHliAAoMDvKjQ7bcFIGAAIgF4wZYC5wJxaxNEPbJFv215cQADe+27zQl9HIBhAQ/k4bA1QhaL6QgCSCKKAbjgUMDILwzgsMAR71tAAzMMoELDpQgBamvSXgJrJChYzEAeKrhAByWGKHAxALBugcoRBQfh6gjcktAAAwag4IvUg3xRhs4EUMLGAm94AwDSYKC7IrSPEE1vu0Z3cTEbCiigqQkFQADDAwoUkEABBnQJqrEuJCuKMUgbQ+8BktgNwNuauoBAzwAwsG3ee6dbM2uigrIAAg/gEMAD1JD/S8M4UoCNQLIQuDUO2a40PQDcJDAASgAkWlHPJPZCgMalACCuAGanm5A6weu+cvAN+RhANwx0L+CApuFwzgLkAETygIXhEdF3x2EU4II3JuBywB8xGPBAMfcoa/SkC+xuPXqVrybqA86rAcUANvBzzDEuXAuHo8Ojv7p1iYIbYZBfHyZXu1+8QRRUYMMzHtg/R6mOTGY7gx5EV4byQaBR54vBCCpRArjlyQjZw14WcNGHM0zsEVBIwAM4WAhRmGBzIXQUpWgCrQ/dDAbhA8SgvDA2BuJhGgJYXwuKZqgJsqJpIoBGCRw3NaRRqwRkMAMavHC2WwACiUr0kUlKQjuU/4mAD5zQhhqggRk7bIqEOVSC3wBBIuTpoQsbDBsLCOAFLFARfSiIRBPXSLM29meHo0gAPQKywBfoggzjgACGDIANx9nof0pg4jbqBQy98QIcwyiGIrPxiAMQgEGQNKQkmUZJVhysJJXgxRuwQQY24E0AB1DDA4wIAGosQ2NSEiQS3iiCreUBGCyghsOKCQ3CzLISM4CdDnSZAF46wpfrWVpDrPkDa+IBBejAZhLeRzxqspEReOjdOcB5Gm8iRJ06sCY8BGIOdo6zKCVcRD6ygQ50kkae3UzlqvzJEX6a0Cj1BIo+RyPQeAIUUEZJaCAJKs6N0TOiRlqoRvjp0FhkVP8VFM1KRx860RoxFEcW7WIj+qDRkhIrpDD6aNlEaqPYyag4KlqdTKEDIeTUlEw3mGlxaOSlnvp0MkCFKRAcdJ2cIueGi0CqdZRaHKaaQ0NJ5ZB1hsUKqlb1QkZ1yICM8lXeFOgzYe1qQsraE7R2Ra3sGatZ6+PW/MQVN3OlTl3fuhK2wnU9etVJX/EKi7++RLBJIexU7gpYkRhWJYstSmPzitjEcuSxH6GsXyMrIMxKNiOWBYlmPdPZyn52s14drX9Ma9fbhJa0C0GtVFZ7WNW6lrVrmS2B+Grb1+aWtrKAbUR8yxLgSkS4vAUCcc+62/Ikt7DLLW4rjosQ6IpWts7/XQRxRATV5qj0B07FqVUXpBCterc7WL1sda3y3aEi53pKuql6EbNTlAj1vYgpalqb+1bpFsE+G31Ff3EIUeaeNxH6ZdYSt+uQ/8opwEcpMF1Pe+CGIpgkDAYrfs3qYCHwd8IKUfAaXAomAQ84NeUwAILElRWUNgqlZTAUpzZchEHBIFLfVLEEW6wDT6HypSy18IhJvANmDOCW4eSMt5o4hl6tIkcwbhWsCCGWI/uFVzAE4BA8rDsiNGpTAysCtwYgCTyBmYd4oDFIffzjJTBkFVjsxyjAoA0ERE1qZahOm4UluwBoChcqowWUt7DkxzT5ymp7xLwksS+2FK0Wf9Zz/yq2hGUoSwlZVv7iAEFBqoHc5KDPvXBXGYK85uFBHPVQAQMuFo3d9SxtyQoABBwgrDMU4NRfSOIxziY/oe500EJwwcfY0LhGrc8OmvIjo3Edo/juOMQm/BgNSsYNGMjZWjdUQ8ikcKNNgxgmaVZzOSTzqlY3o3aEuJEUkme0QpzNCjdsoPGUrEI/CBq1kO6D6x43A1o+onubJLdfjifvFA4v0tpuHQ3iKL1okC9ZPrD2C+bWgtjZd5oi7nZrg0AiUt86DDOQAgbVsIrS4e7YFszyQFyTqIG/gIADccG+S9TAkku63jzuZQu4R4keiFEUbLAXLWOIOcwIwIDVkyiaLf8eG0TgacbUmwMVqOAAVL8gao/DV89ALj4teKSBJQm0Dni9YzuQQA5Zg/KRuL7gSi+bghtrnct1znFJfx0HQ3eeplXFaVZk+DQMmTU0opm1eNRjGSpbhivzwIufM4QXCNpFL3YgAAJkoeuPnneEVceLMtwTXz3oUeQnn/aT95rD38R751VUx87RgCIOh/zLTF9xpO93rsGL9A/AjiTS/xL2wZy6IQt/sh8hYAGZE322eX902Rs4CbXXPZD95HyDEHzbKKF+dD1t1L0bl97R72fNe5L3RmhfPtjvLfcl/H0gWf8g4z8PhKGPfmYbdP21Vb4R2o8UE3X/HNOvsGPLL1L/3EFf60Vv7jWAf6Fs+TRfB/gXE5cT+OcZ18WAycEK3TWBeSFVsiBeF3gX5fWAAGh/ISiCgQWCI2iCJ7gTJYiCK2hXHNgc2eWCgpGBLEiDsuAtMYiDMZiANciDsRA8NWh7PXiCP0iDQSiEI0iELGiERxiCSbiCS8iEyueEKAiFUYh0U3iCVWiF3faDFvMtXeYDZqYDYnh/0UZCGfEkwDIEwpIHYHhl+7eFNRg8KIAA9tMzGKGGglIrR9A4ZaA0GUGENQEFzqImcBiHLBg8oFYCNwBmuBAvl5BGDYBCkCgCkngj8+IRi8Et1tIPkqEnLJBo3NAw7pBLc6YwFwMxuRQr/5Y4A4cmbSFCbq7oB2yBGam4LTFwiwEABgwHBjPTToZ4iCgYPMciP88ka++QB8OWCx8DNpzAjOsTNVMTPIrjDeojCZJ3ArRAbM/wL4ijcA9wBs/wNOjDFu+wPsFmB19gNU+XS1KTjnagN17zcjHAQJgBOd4wNVilhcF4Xj9oP5GXRqlQOpH3PLXDCeNGO/lDDrvDORdDhPaAPmzAc53XBxRZCFLAPy3QMNbAjhmpbz3QCRZJCrmzAnNTjNkEjPyIhEKACT3gAHezCR0EkaRmbg3HAvRzR0AAkasXdy83jzSZbyPQcbVzI29HDj+JP2kAirowJPuoksUVPA3AIM0oPv+W0JIXWZCGIEWJyAI9pJEKqQM7OZE8qSw9ZEVYSXbPYEdlwI5pqYxtMCh/cJYjeQxyIwlT5ANO+ZS0NYyGdHjb0A3fMJPjdpC1szeChxS6QA9gaZAWKZHBhz7F4ElYKTKGpAKHCQ6GUJmAdyzLgAOSaQx0qZSzlGl5mZJ7KYUJsU24lBOrKRF6iZqbhYWu8E62NhO1+ZqnGZsWN5sjCJu7CVi9KYK/CZxvJZwhSJzF2VXHaX/JqZwwxZzK55zPWSM3mIPXyYA7SJ1xiJ2TAYPdaRczuJ3juVfkaZ4hCIHnqZ77sZ7tmWbp6Z7xeV/ySZ+GIYH09Z0+pZv1uZ0CCJ7/MsJe/Cmg3kYb8DmgFmeg4qeCB6qSCQoaC8qgweigizChEVpdFUpgEGqhW4ihKbihHxoEHfp8IEqiCzkbIlqigIWiBJqiJLqipdGiLqqhI/GiMQoZFviC6bVUsbCB66WjxeGBNppYJ/Kfb6Gd1rWAReqAQgpY07l2XkJ/5hB+TPoZTio8HON/VCpZVoqSWNpjWrql+3l5RfalYNqklCRm4klmNAF/LaVldqdjSxCnpWemm3U5uhCkOuAsqdKmZEozlCZ6Fxc2tkmndTqklHRtIsCJo5Atqpgv4LI74/IGAeOGXeqmveRsITMyMABteqao5rIy2+IykxAzGTNQhnqm/0rzcDljjeXjMzIQNKiSOEVzNCwwNiPlp0EglIDzAoLDAoTTlYeTLIozOX34OJGjSZQTpai6T4gadDRUAp5DKnrAQGGZjLlkOqijql76UB/TPT0FPuIDBeRjPjH0ArDCTdUDHu6zrMwqGvEzP9BTAzcQOtYqA/yzNTc2SdyqqyfkcvGGJyD5qy9UmDQwQzcpQmN2Zu5qVITklbR0CkF0RbFYRFvEQ9t6qSBVRJoCAXOEPF6ANHiUS7mgDaLQR7FyBxe7sAwrUoRUAoZkq8CQSC/LSDrgSDMWSRibqxw1CcIUPp6ZSwlwTLmUTCSwTDfiTNJWDTbHsg0rpn0KpeT0Cf956iZN67Txt7NNcE97yK9WayBcappdSyTt6rWGAbauJ7ZQQrZlyxdn+4tpOxNTyrZS4bZqp0pky2IntbZzSxZEWqQmcKSLkqRP9aOJsaR8uxs46qPdoaZN0KPjBR1Ui7jnVaMsOrm7WbkwermYO6OQtbmcuxuZ+7m10bmMVbqji2Gnq1iqi7owJbqC2rr8+LpJF7sNyrqTdbu12x+ze3+5q7u4Fbq++7vTwbuzN7zcKbzDlbzH6xvFu3zMu1mKaxn5mRhq+rgHSL1DJbnQyyQG+J+Bqyt/e4GHy704UbeByrPrIbflqyRPq39GNx3ry76JcL5bIr9lOr86Ub/Dc7//85e/WPsrhEKo2GNjLEZjcxq2pyoe/fu/hWgjT8YVASBlu6JklbevChyG+lopSsCGOca1WdW4ctfA5jtwhdYDrhiKi+ZnCONob2tSFKcKFFypIKK5JscEP9HB8DvCTKJyv0YC6DhscWRsK9wDRJNsKqfDH1YvJ1CHNzkJLyAzLCAyoAqKjvgGKdxwb/NzwIZoGAIvttaLP9MWmwiqKDVtpJi+O0zCk9Q6bOCRAVuW/XZr79Yo8WYMLwxg6WvEELAPdckCHUs+j3MxDSCryNiMQvyJUnMAdPOYhBCNVJNjdwAxxGo4uyNuLeAAC9evapx7+8pyRVmRdhtzQjNzSIzB/wRBx6uglNMjaonDbrGIC2KpHA7XyG4cOztlkv2AA+S6C/QImWnMyViCxGK3O1X0luiLdkpst5bKtI4gc6q8kORaRyKXOy95jWY3y3QXymNZdwckKUxZCC4EQ3SJEQwczKN3wZm3mZyndp8nd16Hx6GXxyZXR/QyAyq0xIZglbI8C8hDCLSjRwEARRIyKWy5R3CQR+czlsB8ziqxv0lsw6twS8QQPYZEBkz5eKMjmNj8BH/HzmL3IryyDAQNDLW4CxRTtL4swsrc0Fzivu0L0b5hzi2dwEBhv3vbFTNN0y5s0/yL01ih0zuNvmt8ysIR1Dv90EUdHEdN0377t+C70v9L/dNCbQTSC55qetR5+xRTTdWoESMumL0zRb5d/VbXO4BhPVPbS9bF6bxrjYJt7dYmCNdxLYJzTde7cZ8ogtbaddcs6J/iKxgB2td1vbwPOthvXdgUmtiHTVaLnaGMLdeO7aGQTdikS9mVnVqXbX81atea/RWSPaKejaCgfcOkLdrh5R17nRdqrQNm3RiqjResfdpxO7jgOdY0UdvdeduzrbZZGtNwwtW8nbW9Xaj+K9xRwdTN/EW+fdzG7dzLjb/NDX7QsmL/I4YFbV2CVBNbtqaJgMDQLd3MHcNJNsN5cNE4kMPP4kYdA6iKogaEaDDBHd7ZDd0JY2cY8zBCN8b/E1MxFyMz0rSyv30pmTotm3oJJvOphTfGovoypeqLDD3fYwvdaIOwaxPIbgM3/XICyWM3eJOs87R7JmRwgfMCg/MChSOsiZPhjOM4kOPhCBTgER63ZkPH6LY8rVywUCA91NM+IA7em+ytlACutCSuUlw+vdx66Lo+6lodyi3jxF0RModB0jzO8vpBuZCwjasVb+R2ArdCAgsA4lywMtQ5CGtDTv7kwP3jYXSHZESyJopGf6SySo3mebyxckRmdRSyCX3QJkt8KAtIm5zmEu7jrfRzsEQIy2RLuARNAA7hdK7M3QLFxBS0Qzt8t2C0J420DBe0u1Tngz4U8q3exZ0I/+Uk258i6qAe4tH96UqwtfmU6qru4+q33uIt61sR66he66x+6xuR3DHe6nSS670u6M8964RO7CPx1X+725AA2N8z7MnuA65tHIU7GadO7YkB2x0o7aBl2jXc7QH47R0R7tk37rBb7h/C2eee7spr2e2u7uzeu/Ae7+9O7/Sx7ve+u/JuvPoOvJnt78TL788b8MKR7wW/HAeP8FWR7YFt7deeBA3v8OS18Dz17O3SRsuupNGe7r9e7McO5RV/Thy/6j9O6yIP67b+6DOO8inP6yuv5i0vpSRv8pAu7DI/84sgZm1md4+B3aNe85ACp+X9A18WZiPUhjM2wPKM81GrCP/DB5M36DX50x5QsWntDVAes3KYJnSvJ+BND/T0O5RJMw5Vn/GmR+AHboZnXG3abNDH9/VgH9/vewx9aJ2CTWElH0gj/gIIJ3SZjDg2yUd0cyJj7fGyXiXmNgZTn6+t81lWD3tBDkKKSpY+N6l0F3RH1AdFZ/NyP/cwHUH2inK6rveb3OWPUMtDYm3ygwdw3/men/cpR26ib/akLugbazQAI3Ur3XourG2w3wpT4gAQoAnBU/aPf/YSJelf8HtesNDPRHxdj7ZRPc/AT98vD8PGbv0rpf3BbhM03+2Hn/0gz/Lbf/3dD+wxb/5hf/JBX/7rXym5jZ3NjmTPTv/wX/R7F28Csi3xIBCII1maJ5qaCNC6LxzLM13bN57rO9/7PzAoHBKLxiMyqVwym84nNCqdUqvWKzar3XK73i84LB6Ty+YzOq1es9vuNzwun9Pr9js+r9/z+/4/YKDgIGGh4SFiouIiY6PjI2Sk5CRlpeUlZqbmJmen5ydo6F0IADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5248=[""].join("\n");
var outline_f5_8_5248=null;
var title_f5_8_5249="Algorithm for preop eval";
var content_f5_8_5249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50702&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Evaluation for lung resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 670px; background-image: url(data:image/gif;base64,R0lGODlhFwKeAtUAAP///wAAAIiIiAAzmURERLu7uyIiIt3d3ZmZmWZmZjMzMxEREczMzP8AAO7u7oigz1VVVURptLvJ5CJOp3d3d93k8aqqqpmt1v+7u/+IiGaFwjNcrRFBoMzW6/9ERN/f3+7x+P8iIv/d3VV3u/+Zmf8REZ+fn/8zM/9mZj8/P+/v78/Pz//MzF9fXw8PD/9VVf/u7neSyaq73X9/f7+/vx8fH/93d4+Pj6+vr29vby8vL/+qqk9PTxAQEAAAAAAAACH5BAAAAAAALAAAAAAXAp4CAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanfgGqq6ytrq+wsbKztLW2t7iouruUAbxbvr/Cw4fBxFXGx8rLecnMT87P0tNr0dRJ1tfa213Z3EPe3+Lj0ORH4ebp6kLoRBcD8BMPjxHzAPVc7ev73/pCFxOEPOBgjxG+L/74KZyWEOCQBxsqDJAAQMIAEDHgDegQYQM8DQAeTJgwYAOIkPE6SIRnkkgFjwNihBxZ8uQQCSQHXKgwQWYM/5MPUgLQmRPeBXxBS3YYCvMClISNcEmdSrWq1VwL2TQMKMQiAA0gwQ6VMSTCCAAdNoqsAILDhQ4clsY4K0Qi2SEjzsKVsLat0yFuAcjgAKAChxETKsCVe3YA3YP10i7VEGHoPJFPOUEVtjkrsCcOBW6oyEFihZkDNIA4qPNBZQATLrzTOIGjxr9CYguJcMF1btwrNZ5+R3Z2vKEU79mrFxoncgChnXRWNH1Xdc9XtgoMfG8DXcBH58kYUME37Ldxh2gYDUInkbxoJ5rXDd7l4cSLiUzcLVO5ZAAjVLZfdE1cV4w4BmJHRUO04TYeRW2xtJpGl72mW1KpScDBACThVv8YTDLN5yFO8fA0zwhAaQTSftAZhRRLSw3IlXSaIahgGgmG9JoRB4GSIyE/khLkjTRaYdhdPBb0yZCBMBmKk0QqASUqU/ZR5RFeldEjjlGacWUpX+phjEUgVZSackdsyUSWZKh5RphdsiOIeWO4iUyNXcFzkgZnbsFmnUqiAWecg2I4QgfyCLFeexQuQacYdi6Ip5n1tLUBSPVY5FF6+HD4EUuFaWTSnygpNRRAZZq56VJJbbDUexRewMFJEHUAU2NNdffRh7saV2YEO8oZ5xhwxlBbYRFIINlgp7k3nk1IPBpGpFMMeseYRD1AGaYPWERRBNxa9lViEiUXqgx//kf/2VDf5fmtBuoGuxaausUGkX6XEQasmRWMAJJhr7Z40r5EWBulgS/BE2I95AGG5EMbTHCXewMV4etMG45a0gDpacixU/VEIE9OG8BEFp9GoeltdpNaxNNG4CqXpVidUmTeRLYZ9WdzAbF40wCKasAzEWKh6ZoMAfVbklP7uYyPaUXpdAFMDZ8zLLFWwLeXSOYKUXURJQ0hatfuXCQSCCDIs3LMBEE3a0enrSXRPOuqNxo+K1thcB3YlldZzJkC/VW4+90swXoAtHdBuhsBKCDZM8PbeIBEnJ32PJYqidl+xqJpmr9E9CRYwwSDc7UYBtLHm7QAcEfET4meCtfD0FHt//duGkRumtcVHGS4jiFtyCGaWuxNR99lcRs5moW/NpHHHZLaaoyQCy7W9ESAsGnsMcxaqnu0fTuPaQnDU148pAcLgPEKGqi1fOoDYCxFvUswXgX3nypYekOIfr9vhlmc9UDStoGsxh6/c41d5BcQvPlMUptgXxoi9cDinS4MCAMR8IyAstSYSFEmcc9MTiMQ9J0PHmdZnscC4zvn2exv8WjgPPJ2pwhK4llIqGAWJOgZHmrCh28A4iOEyA8iWsKI1bDRBRGiECSqwYnUWSITizipQ2BoANrSCBZ9FjsvQNEcX1QD66b4Q0VgRj2pAlCZLAKtbkjRi3TQInm0KDHvhf8qYFV4VHBi8o8ZJW4EGpGJBGDiKiOE0UtbEAlLTFaRnDglJ7WZEMdgMz7yeKs1QnmIH4smhMHsqV1ufGM+4gicr7XuL/fCgh4bNsizEKhkJxmkYX41gTaur4pXkBsWv1KZwAwmdDFgY/8qWQGLzCM/c6mcFr+iRadwQAZtMZctsXBIJZYlJyLjWNxSEhyT2AqF5YJOQFwTFKXVRD+lJKEQYmChQLlEVCDQFMdYpZFg7S4+IIhOWtqYSiE8swjVJMOQEhiBPW6kgyDJSNsSZZosGWd4miRaGuU3guZoAJTUFOUoibCvd1BEHsj8jl36GU6HcC0kLdmAkrT4gD0GZJ//GpqmEeyyNsm98J3qnEh0nEO0YNHHdDbUAkFPOYR3nORSQ0hL70BSzizlxwhnDFoR0qJS0WCUZRq1IEdnKDjm0DFnOlHaBnYiow12sE9eS2cRVFq08Ew1AreJXGhWScJ96tOU/Wwd7QKKNaG6EHgk4lD5JpA7FZlpY8UU3PfSGFVm3kYIHlHnA66qt6xqtSxc3c0DnvoV9ohwJvoT2QYhItPP3lOTHEiOsQKFOMVF7j+UG8LuBgmSV0akIhHpk8hsyVfUeWKyobQsVjFrJs0uFnqYTFmrxrkjQKZMbKWkjRDa48cRBAq5ApQqyjZgT5b+g6W9gwcHBElIPAqrjJ0A/+5GhVvZQ1iXD73FYCe6x4HRfIa97TXEe/cQXzD0Fwwg6IBK1ovfah1iAxwYL39xeY3/MuQQiumATI/HYGo4WBoXNkSG78uNDS/Dw4MAcUb7UeAa7kPEw90GiodxlRa7+MUwxsoPY0zjV/SgxjhmRYkvsWJR9njHUQGylYR8uh9L0chERgSSL7jkJBeiyVeDspMFIWVCTblLVcbylQ+2ZTtkucsLBvMcvizmc+T4zGheBYbTzOY2v6LM/hUFmX3LYjiTcUkYJsactbHnAuW5znYOLp6f0ecdBlrQnig0HAF96MsOmhmKTnGjp/CBFQhrBR/QRKUvnelfbPqWAMD0Kf8+HYwPdHrSUFBBAFJgggCYIAUBUIEmVM1qV8Na1r+gdatfHetTqMAFtcYBrE+N6ie0oBUt4MSxWZHsYSx7Fc0+xbNVEe1iP2EFrbD0JrDNCm0Lg9ur8LYpPtAKGlhbCrBWRQo8ke5VK6Pd695Fu3Vwbim0WhUm8MS9Xa2Mfed7FzhYxb/rDQUXBMAFoDA4wpehcGHU4OC4JvgTZhCAGYCC4hZfBsaFcYMA5EDiUSA3sTkhcmaUPNcBGDnImWDuULScGS//RcxXTvOa2/zmOO+Fm3d+iyXw/OdqBgbQhy5jbBD96LTQcybQUWUmRRobTHg6EqQOQR77HBJOl3PUtc7/6CNefYgETvTWn6R0TDAd62HvRDuobsiyW11KaOfwo6FO9q5X4uxgl7vYv+4jt3sd7nl3tABYIYAEED4ABRiCAQTghAIcAAAFMIAqKCAEAqgiAWcQAAHazve588KImkck4B2R9SEIwABESADmhwCB1RcgAA5gAgIUoIDHK4DyFgjAAU7vgAMswAJmCD1Ax953uwPA8quIPOEXEHsAHCAADMCC8IXw/FVQHgAIQP0QHAAB6zsf+QZAgNVGDw5WVF8VBrAA86kPfSsgYBWLF4LqicAABaCf8QWwfwAUEP3hy/30qbd6QqB+sZcAELAEAqAABJB48sd/kcd910cAjGd6/wawAPsXe913ga/3eggweKrAAMoXAOK3f6qAAOcngKBGflXggapQeIfHgAAQf1AQghF4eY72eUZAACgYfkSwAOIHAAmYBdPnfLoHeQpwgNlHBLQXe/kHAEsIhO3nf3RXMD9IhI83BD4oBEHoftonAAvAePNHfQuwegIAAb63egRgAM0HVIKnY4a3CuL3ew6wADC4hkNgeFUoBPlneIwngZWHgrznAIuXgLGnAALweozHAIiHheKnfuvDeAA4hOc1hVYAgHeIgq2nh7CXBAlAAHnohLine7zne8A3YpyRgzuYhxSweTE4gUdwfgrgAK9nfwsQfSzIiux3hYroAEkoBP+7SH+bKAQQcH0F03nsUIXPd4VCsIpCIINIgHwEIIuIJ4JD0ItAqAAAEIbXWARbKAS/J4WGRoEBWAQUAAG9uHvax40KCIPfOIcWMIyV54pAyIo6+IaX93pCYI3npwrPl3hJKIkpSIkrmI7ZiIIEmI0HqAQIAAFj2HwJ4IBqCI/HJ48m9gvRgHwBsHmStwoHsIsFsH5L8HwWsIHHlwCKmHhDmIzgUADWGHlF8H7jCI7jVzCrIAD7iHoeCZJHEIiGiIgvmY74qI2FVwSdSAQ8WIz/R5Da6Iv7N4EFwJBJMHu1BwALQHkM8Huj+I2mt3m+14GxOAT4CAAnyYgF44+o143/bCiQVMCCvmCP1CiHdLh9UkKNexgAfTiBOhiOp1gEeal4n2iIYYgAfkh/GIkAYal6vZiSRSiWsGeNiqiMjLmGEomUakmNuVgEgLl6gkmRYVh4YUkE1hiEQkmQ24iFpZiWpgiESskKP2h/yniVS+B4kGeBAVCDAYCCUKgKCZmBIviZLAiCG4l6i5iEV3mblKmWU2CJ8oeb5XiOygmaDJkAzdeOvyeRgylp1oGKRvmJpxeXAEABztiAAOAAvRkMqqeI0QcBuGiFRoh51uiEU9mEBvCVg9d/xzmT4ICMi0mB3gmeFBmIi/eZ1diFWaiNvpeQZfh8aKiGMomdUgCbXQCQ/3SmgmuplLipiIaoh1BJlJ5YBFUplliphqSolxapnYpnfuMZAAQJART5kSpansuZjaqggESwjxP4fjV5AMj3oTqKfp84ifh5jENwk0JAnitKkcenCtEooPkIfz/olgWQfzOKf/rHf5x3g1MAoVwgofJljBWaeqwpBK45BFp6h60gfi5am5VngySKg1nAokNGoVQAp2OWdlGAAAuQp5BJZcSnBmUaRH5nBXQaZsg5BYMaB6VnBQywqAfipWfwp27AdlLwIwqQp8TYDI4qBZX6oXKQqGjApFEAqg7aoGaAp3qKqIFKBR3JAHaIB3h3BavaqpFqp2SAjwDJpWDpJGvXBv+Lap+AanyT8KpBpndmIKpauJ5HYKwVOXUhBoPV4qwB6aZrqQpZeAD696NhcJ19GqRKMIEZaKXWWoJvAq2kuqxSMIsqGn0iaAAJEIJoupG+EHohyIIJEK7GGYLBQADIWnWF+gW4GgWIB6rKupLlegr+wK6+Sp7AB54AAAEHmHuyCgbamqmoiQSnt3nqZ3uY57AAALFeQq73OapP8HrpeYABkJBZ6IhfCHnxunkre6zCiHm+d5X4l6/7amAU6wX/+hQgy7JRB62SCrBPkIAZ2owQ4ABlSJWluIhDQAD6J7NPO4+DdwAZuAC5aQAgSIK1iKOWmbPRagQUMIZX+Hx3qbT/7OCsJEiXGyl+EpiG9nqA3yqNtMgA9rinFZtfVBCWALiI+6h7RWirBKCSMBuDrPm3urqt3XmBDTuj0siBv+mux/e0J1gw1zqRbhu19hqwvvC2wWmvUJt8BWsKm/F6RZiAaZh4TNu1x3eA6JmJM3t6KGkAuliL3wkBJJmXEyunIWuU+ymMEEB7j5e6eWiXQGi1KWu1Tvt46ml6X9mTi5iXTMusxBqqwaAAmMe0WYiFkNiyVOmKW5iJ2guFlXezk4q4aiiIAkCITniIxDuW3tiIyLt5r7d7+0q8Xhi5yiuztbi86xOlvsC/Ptuw+ssA/Bu9QJqdTkC0E/iLr+eOZ0sE/4O5rqwpfNrItSp6mJiXu/16wOQotlqIjduolQa8iPPbCjo6gUcpo6vQruZ5vT3LweZKvTMavAwYgqiHo/Y3j7PZgsVZr/qnezhss20apMJXj6zAwvmYjn17wlYIkCSse4MJr+v6g5obg1UYllKcfVQMtKmKBAgLjMD3ftz3sMEYjx2re+A7uKc3u/aJwcd3qV6rDxdbvI/3kA1Lxna4iAybvWbcsLiovpoYowFwmtyKt1MwsH+wq0QQel0JyAHsvlSZh36YjGj5wAw7mGl8x4zpv36cqxiIiaxrwF+rCwdrwrlZrZULwTXpfD9Mv01Lrbl5m26Mo9h6pdLbBHg5o//RZ6+fCH+JZ8MTSX36B7dw6MZvaLcwzK+H/GOKbHqrsJvFbAyPG5zBnIw9TJMXHMyszJEMIHn2x8lv6wD2J7ut3M0kyMXA+gUa/ERemx0v3FdYWmEyubPd8M5v0sXqjKRJpLvFY89dGs9BpYL0nA/+XAZBmxlm185AQqvoxc9Lh8+RIKyM4Kl3AK9myJ5FypuU16MqWsuhm8wPnc4RrdAhxtBywIM6KqL7+YRN+IT1ua2FHNAlmtAOrWEmzQ4b+YYgHLew6AD1p5swWZCWS85s6pemKbi/SKZlPJkbDNI0vZdv19RPdtOPmI2y24/qW7REaAHdGNTzl7wC7Hy0a9T/8Si4LgmaybCUtyzVfwfVbb3WE03Viyh8iOeWJlmYVLt/CODVGYzCYUrWSovUvZvUDQvHMb27Mv15SId0PrfYbCbXKMmKiOfIdkyeVQi7umetfR2zXix+KY3R8Pl48kmfUVjT6+PYqK1jlnXQoxynUhLZD8ybhmmBkteBcJikC2C92py5kGnRsbePgbujGw1+Ho3YfJNzMJ3Yicx1hIrccC3P8MXcYuLcpn13C113zU3dH/3WgMDarX3c2n3YT90k0o2p4S0EpCYEogbd2a12eZDeoaZyN6drttZr7D3d2G0H9M1rEefc0xYA1dbQTZLaBK4H/x3gyA1uqiBuAq4M/96tBAoeAAzu3PDmecfw4EpQ4ecNAP5m4RBNCh2+4QDQcB4u0qVA4iK+cSXu1rug4iJ+cnsHacMA4yI+c/eNwMJg4yJefDK+4z7+3B/+43xD4KkNBxgutFZC5KiN4yt+z4SWCuUNJlHOzk/u2k3O41du0H8W3fktulPOJVXO5Vju5V2+zz0u5lke42kOzx8G5WUuJF8uKFve3jeu5m/wKGMEBToE5GB+5nTOBluS505AKtXt3kwwHhNFBXmO5/GTBDq05+Iten6O30uQER5SBZES6I2OJYr1M+VAyk0ALHZkBYsuL5v+BJBuy1ox55SeBG1ROlaQ6Zpz6k1A6Gxt6P9KIBGI8hfORRgY0gGBBTIwoQHBARaPJRIZAwK+EexEcEke9U2OgRzaQ1l32+dtbuVIICu7Uz5n0eulciwbIzW30UHCvivL7kiVwzDv4Dbw0C1AgyjutN12fgT34hvzEh/m4kv6ohdqoT6IYzny4Bv63uy7hBx5NQAyUFUkPaHXjuZIEAEygQ+xNUJCEFLiUjFqgjhmER8dIPBO8UuaRBFeAfE/gyhkE+lZHjUVwEnRYVC9Yw+t8RoDcRzmAS4KJEfqxCYTIVZMU19+9quTbt5J4FLngUZFRUfP4TQIJDwylFY3r0WS9RpeMUgDEAHAzjH9sfDKXQTCdA8xcO9pke//HoIP/zMaC9Q5AOQWHs/pYmMumzM1tO7UWh7mfw4x0/VMEw/2/OM1FNE5JH/2Tf8/vXTpAiH1ne4v3tI2Wt/gHPQdsnIP4vU9wA5JkN/uaLEhlBFD33MW534cns73GMI0EqA9LXHrDO/gbp4EXXRR3F75vm5Y4dMiOgFXHNJAjdL5EFX4eVL5teEVcJHo8o7rYEAtFAb0DV/3WpDqxU8lgILtZn78rf4Fyl+noP7m1o76zl/nwj/vVB70rhrn1s/43Q/9Qr/m2j8H06/Mz4/9Dt8H6V++1f8H7w//s0r30e/+J5+aZE7wHgEEkw5gsBkMLgDJ5JicPACVQeXBLBoH/zIlZ8BJVpkbEGB0FJOPHM1xGjlGxgPrugh4AkAcLYDfBwT8AgUHCQsLAQ0TFRcZGx0fCREhJyn7JAOLmgAisDSiOgE0IvgmLiTkusoGYj6PWMGKxlTPVNXYqMyGUAfoNkJHN1kFLyuLjY8ViZUGhkZGiKCqALwAZDjsoKSoJiqkoESnoS44QKoq8i4ezjYezPsGJACqQEDYoUO5pSQuJgD4D5EZUxaQYEGDfw4mRDhoQLRrEUadqjDCUwUOHcDZMQXPzqgLA8g868BBgjl06sawc8eHYwdmv+5pyAdPm7ZBAxXm1KnsFB9pHPlJYTPljrYHwDgetUmECrBSdI5okP/qh+NUeZ6SIpWQR8KGJJF0MsIZlmzZhWaL4eQoMUI2okMvZCzVcxOUnqX4REjnNO5QqZ7exfunpF9WlvHaxgA8DG1jgjxBAtiAVXA/an0ieHow5ehheaM4OCzHF2WflUS0zANxxzCReOquAVgggLHj2rZxHxybGyDDeDH6tY0yhaIfaRK80BXe0xkAlyVJn/HJ7Z0Wl81GtV474SJY3t/FCjplpoJrf/2WHEFvhrPWz1u6fOGLRpObLqGOVLAPx3xn8yAaAoCBBRy4jbfdwEswGQUXUUs9xNzqBospKggjuciWA6kCLF6ZTxUkNkkDP85y6c89yYC5icEVA4GMRWT/kBuDAtoMzA3BF1+8kUG14sGxEq5681FBF4WkZANhgjywyCX50HFIQjhi0pEYfElSStucvFKgBLPUsrEuvwPTS0jEHPOYMs0MDzw000yITcfebNNKOXMqM4AC1sTzMS7p5PPKOPtsMdCw7NSTEAEIKKgAYu4sCNAzB1Xyz0iReZRSFck0dBBECdUU0jUvxVJLSwclNVRLJglAgQACQAAAA2g7IABZWU3ADwFYDYCBAhYIYAFXCVg1AFsR6DUAARYF4ABhG4WAVQUcWHRRVx0xlRJrT00EW4W2bbNbSu2kTYAFXo11Vk79YKBRPmYDoFgHCEh00QMIoKCPZCFI9I8C/wSAFgAFkD02VT+zLetbg3JNWOGFGW7Y4YchjljiiAveM1MA5oVV2XP17QMBA/qQ9YAm6TX3gAJWJWBXQAyg9s4EEk4g2YFBrZisg23OOdBCAaAAZAJsxfWAfgNR19B2x4XX5D4gkBkQCCAQ8M5+C+RjZjIJ1tlNrbnuusFUWTUAz0VVnXXAYW/NdddefwWAAJMJCHtlAQ0oG09nWUXg6kdw/tprhP8OXPCzBvej7wUL/zTxxQs+fNKaGb828skvdVxKy+ek3G/NOfeWcsy961xN0Ul/XJG9swUd09K1Zd31Ip1MFl2BPIVc0tdDx133rA2RveO0ag+T992bJN742/8DoVXVaGfNNYFla3UbUVgNqNvfugMwgAGYWT0Ab3/vxV4ABJwHIAF9W4aXVXJxzZ4B9X3N3cbjDafffrQQlNUC3/loWtkFGBCskQnAAAdwQNv6YAB7NYpq/6IRux7osQA44Hx8aNmiqjYgBvQMAhg0hOpqZDwQ3k93OAlgrvQGCHRhL29v48MKEUDB8jWKe9Hjg8g8xqwDVPBVrqKAr8aXMJD9sF2rQ97xRkjC1+EkAQoAgANaJTsnAsB/fXAhAGBIvgIpwFYBsAAWwReIIr7KXhY4F8h4RS2paVAQ6hpZCEV1vyQqkXU44VX2ogiIsz1Ph1eEIfSyZyvueQ+Ffrj/47HaV7cDHMB6vyIb2to3rEfayojzkyMdMQm4yc2xeJfM5CcVxzhOEg6JoDRlJUa5o+ERL5WnXFwrVwknEsLSlYOzVtx+Z4ngqdJ2pazlLxEXEAsQKBK7fFIvRQhMZWauErMbhjFj+aVZLpOagqoEICmgPDUC8mX6qhcDhBW1srXKbcKyFSCJVT5URhN3tKymzt4ENQEtgF+5zFeTCiAykRHNEuIiV7wwNiv/HQCAEqwazYTnyXdS800t4wMBEODMHuJTehQ4p7MU4KpGzcuFImNhqxCgw3Uik5ULrWY8o2Y0icrTaBgzQEH7QMB99exnJquiBcs4q5Em1H7uNGnj/4qBTSzmkgHWW5cC9BVJjYYNTx2dFTeHFjadSo6ku/PpT0+lugPucl2yrGoJsapM1VFgijeBZp3YucSwAvOquBllW0231lPC1as8pR9d5UonvOIvra7ba17T9FeDcWlihTXsYRGb2MQCdq6fUytjITvYTT42spXllmIxm1nNSoyylvXsZ7UmWNCOlrTVKu1pUavX1K6WtUL6AA46iYMPtJa2tcWNClxQgxsE4AY1cIEKbBtc4YYlBwrLwXCRm1yCfEBhs1Xuc6ELiRTkKgXRte51E4GDXMEWu931Lh9qEIAafJe82N3tDcqbXuiqIADAVe97kUsD+M6XvvW1733xK//cze6Xv/31738BHGABPyy/ORNtga2J4NQpOLAMXrCDvXRgCAdzwkyScIWZiWEWXVjDcOzwijj8YVSJ2EchJrE7u/odRgoMtCYWsTLW9TGdXNGFKbYaIiSqEArkkhBXzMnHnkU+hR0kxzhy8YdhrCcZ58THFA0E6sgCgQjyxozUSgCNmlyQIueIxHJKMh9kXCxWCQCdfijWC52YyJWtCoBCblWNC+BmW2EPVvJim6sIaL2DGrJs2sOi3P4AZBQiIgG2+iGrAiiuZ20wWDYcRNwCQADmTYtp9hJElnumNkBCQM5YrN7yQuY8oRoOe9yb4vccoDxogZNVnCa0rd5GgAL/mtPDXbbwM8H8M0tT8ZwwfWLbfsVGCnSwUUCT3kNp01UtzoxT7XoXAQ2IwCfriooQELY4o3Zs8vGh0H/4IrLVtcEKAnRemzKAAxwAsEVNGaKPnrK3mcZjLUL7gGocav9SSk/D0SYBBZQVv/wFsFBbgJ/uenU5RzZQX3fS1mP6MhgxlrKiJszeiLIAyNycvZl1m8bJjrMOmU0AHP5haOiz971w3DIhzlTbByfgsJS25ALUdGNvDES3seg0QdzUD5h+eQIc4FAw6xCGtzL5Q+3NQH29LGYnzBshM7pt88GaRh89+ZE7rAykPpGLfmgaz/0gK42x8cbchrWl4axAAJjx/2QTvDfSCFT0e6KcD1wku5NdOK9lUZJdCHhbuKmYKKeObIyeRjesoGxGGl0Z2YX41dzJuHaOWbDip05pipWOzwZy24lQVCMB9d71K4K9fg13eBuFJWm3yQ2qNyfmn2u18XS+2eOJnFW6s8epO7at6PpG+bMGOEM90dhXXDzgs5QGewUw2mQD2vPqI828TRmLAMOf8vGXt2nbl5zy6eoVH1m1a4qiq1kovGPdIlrIuC1A9DRqfelNP6qKWSCXUEbLjEyJdQ3rnxH2Dy7/KwwA50sAIYwA38sAGQwBFQHTZizSYorHEoIB8ySU4u/WcEQCG8HnBO/d+KzsimGY9mzLGv/B/3qOA3NCBHWJAisQdnwEAxkBA12QBCFBolBwEWSw8dCiBlkuLVYwrh6h0dCmzBBFaPCGfQBtnBDAzeytCJVvg5BQCWOtzsopenioZegsWYQqz0AtZIQlmwrphRJFY/bp0/wlkn6HzqBP9ayI1srMcD5GZrDHh9Rm5vLGpcZM1NiQWc5qc3qQBSmBAC6PARSOAUDP097o2v5AXGjuVgqIDwCvggRGpmhMAQZI8AKxClOo7FiKnuhN2qptnuopEDhFDM8o2hBAXb7ImZjt3NItggBxjQbRcLKtbYYJ3vpu7chljNBlEOfOxhCqD4WETa6oVawOXXDO4HIFZBpFxrL/7BhlThnxhBmxjEY4ZRgRABNnJlmEDqKKLoGohRtzaRRNJotA5t7obupeiO+OLdCsznDwRHm65+fUJWFGzhytTuh8EWuA0Q8nwYXYjufQBdocceGWUddEsRHXKPBmihnRjho3UPKGBo0cye3w5fJCcaKYxiJpUPCCZvJ6CPAgL6AKhIAOzxVp4x/V0R1vURB+xRN18dTUkaXykW/2kR8hAdIEBqpmB9KMMHoKEhntjSebcCExroUcEvpyspFiaFXEBhCy8Oi4MPzM8QEDqmy4b6K4xwB+B/d+hlXU8KFyJVZEKgXtMHuwD1roMHswxlgEYI+gauJWZQ8prCY3rBJc//CUSO+V6LLE7NIETQnSKJFzFBDBBpO8CjO/DtO7EvO+FhO7GrO+HtO6InMA97KuKpOXLlOyMnNIBqwzPfMzQTM0RdNhNrO8JrM0L/M0UXMvVXM1a7I1XRMYYTM2e3A2abMCbfM2SWwFasAE2EsFTKAGVkA3iXNMpssFAgA5q6s4mVNKTEBhTKA5pXNJwotVxms6sRNHZiBXZiA7vXNFmItVnOs7yfM7WiAAWqA81ZM3aCAA5Gs94dMx0jM+6bM+7fM+8bNSRnM/+VM085OOctNMAvQ/d2q1BpRAfzG1DhRBabK1FpRBGwFM7nIqtUYHLQZCkyltWs3mrMgvqfLSPP+0KlWl7YAv4hYtEHCyVYQIBG+I2ozBmeDR0paMDxwAbwLAXlDmRCsJQ9vJD3xmg+ildia0yO6y3ADRSCGAoChJ1vbM2FqUQxGo4IoBRnUKZaJmRv/FX1BGSR/q3HaUR/3KDxbg2/qghoBF0RCNFLnPTJUwLe2t3EBPpwhISse05/iuHnsGffxS1ZiHzTbIDMNuqtTFAWZ0UG+lrGSDTOEPTHvUEjjUD5pIelrKgsbxdyL1imiRXFDOgLhoXtKt0M4wKHNF5FZuUHnl+QZBf6TFbRKgpajU5u5kRmfu5kL1SxmVdC7BE7HIWGoKS9WUU8YlbI4NHqdKRNEyV6CFThX/1UlrLhAABuf8bsqcLo/Mbsle1REnqFCLFeL6oE5r7VYF00fFRlkgyotoSlK7ytiEBlH051zrZSWnzebKrUWX1Eut6E631dN8z2emLFI9T/ZA8ndwCGWIpRzrLjC3FG3cxl4TDFzr6OZEDdKq59giaWWsshrDpiijCA03tWPvRViWD0XxNRlpVC2ZZsrOj1rR0dQENmFoJOPIjCdxFGQ3yFYdVnMCVMrk72YfNnJ01gd5NlwZRwEWYAHEzyaDVmgX5wAY4H2ANmkny0GhVnT6s2qtNsCmVr0eNGtpa2u5lrW89msVVGwxNGzJtrTM9mwt6wPeExFoYDzVdj1xSwee/9MEdOC34pY+zzNh5jNv4TM8cwVu/VY9p4tVlnNw4fM5WSU6ETc+w+s6Gxc+t7M7Ixc+f7Ny4/M9MXdzObdzPfeVrjZ0B+xzFeqT0pZ0M6x0UdeqGmt1MxSUTtd1GzaTYld2R0xDAyBqHglhabZF6HFFX09WapYRznJkzm94byZ4atd2ScnTlAXxdAoQuXRh94ycnlRMqUVKk2cBgI4QFMBe2oWs8Ed5mResDrJ/nGaAYAVRvbVJtmlbd4xSDYGCtPLkgu4UKZJRhMVV3FR6ZG3TqAj5tBBaauhRl9d2lUGmBiSFOBVU/UDomiQs4RFkTPX1EgFXDBZm5AUR5rVJ/P9JNlylFgVIIdFsiwSgEzWKfMu3s16ofHbXAZTVDUPtUZ+VkqJVEOi33QKhaQwVdTaqeejxiiC4hoal6PLxgGU3gQ02oGxOVuq1et/3UQloXzUm7Lh3zxAg2xQgasIXUWfKZ0C4BPunYzbPHjVKUW93hUtHifmMQ3NUVZA30EKNZJ/IZPtnyoiVgkHWeHvFzwyHqcpyEQHYRiPq6AZpdtW4c1rpZx1FLh0lkXs2QRj5MRz5QiFZkRWEaI22VC4ZVxWEaZ12ZzqZalt3lHG2lE05amE3lXFWdF35v1i5a2N5M5F4llnXliuzlnGZhXe5D3W5l9cYmF9TmPfxl4mZb17/OZmVmbOO+atQy5hdU3wTskFtCydwJduquJkDIeho43sTVGqnr22yWZsNyWjPrczEjMW+9bSsGVYIRGPaJ2TJGWbuptcC6GjXGW0P5dy4F1YeEQKBeWasLkdVRn7AWRBkqn3GpxxnlZxnJi957gOcCxFWQHBHS6I7qaIZ0YKOJWDJOaBuqI8ArQ/YKwXqNgXwFrVK+qRT+oXKkXzQVJ4/GhL2Nlf6FrVqmlVueqZzoj0TxqJJy6cDl6fLQgeoi7aM2nCJuiwUNwAYl7Wa+qmXWieQE3Jbq6qnuiwm17a2OqvDgrnci7bA2qvJQnNry6zJOq3Veq3BZpnd2q1R6a3l/7qwShOaLembAbSuZZmqVpmW9xqvlciuw/Sg9bGvM1Ow4wiwDaIBMOAYMsADLkevpw34dtd4e7fnEiYtxyx4XbRaABknFy8sA8HNqvgYBURYNOaNZRrMULXuHoheWAVPiFhZ9tdm55IPMqABdPsFROARMKABAoGxKeGxcRuyD0K4f1sF6VIZkBRJp5dJ7fSB7S1KvVgs8OyfbGVRGOBH1zKCrLVdjnF6BSBJubdLsXgBkpTP1NkAwsi05cmMUJVNlMEGQoAFAEAEPKCxjUG4J4G4AcC/F1u/K0Wy29jT4HR9xXRZ1RGC81R+D2UBFskTycmNnLQlyVRKZ5RojlF7Y//4IK1NjHFxz7IST7zVF+VbEEpgBwIBA0qgAUqABADAA05At1EAAEigxRsgA5JbBGZctxv7BXT7BGDgt38bxvmAx3XbBkRAtxsABTIgBEKgAYT8v3W7vom8AYz8vnvcBgDgt2e8vlGAyUkAuJG8Abjcy12cBWDAA3S7BPJ5BZn79jpVzh3YGzHbK1+FHiu4tfuArAROhvuNVQ3u3zxmiWUVEDY8JXmo+waBnjv0hYzF97iNXNbFeheVmvugAXrbD0ogA2y8BNYcsn8bv7mcD5L7BYybsTNgyk9Ax3M8EF7gBQCABUoAA/z7yUUABl6c1u3bBl7gtz3dD2J91mv9t+3/e9iRG7iHndYxgMhjHAV+GwYMerkF4YVfuMMfasFProbBjAHZexgADSddpX0x3GA1nO9k6lATHKEN4MMf3RzBmO5KvHZOPBBe3A+WfNM13QM8Pd8xYMY9gAWSOwSMnLHDnMmhHbgDgeD5wANI4NaNm+DHnMlDILkX3sgd3uKfHACSHQAYPsZJwOJRoMZtwMWD/dJZs9qLtYOd2Lyj284ZkYrfbcfGWY7vFVL9jFe8uxzHxVXCG71fKEkVFro9Br0fdR2FzYlCtoLe2+0QOUIFgb4bG79Z3NMzANT5/b41vQ9eIOEBYNlVfcpNXeGFXdZZIOyLmw8Intf7wOLLftYZ/9viT6DGG0DFT93s417hR74Pzn7T0ziXVV5et1W145hZ8zxXRgaKlniSDU9dki4oFV20zSwZrSyzVZs2CH+0UfWReP5EvwdIa/vNp/3gm1wEWNzFYTzr853NG8DKgZsFonzGf1zM3b4PypzLab3J/Zvhc5vGa//It7zLmfwEevvgx1zLk1z4+WDkf5vGRT/+FjlEHYuvu+b3NemwGYTxg5n6ucb6H9mvE0ST8ZmUuR+TEHv7wQOU+VxpC9t0CdxAC5R2339sr2Wu7R9i5v+Z2fpm7h8IAsIhsWg8IpPKJbPJBECj0im1ar1is9ott+v9gsPiMblsPqPT6jU4wH7D4//yOb1uv+Pz+n3Zzf8DBgoOEhYaHgr6IS4yNjo+QkZKYilOWl5iZmpublZyfoKGio6ShnmWoqaqrrIanrbCxsrO0na91uLm6u6C3vL+AgcLczkVGx8jJw8NMzc7v/nmRj9TV9NSKEAxBDB4TdfeCgRAQBkIWKOnizqYAyhQfH3Thi8sIAC0q+vvXxYsUBhwcECBkAQAECwQcm6KvFnhzC1gd05cAAXd+GHMWChBgAIAIBg8sIABAXhWGsp66GBBAnPbuiUgoHEmzT0F/BgggqAAQQIXpaCM9RAARQEIDEApgLQm06ZxbkIBWUUqQ2Aqoii6GkXA0pwCXn6U6XQsWTP/UAEMHHKAgBADP7EC++Aix4cAH3K4+CCFKxQEASYKsVh2MOE6QVfxKMKjMOPGgA6rwlEEh+PKlg0LqzGkxuXOntdAVnVjyI3Ppk+LCZ1KhYsALrSiji37iupULQK0mK17N1xhKwKs4C1cdu1UM4YjP108OfPmkpY7jy7dlWFl1q9jz25sOvdH0Ld8Zxa+O3nQmMuOL6/eTHrag9uvj9/mPFn48u+Dpy+nAQYzGTxAYh9+A56kXxQZNJDgCyJ8gUEDU/AnhoNQ/PdGhABcOIaABHLY2xyn2BACCwCI4EF/ZWTY4IMAVMhGin10GCM0BgJQwg5TYFBCAyWQAIAHJySI/wIALADZwAsTilBkhC8keAIMDjrYIxRJJmgDACEkGEIGIWDpJItZsgBlA1JC4UGCHjzZAJAiopBgAyJEaGYDaDoIZAkswCBnCVRsKOOAfXoYxZtTlJABACSUkCeADoqQwQlRTPgCgBhi4CgMAJyQgYOGSvHCC0OWgMGELIYgAgw8snAnADYc2QCnB4YAAwyZOjiip5RCwd+WstIaJwoOXloFoH7KNywAp/AoBZwMYliiocuKwOQJJEwYgpT8tenmrytKYW2Z1K7YorUkuNlACKNKgYKQLG5LYQi4Uqouhe0CIK8NO74aKLH7mkJjiP2VmKOhGSTqwbODuhvppyzo6v8lFOhGcSvDojZwqbgkpDriw9zCKquWo54gZAM3UrorDB+vKC8UDDOrL78vE0NjvdqKkOOOPRpM4psIJgjukF0u6abPU1DZgJWzmnvxl0FCHIWcdLp5AoPZwtnf02lCoa6DQfIJs9e2yMxK0+Z9XTYlYa8ythrGmu2csWw71LbcVdEBd0pz430s2jPZnfdub2sXuOCDK+O33H0bnjjfijMeHeKNQ47O45FT7szklWMezOWZc67L5p2DHnfoozP2Oemno2I66quTQbjrr8Meu+yz01677YV/rfonurfNe2O+awJ87mULj0nxMB+PXlPJ88v8WM5HAr2f0jNFvSPWd4j/PT+wZbW9h7CxvsUHwekNwAp6ySgXXXbhhb4+6td1V17hd6FCACmYEIAJKQQAfoeJEWExGAHgEARIPy7chgi5IZZkiEAZjDRwCA884BZ+QwTyEUszQuCMRjQYAA5SkAv8E0IKXjYaIZRGIycMQApDuIX8CcEEL2ONa/y3Dxq+xoVdaI0LvHabBc7khzrswgwCcByY/QaDGkniELkQv68dsSZRbKIWaEDFK2Ixi1oExu266DoteDGMgaueGMv4xUxoTw/fSGMe2EgdjbjRjXdYo+Sqtzg01jELcrTDHgfRxz/EMY9ns8YfA1HIPQSSkGAU5B0zkshq0FGRNTmkGoPH/8gCSZImlGyjJctAgIWkIpKQtKMoIBAAC/Cxk1NgS2AOUIVPQgGWwiLCAYhgAAqI5SAL0AIB7kEFjgTGI/jwJRQoMg5XAvMvmBwkQ9rikSEYQJjJBGUxiSCAZP6lI1HIBxn80paFGICYB8lJRTwigISMwwHCImUzAxBNALBSmQCY5hSM+RdsikOY+KAmGUyJyigkUwHCDKcUjhJMoqATAursGh6pQACDrISfsVyILPlEzFq6UhsByGhJeClOgBpkntwYZhQA0o21FMCkAPCHRMvHTKDc45zHiukuVcrSvSwFCgkIaVRCepOFdnMp5zwHQaFggQD4MgECOOo9BkIOhv9qUlg0hadBbsIAmy6AmnwBqRSo8lM0+FMKO9XpSIsKAKbqdKlIRYsCnko3470yJCNZaULs4U2kEoAgAeApFNYKBYxKQQHnqOVbrNDLKow1KvAw6wL+GYXGbiUbUHWPRQGwjVre47KQLaZki5nTefLVAhGZp1urgBAhkMMBAVgAW4B6lMiSVLFTgIBJLBsAoLoMI69Y62UfCgV7bJYonSXKZxNr1NEmoLRUQOc4zloRgihAncBMiGNBGwXaxvYjtZWtRnHbV1VKIZ4KuEdWdekAWRJAJjfJaF+HIIBaQlO4RMmlaY0wBeMKQCZm3agUaqnP1052mTCdJ1LW2hL/RgH/wNVcBjbJa4GV6NO728iGOCig2iG4NqdQMethpcBNwL61kQNuCVUPslFt9uWz9hTpEBwM4Sh418MdOapM2CIAcZAjrFwtpn6J2eFtghLEQAFvFHxLFG7w91hroehgk9zXizoZAKplQFERUNFVflSnPMUuYz8aXAEMN7chxkpbugHNbnx5uFvV8hQoAAEAH2DN1YTHUaO7WiooGMzZpcp1a7uNGG8SkbN0Zzfi6WDYbqW4fAWAm+EsZyhQgAgWOCo5Ii0AS3/klGLd8mKJyWfu2hbQRI5lSM8ZUYSe1ySwFPJMo8DqjyhgtIzmJpYRG1KOuNKsAPEISlvSjZsGeJ2V/8WKOH1NV60qegoTXkgBILBLKUz4yBa+8xQAfM57mPWoC1GqX5raVmFHddikFqtbjo3TTSu7Isx2dj0DIBN/UprRf6kwPDW9Y1xnV9tp7TZblfvdhq4Smvfwx2rv4U0rN5m9rf6rLY261662FJ5ZZnFFLkJOIVA8Ach0r4A7/uQBi5Xj5waoTqBAEPYy4NkFRSdEqV1QgZeDCAgVAgHMmdAYu1TExA7vouk5crK22OROTvkUHECQBRBk0s3FNFuQbm+gVzzmyzgnzW2OWpw/shAQiLig9UgIoiMi0JUcBNifM2pBbL0QogxE2d8YbkG0PUBnB0Ss/0GItf8BIfVQuP8f2QkIvS+A743I+iAOwAAG4LzrLwXE4Qvb90l+/fCTILzlFplJne+D8gFXyJFRW8yb1/MK+WSrECYOhyt7PNhkKAB7b7IQikTXDvllj9/ToFUUs3LRckD9GTTP85Vygy8HMAdandrmAGy3L0LwCATIcdTEs4H3qh/zGBCgAAVkNOXKBMs7ZE/f1NTeDFzJpTfNGRCRVHf3XNfQ3IscUntsFSTY7W7ROZKAhYr2qB7ZLIpjqdeQ/N98icMBmNKdUYRb3MTRMcBdmd6/LV4YgFnNuZo9tIOezRdOJUTsFWB03cRNIIAxMYBSlB48/R98PRz7QR4aUABLsFf+adP8XVn/XhUE6T1cfg1gAe7SAZqZXiEAA65N+42bX8QZUqTcUQRZlMkY8LGeNqGYX8USObyEVIgEA3CF+WXfXLlZB5aY9FHf9HUBR4jT8BHVRIiFnHGFA0gEmKmTYLmebemTPZzVLqUX8MXZ9/VLCppBTihcByIYevEVAUAhN0jhSFQhcV1hN7jZsUwEUnBh6wBhvY2gMRnE/IVa/e2VdBWBP/xT/8HTQiDVxSHV7FmX8kHTWYxVI4rZkJVBBArTXSmEBYoij5EaNiXAWSiYCQrBkqHFRsUiCr6dGaygxkHd8sEgNcnSJ+qEKBqXKxaYR7wWKoIfwBkWX8kZvxmfFERa8jEc//M5322F1zkcFQFSYxkawCFGgSkaREd53TqagfVhn4edA/dt1+yJxAfGXlL4wTa8oTitGi+G2R3+4hmMX39p0xmi3zc6lzjuBTmaI1Y4IyNqI+1JY1z93OddXehZAYKlhRPGEsdtJC/mEivl4BDUoh+M1cE9oBeGAevB44Ld44I1V6aV3ll0HjeIoDt14i4aXkLonjeEn0ASpDDl3uYp00fWYZEJwUjOoDa9Fkqmge8VAjR+iOX9QS+G3U/ugVS63SU4j1bGAd7pgVUegthx0iB45d09IhdRJTWQJR60Zd2k5S+AZTO8ZSrBUVzywlyKB1amA1QKg14OQ13uzeVZgv9gSmRK7iUe6hZe7gJg/iVfXtLkmdFkHgMYUeZlNgEZYeZmVqZTGCZcblHqEctnTmVoghvyLI9pnubLkKYctCZvvKbnpKZqduFoziZtpiKBjM+/nQ8/7Gb59OYW/aYfBGeM2A/+6A//2JA1HGf+7E//hGZzJid0+kkCDQEQ7YN1CgF2apF24sa+WNAQKJE+hKcQjGcWlSdw8MsI3c9MsGcJ0eZ7vgwM6c9M0KcM0eZ9wgwP1QR/4iYA+OfLFNEUZcSA/icAGCjMPBFNLChuNujLWBFTROiBTuiBWuiFYmiGmgJncijsgEeHDg5zgGiI7k5nyENbxmb0qMIfpSgfnOj/iooojJboZbxoKMWojc6oZdRo6twoj+ZoHjxABEiBBAxAGUTAAwxefpABW9hhIvSoGDDpVf4oFIDAAEzAGQSpFWRpFBBpFxwpFXxpHIRpmILNWsKkv02BaEGfFxhUORkTObhiSxQBP7Wod1DBm2aBmp5BmwoUnsYpKMpTbprdFDzABnCABJjBllKBogJAl5IBmb4BpMaDkp6bGGKBWIYBWs3TjSGFGCrYOd5CnV7PnXYqrd1pk4KBpiqV8JnDp+KjaBYmFUzAA2iABkDBAwxArnaABExArj5ABWxArtrqA0wABwzABnRArg6ABlyAsg5rsR4rCHQpsArrFAzABUyA/wYcKQhEQK5yAAB8qQZsQAVw6QAQ6QXgqpV2ALd6KwCk6wR0gLsqa7pe65emK7ICwLHm6gXUJvXFXy2S0z18UjyFYmCY2VHEBDkRQE4EXlcl37+6KvDBKnGQak/dpMDmVzIa7EwZQMLSHMMqHCV6Vk9FLE326+RNAZFKKweAQLIiKhRwAJJCwQjYagVwQAcQKwiAwKwyKgA0Kwjk7M4+QJfSLADYbLxGwQCMABQcqcpGwZFqa8oOAJJ2wM0CQAyMgNMCQNXGK9a67NPK7JEma7xG7dS665WqIjsmmmUB1z2IFgm60uyBRUwcy1PNoV94BK392MgWYZy+6mrCZsUWIf8cvm1exa1MzK1MxOTdapPefhRf9C0R+FSo9sIUaICyXiu2RkEFDAC5QkGvKiu6Cim4asCWXkCw5moFbGkEaECXgu6+SoG5Mi2SxsAAxCy4cgAHeG65QkGzKuuV1m7M+m6uToDmgu3sGi+v5iuiGq+gOuBWkCQubpQszR6AKcWxCOU5nMWVfVpNGkTJUm5ynIIkSq8uXqD1NuNESWxOXteiSeI4UYHJpm0nSAEIcIAM3Cqyyi7MyiwAFG0UZKnNousGfG4MAIAMdG4Ac8AFEK2tVsH+kmmyVkAExIAGTMDuNmqRbq3VTsHYcvDW7i+4GjC4PsDY+q+Qym7zPi9lVST/HBbZ6yHuSEGA4mbv+l6Zvm1qNX7W36pkbIzvZ7mw+l4gWMww9qrv9lITDq/qZ4HvxA5q734rFHAuzirrrhrr1FJr6tLr0lbtsr5rAivr0k4r6nZu7L5s0zorCQOABSNtBgOwsxJptdLrsFax716AveYqvqYw2jpvzo3sOZITI8KwS5pZDSNxPaFTzVWj5PLwyfpwxQJyW7CvKMJeIR+xH6Ae1blbASwySTby/DLmFvRsYFJqKYhqkuIoJ6THKD+mmY7CKTMCilYujZYyKcDyIsjylP5OLb/yk9ryLOsoL4vCLUupj6ryiCJzdnxoMmOHiDJzM2to710oMZMONZto/2dUaHxYMy1bxoOuxzYHs2UkaLFM82UEqDaXc2XoJzlbKDi/gXyy84G68xqk53l2xzzvsmN4J3ca0jP78z9vR2ACtIeygnQ+53K6qFyS8kJLQysMJxQUp5PmJUNrTmOKzlgqdCtrNC60ZvHAsjVvs6h2NC5ndEVTNDhc9FY29EarpWzeDSF8APr4QUzPggpohR/YdC48tPm4Ty3sdESvwk/3dCoLwnFKBg4o5yzIRQvETwvMDy4YdFLnQlRTZytQNUL3ciHscy0QkBAYEC5s9S6EdSyM9Sr4Tj3XAg0UQTbTAlrvglvHAlyb9SHowBDoQC54EAjpAjzzAl/Lgl/Ptf8hrHMtrFAL6cJg7wJix4Jiy6ghnDMt4BBWz8Jj7wJlx4JlEzUhjDNYfycwbDYvfLYshHZjF4I304Jp67RdCANqwwJrG7Ng/wKB8gJbz/Yu0DZpR3Nuo7Ju8zZJ08ZAC047AbcyA8Vwy45wG7d1kFlyX8fYOfFr+zEseAI1TzdKr7B0OzfgtkJ1z4Mjp3R0b3cf/3JZPrcpe7d5g7JFp3d4Xzd7uyViBrZ4Z7V8u3d7s4IixCbiREN+n/d40/d99/d88zd5azeAr7eB/3d823d8D/h7s/BLJ/iUUneAD3OEq3J29zB0N/iCW7eF0y+HZ/beFIdgARQ5aLJCYfSBk7j/Tpk46N3BAegTLm3TEKAqKIeHnu4iA6xFWzTg43m4O4BScs1cOqU4eHfBipPWkKO4Sos4GWzVSiidt6HpY9TmkzdW8X1bHTCAswkTzW1Tj4/ZeLiwnl2fOomD46kdhUMylGP5lAPSj1t5lPdbkc8RfG+BajnjLlHin9EGOQFTNphgdJ3TAdSjIx44nuuSdkUBn5+EnwfGLgaGAwx6oUtBAeQVP8UiOb2j2hp5GMj4PjG6olsBVwSGXqFSMiHA8MEDNqypTx44FyA6Qoh6JTZ6QTx6oEt64FF6NHb6nTOlnvuZN9b6Xt36EAi6rgcxQNb5g4cBdsHSh/GXAzieMh0Y/4IxHCphA5Lz+oI7+xi6WrRP+zlUe//VErZfHz/5RU9apdG5ub6Mx5/5gwP4BbpZlndxBaFTO30lAKAvAASU41OqORV0+z59uytJO5+Iezla+y6au7YD5HIMPLQbfLgTGL7rU7kz2rnDCIFneJ4GHn/t+W3pnXIVpFh0BEkEHT7843y8umgBVsjLez2QvDmZfAGg/AiqfBVYusOLJaaGuRoI1liFOnbVnT5doBHPniYvhV+k38b/eBy+fLDHfL8zBM33lc0bWjms/KSCuBa4PMhL/chX/dGffNbnvNMve3lnAdKJhTV+2wGo01w5JNkXwL5L2VrhkqmyfG6yvfJJOf9axP1blPzV271q3UPeR9yWL4A+iaKloyGJm1rHpQdXLL7Wm/lImVNpiWLJYzxAoEW//zsacDcZ9L2J/T3cA4DcXz3dFz7eL+z6USp0lL7bkwPqqz7S13zrH/7ro71dqj0WRBoxnThQUdnYb34BEFxOfGBAbAOYc3o0BP9WuLhl7fDgY2/yhyLzc+QUwHh75eJGEoA6pZ3kq4Fq5dSOu5M4jb8s4j4kGkA5tgMEvGTvQ0f0WySRa0P1W/31JwQQGAIIgcHBGAKUS2bTCQgso08qlZJUChaBAMSxZBiagQJAQFCSC1sh0YhEVOXSed3unFLzd77zYLDoE+Tbgxr0Azz/VJxzWPjSG1uUpECTtHwqLLys+gvclMzT/ET0HD0UNcWUQ03tTFXMtHR9pTVkYq0FoMxdjOVVmv2tCxUGCC6uwq3lYm5mLoZYkI5Dhry1jJ6uBo3cRpJW2B7u/s1eoBa/ToOWPk8nf1cVPmJgiFenk6S3v+/z9a53oB8eeLn2DbSVkNfBgcrSOfxFAEEBh40EcsMXTyLFOhYt/btXQAyZOhIXCUBXECKvjRUXXOyV752ABBxLpoyJMOOcXUoSNLuDQAyTA45sykFQKVmZVQXl9ASwJoABfnWENinq4GiVpHNINt35RMCSokwPKOCCk1MAmD7HfuXkSA6BsU4sKICQ/0BB23Vhq0D9+czOVaJGHXZdxTSZTCd1AVjIg6CZYjkH2DYxUGArlaxzHYPV2ZfsggSPpARQmiCBIMJLaEZ1aPJjwaKlx6BesmAshXCDh7pevfmJbIyMGxuoJIALUwgQHgcwXfnyEo9wqbxWZBkVSGOko0PB7XN1n9ZZgsdWO4hYEwc/6xLgsqS8HcttRcKug/3Symqa2iNP6YwlAsuMCYqEWAACLigAYL4COQpDgLOYKaMzAoRADUGB1AgArQWqEi1EJf4jzoxKkPhiqwMDSHDBBn9T4sEoIpxwue6+uJCLHF+CQrMOWQRRISGXoIA0vr5awBPrpuIisHDqYwIxMv8cwAsABbmoS0YEr2SQLijQSuIuCAjYi6CwSAwwNS4KXGLFFgNg0MEyIDRAQjBJshDDHTf00cMg1wMmgQUYNDAyZj6DAkMnjZnOLfwitPLQGMsoggsFwAzEyx+xcKqhKpT7TcAmBC20DOQajKK8u5SgKIwyIOiNJAoIJQANyUx9y8cyCBjPOFZAda0SmyiCiSJTbU0VxlVhc9XKWMuYVYlaUcW1R2MB4FWlJ4TgKw2mvuIUirESMOAAywqAcgkFlLxrLC0E8nLZa0+VDNu33A01PSF/nSpYJ0htkyR6k2VC3gCahdVbXWhFtloOd+1VtDwsgzFgJyQDMYBxyz03XQD/HICO2QLftfex3oowV2MAEkBDU3zlCW1INJkQtVCbS+aoPAjqomjQGKkh6UNpx7JJUx/F05Y9cksUFUX8LMaZ4CV2ZpVFQg0Augyhox7a2ilUS9qJIhM4kqkkFZaC0krI8JiBBaRYoDewS6b6aS85MvpFO7j7eOk0nVBxirulVqLunq/OGoCtB++aQ6Tx2eMAQQmFegzKSBKV7UYFcA42n1cez8u6M1e7ZJLmExGhQmr7zkR17WH5ZsZbA/kRY3Wz0jkkCliWa9OPBj1sYLxrTCnceZOdaMJrr3qNsZoDYPfeGf/dprl9laMIpXos3DnIosN8bXQbjTYNBBRAowgH/xyok3m7lf9d73F2Yr3411fevmj4aQ8ZNudzjx4Zpge/6n0tYgnxj3sqB4E4IEAuaXNdjzy2rubhTn3sE4D7SOe6vKFuSJ4iijOG0gyBXEkBINIffiRzqM49ijRhYFIB6uY7o1nvgNzRDjNGyAyBSIUqyVNhMzhnMbclAIZCkKFjqFdDAwrvOllgxmpqhJPweSuHqNlaj6ikACqtSQBDrFrX8JYr+XmFNiJMAw8j1SEUCm5/QmwhhF4oBCTOcIm5siE5fiUtZsRBOSyiYukk2AwCvC2MReziVL7Ywg0KqIMVSx0I00HBOSDBaZvgGzIoKQdL9m8/nUJG76rAvvOVgv8WmSzGJqvQydbBwjjFKJ8cSKnKT8bsgwihCJZSgcqB5FJlpuCl6nRUjGCGRFLAfKUww7NLW96ymcj0yzOhmUxpCqOY1SwOf7ApCG0Sc5unBOU3ixNJcYIzmuV0JTnReYpmdnOdiznnO/0RTnnWkpr1JMQ98bm3du4zJ/r0J2jUGVB2xpOg1nDmQREaGncS9JoK3UlDIerEicIzoRUF6EMwOr+MYvShG4XZQEEKKJCGVCfOQGlKVbpSlrbUpS9l6W1gOlOa1tSmK5XpTXW6U57ONKc9BWpQfZpGoRbVqCotaVJzIdGRKlU9ThUoVKVaT6ZutKpWnapJs7rVb161ol7//SpXDSpWskqyrGPdKlj3qdaztvUTbD0oXON6Vrm61a4FvWtdA6pXdPL1rn/lqF39uk4VfKAvH1CBVAt72MQC1rG0WEELDBuFD7RgBWSN7GQBUNnLkvUDAWgBDQJAgxYEwLBQ/WxoR1va0z7WtaOoQQBSINsA1OCssZ3tbG171tI2owVZ7S0zfvta4m7iBs64wVmP24zknlW0zaBBVp/LjOgW17qLUIELmOGCxpI1u9vtbll1wAwdcHW8XCjvddV7iOAOl7fCtasJmGECrsqXC/Rdb375sAJmdPas/OWCf8/6Xe5ylcDh1W+Cq5DbuzL4rjkIQA7ICmEJK9jCVZAv/37dmuG/fra1W/XwhUX8hBQAtsSA1bBYUzxiFn/YrS5mcYxlPGMa19jGcT1qjnWcXx332Kh68HGQYXrjaU51JUJGckvvMFhpbqekTGYxlPvJz6ZSOatOrjKRMcnVIz95yVxeaFi1vOW0fjnLZiyzViEqZRGzOWZdPnNUoYplrI7ZnkY2c50DK1U6e9TOd+Zznv1sZTyrWaFutjCil0yZ/GwPzXueKJxtaZ1G59PQn8iABzbRAAxw88+zcQJ8wtUfRvurCTWDdJhTgYEGbLrT8yT0EkStr19Q2tQ0c7ScQ8SCEzSgASHIwCA8EOwlZHoRnFYCsmH96XSGGlGk7gOqH/89bV77GtiDMPYSWL2IYSf71ZZOdcneYevs5dqi5BBBCVCghAy84BLZPoSylQ1uZj91OMrzkxmYwQC6XKhGq1lhAAC+BZWZ0AE1sk6/64SGK3CBAQISyq7MfVGZpHvdAGj3JbatiG4DYN6C1nXU8v3Hgyn836hqUoMI/jxLHfxOlFG4gBp+MIgXaFqGzkMGTuAED/jaAzBgda9LwAIY9LwBJQBAtzPg6wZoGgMh8DUJkp7pEDBh6Q04AQtQwHQRYD3qAHj614ftgaqLtN7nZsLgILY7WZcpL92pimQcQADKCYCLAFAA58SX9jIJKAClOMP5LnJzM3FU5zz3OdC9PnT/ANiA6Swwdth9DXaoN0DqYy87u32ddRIwvfO9tjwARAD6dWd66SIwOznVji0jwoVMJZRiFuVOd9fcPe9jQpu0+o6GvwdL8NKaOJ0zcPFihwAGMDhBBljdaQ+ggNUwWMKwWYBsY5dA6jtAugdOgPolTJ8FAECBpuUd7AxU3foAwH7St4/Wsxe+CdRTTXm8BAAMpeV8PCwAWgjAgMA0CWu5FzcBqZTS0ILeC7fCG74mKL/jS77lS7p1a4AdKDZNK4Fg27bzSz/t4z4l8D7w07SOawDyq7oXWLd0g7wQ+DaKUz0Cij8Ymb/6G4L744IDyD/U4L9mIJfEkbW6EEAhIMAt/zAltJOJ8msCFLi44ds4I2y8owu2YSOBssu0rmO6BhCBjluCJ1SCp/O4V0O2J5RCrrPC1Gs/UIK/1lOM+Xu7JTAABoEMmMgLuzMN6GG7HcyC7TkHu7sVJaAASBLDnMs8JVBCjHO+VgO/0oM6FICBKKRCsKPCKaTCMAQALKS8qfO2SKy6yos6eOtDKijDORS3NIwRNmyUN7y77gkgmONBOyQCBchDXeDDW8qDdHM3jHuBBYQBYEtC4pu+KsyADnwBCpS66CO27muA7/tFj5PALbREADg/YaSnMVSzWcsjkuO3ukC4A/gjbhG1H7qSIYAhtEDFOmyEloO4JGBFVUMoWf9kt1o0vltUPkIMRCWwvuojv1ZrRiWARF/8QBuoRCwkQavTNPYTBWlsImqcv2vMRrbYRnvoRgT4xoRLxXHsEAcoxzg4R5xjAgwAveRLusTLRVbztXXrtq3DOqervKqDRIzbvO8jya7rNCyUPJQcRjGERppcp0ZoJRVUCI3cvCb0SHhExBLYvETUtM7zOsqzNkpUwJWMxKjrwqobPa7TRJ1UtGLASXTUSaqqSXoLtFiLNJCbM6ycq630SqeStEE7QC+7NIciy7JUqrMUs7SMs47Cp6rUL7aav/0otbcCyzXrS0XIy4/YSzJzv7hsSyFchMAEhcHsGryaNsMMuUNQzF7/YExxs7fCTIVsm8paO8zHlITJhIXKHKfI3ISN2zhkgMvPfLbQXAax3ITNRM3OjMw6YRQa/BGhMUh3WRN7wJAfGgIDiJgreZtNiQOpcAcvoUaRSAvEXEuNI0SNckv6G4v6oIiR2zfk3E36y87fDE4uGE4wKc4tOE7ddDjlHLVoqioMEMrzKz+hzDqmQ4HIW8/LIz0AqLYGmMVmk03MVMPpZItr4RVPpAu3sQcKaCH6Y5AuOLVykYKXwR0HmjsB8ER3sABDak66pIKobAB+bE+su0Vr2zYN5dAQgLoTgIH7zE/HnE3/tM21cz0JFRoDZYI1hIIDNQMGTQMHHQsIHVC4/6BQC+XPrHyCCozEEkjEdgQ2zaTAYCMBI/UAp6PCwwO0/bwn2qROA5I/lGgGI+i/1aC06+EeoUgXhUSJ37iiRnlGDH2CF3A3FigBDLBFXCTEbWNT+3zT8hMBGJjHnZtSsbTS/8RSF9RSHWqPKOIeJgDT0ymX6SDT1jjTbiEnpuo67ovSgGw+JZ3UZONF0aNCEXgBrAtG/aTSe8oW5bBN8RBQGI27kFEAL2U0lIGgq7AgR+hRxXAHz3TNOgiBYPQAEsi25jPNVttVfPTVgNxVTwXV0WRO1tO3UwWdVCVQ+WBVV11QmFBUxXEXWpVQH6U1aqoqIs0AIzW2dPNVPqVHjP9z0mDLVHb7w8sc1XvKJbRwVrDJTX1rkhoBzkNNO+8MUzEwzjjAzvLszWVNUzmo0+mDU00j1+djRAA4WE7LtmFlV2UVy3gFVKSpV5IjGzDJV1sTteEsg6v415JJzoHFyvScT5X0tTYVyvh0upTttkm9utD7p3e1yUP7yzsQUZXFTwBAvl8LUdDjUGP1Vc+j2AtFy4LlA9gcN5tlv6+MzkNgWuiUSz1T2juYWnGwSx4Ds6jFtoBUnZxVyyAdS6cVUpz1Wn9KTbPMVbU125stW1xF26pN2qeVp61dL7yNh7WdW7lNqj6DzHfV26ZN27US27mE275627ONW9Lcq8O1WrtQfafBta4ks1yaglzD3ZvL5Vwlw4TO5dzFLS7QDV3RNd3TRd3UVd3VZd3Wdd3Xhd3Yld3Zpd3atd3bxd3c1d3d5d3e9d3fBd7gFd7hJd6zCwIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PPO: predicted postoperative.",
"     <br/>",
"     * VO",
"     <sub>",
"      2",
"     </sub>",
"     max &lt;10 mL/kg/min is roughly equivalent to walking less than 25 shuttles on two shuttle walks or less than 1 flight of stairs.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery. Chest 2007; 132:161S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5249=[""].join("\n");
var outline_f5_8_5249=null;
var title_f5_8_5250="MRI myotonic dystrophy";
var content_f5_8_5250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54809&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Neuroimaging in myotonic dystrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Axial fluid-attenuated inversion recovery image shows symmetric, confluent signal hyperintensity in the anterior temporal lobe white matter. B) Small basal angle (craniokyphosis), prominent frontal sinus, and diffuse thickening of the skull with ossification of the falx is noted on sagittal T1-weighted images.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Donahue LA, Mangla R, Westesson PL. Neuroimaging in myotonic dystrophy type 1. Neurology 2009; 73:1931. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5250=[""].join("\n");
var outline_f5_8_5250=null;
var title_f5_8_5251="Patient information: Endometriosis (The Basics)";
var content_f5_8_5251=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15431\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/4/44099\">",
"         Areas where endometriosis can be found",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38534\">",
"          Types of abdominal hysterectomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/56/14211\">",
"         Patient information: Choosing birth control (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?41/23/42353\">",
"         Patient information: Chronic pelvic pain in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/41/3731\">",
"         Patient information: Hysterectomy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/16/11523\">",
"         Patient information: Infertility in women (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/25/11666\">",
"         Patient information: Painful periods (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/16/6405\">",
"         Patient information: Abdominal hysterectomy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/55/32627\">",
"         Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/63/26611\">",
"         Patient information: Endometriosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/32/22021\">",
"         Patient information: Hormonal methods of birth control (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/62/40932\">",
"         Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/14/10468\">",
"         Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/4/34883\">",
"         Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/47/755\">",
"         Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Endometriosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/endometriosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H463000859\">",
"      <span class=\"h1\">",
"       What is endometriosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Endometriosis is a condition that affects women. It can cause pain in the lower part of the belly and trouble getting pregnant.",
"     </p>",
"     <p>",
"      Endometriosis occurs when tissue normally found in a woman&rsquo;s uterus grows outside of the uterus (",
"      <a class=\"graphic graphic_figure graphicRef78942 \" href=\"UTD.htm?43/4/44099\">",
"       figure 1",
"      </a>",
"      ). This tissue, which does not belong outside the uterus, can then break down, bleed, and cause symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H463000866\">",
"      <span class=\"h1\">",
"       What are the symptoms of endometriosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some women with endometriosis have no symptoms. But most have pain in the lower part of the belly that can occur:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Before or during monthly periods",
"       </li>",
"       <li>",
"        Between monthly periods",
"       </li>",
"       <li>",
"        During or after sex",
"       </li>",
"       <li>",
"        When urinating or having a bowel movement (often during monthly periods)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other symptoms of endometriosis can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble getting pregnant",
"       </li>",
"       <li>",
"        Growths on the ovaries that a doctor can feel during an exam",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not endometriosis. But if you have any of these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H463000873\">",
"      <span class=\"h1\">",
"       Is there a test for endometriosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. But your doctor or nurse might suspect you have it by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      The only way to know for sure if you have endometriosis is for a doctor to do surgery and look for endometriosis tissue outside the uterus. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H463000880\">",
"      <span class=\"h1\">",
"       How is endometriosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Endometriosis can be treated in different ways. The right treatment for you will depend on your symptoms and on whether you want to be able to get pregnant in the future.",
"     </p>",
"     <p>",
"      Doctors can use medicines to treat endometriosis. These include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Pain medicines",
"       </li>",
"       <li>",
"        Birth control medicines &ndash; Certain birth control medicines can help reduce pain symptoms. This treatment is not appropriate for women who are trying to get pregnant.",
"       </li>",
"       <li>",
"        Hormones that stop monthly periods &ndash; Most doctors do not recommend that women use this treatment for longer than 1 year, because it can have side effects. Also, this treatment is not appropriate for women who are trying to get pregnant.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some women choose to have surgery to treat endometriosis. Different types of surgery can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Laparoscopy &ndash; In this type of surgery, a doctor will make a small cut in the belly and put a tube with a camera inside the body. Then he or she can see and remove endometriosis tissue.",
"       </li>",
"       <li>",
"        &ldquo;Open&rdquo; surgery to remove large growths &ndash; When a woman has large growths of tissue, it is not always possible to remove them through laparoscopy. In such cases, women sometimes have traditional or &ldquo;open&rdquo; surgery, which involves a larger cut in the belly.",
"       </li>",
"       <li>",
"        Hysterectomy &ndash; A hysterectomy is surgery to remove a woman&rsquo;s uterus. Sometimes, the doctor will also remove the ovaries and tubes that connect the ovaries to the uterus (fallopian tubes) (",
"        <a class=\"graphic graphic_figure graphicRef57901 \" href=\"UTD.htm?37/40/38534\">",
"         figure 2",
"        </a>",
"        ). A woman cannot get pregnant after her uterus is removed.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H463000887\">",
"      <span class=\"h1\">",
"       What if I am having trouble getting pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are having trouble getting pregnant, talk with your doctor or nurse. There are different medicines and treatments that can help a woman get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H463000894\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=see_link\">",
"       Patient information: Painful periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"       Patient information: Choosing birth control (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/41/3731?source=see_link\">",
"       Patient information: Hysterectomy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=see_link\">",
"       Patient information: Infertility in women (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/23/42353?source=see_link\">",
"       Patient information: Chronic pelvic pain in women (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"       Patient information: Endometriosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/47/755?source=see_link\">",
"       Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=see_link\">",
"       Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"       Patient information: Hormonal methods of birth control (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=see_link\">",
"       Patient information: Abdominal hysterectomy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=see_link\">",
"       Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=see_link\">",
"       Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=see_link\">",
"       Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/8/5251?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15431 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-8C269A7C77-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5251=[""].join("\n");
var outline_f5_8_5251=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463000859\">",
"      What is endometriosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463000866\">",
"      What are the symptoms of endometriosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463000873\">",
"      Is there a test for endometriosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463000880\">",
"      How is endometriosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463000887\">",
"      What if I am having trouble getting pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H463000894\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15431\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/4/44099\">",
"      Areas where endometriosis can be found",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/40/38534\">",
"       Types of abdominal hysterectomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/16/6405?source=related_link\">",
"      Patient information: Abdominal hysterectomy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=related_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/55/32627?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/23/42353?source=related_link\">",
"      Patient information: Chronic pelvic pain in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=related_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/41/3731?source=related_link\">",
"      Patient information: Hysterectomy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/62/40932?source=related_link\">",
"      Patient information: In vitro fertilization (IVF) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/16/11523?source=related_link\">",
"      Patient information: Infertility in women (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/14/10468?source=related_link\">",
"      Patient information: Infertility treatment with gonadotropins (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34883?source=related_link\">",
"      Patient information: Ovulation induction with clomiphene (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/47/755?source=related_link\">",
"      Patient information: Painful menstrual periods (dysmenorrhea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/25/11666?source=related_link\">",
"      Patient information: Painful periods (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_8_5252="Amnioinfusion: Indications";
var content_f5_8_5252=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amnioinfusion: Indications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5252/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5252/contributors\">",
"     Catherine Spong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5252/contributors\">",
"     Michael G Ross, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5252/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5252/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5252/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5252/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/8/5252/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amnioinfusion refers to the instillation of fluid into the amniotic cavity. This procedure is typically performed during labor through an intrauterine catheter introduced transcervically after rupture of the fetal membranes. Rarely, women with oligohydramnios and intact membranes who are not in labor undergo amnioinfusion to improve sonographic visualization of the fetus. For these procedures, fluid is infused through a needle inserted transabdominally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rationale for amnioinfusion is that augmenting amniotic fluid volume may decrease or eliminate problems associated with a severe reduction or absence of amniotic fluid. These problems include an increased risk of umbilical cord compression and its sequelae, an increased risk of meconium aspiration, increased difficulty sonographically visualizing the fetus, impaired ability of the fetus to move and develop normally, and, possibly, an increased risk of chorioamnionitis in women with premature rupture of membranes (PPROM).",
"   </p>",
"   <p>",
"    The indications and contraindications for amnioinfusion will be reviewed here. The technical aspects of the procedure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43203?source=see_link\">",
"     \"Amnioinfusion: Technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1509090\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placenta previa is the major contraindication to transcervical amnioinfusion. The transabdominal route is relatively contraindicated if the needle must traverse an anterior placenta, especially in isoimmunized women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     POTENTIAL INDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Repetitive variable decelerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective use of amnioinfusion is to resolve repetitive variable decelerations related to umbilical cord compression. Relieving cord compression can reduce the occurrence of persistent variable decelerations and thus a reduction in the rate of cesarean delivery for persistent fetal heart rate (FHR) abnormalities.",
"   </p>",
"   <p>",
"    In a meta-analysis of randomized trials comparing amnioinfusion to no amnioinfusion in women with fetuses at risk of umbilical cord compression because of oligohydramnios or variable FHR decelerations, amnioinfusion was associated with a 50 to 60 percent reduction in FHR abnormalities compared to controls [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, there was a significant reduction in the number of cesarean deliveries performed because of a nonreassuring FHR tracing (RR 0.46, 95% CI 0.31-0.68) and an improvement in several neonatal outcomes, including fewer neonates with: umbilical artery pH &lt;7.2 (RR 0.58, 95% CI 0.29-1.14), low one- and five-minute Apgar scores (RR 0.47), and meconium below the vocal cords (RR 0.53, 95% CI 0.31-0.92); however, there was insufficient evidence of a definite reduction in meconium aspiration syndrome (RR 0.14, 95% CI 0.01-2.75). When only transabdominal amnioinfusion was examined, there were similar trends toward a benefit.",
"   </p>",
"   <p>",
"    These benefits appear to be confined to women receiving a therapeutic procedure after the occurrence of FHR abnormalities. It is not known whether the benefits, particularly the reduction in cesarean deliveries, apply to centers that use stringent criteria for performing cesarean delivery. Further research is needed.",
"   </p>",
"   <p>",
"    For women with oligohydramnios, there is no advantage to routine prophylactic amnioinfusion when the FHR tracing is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/2\">",
"     2",
"    </a>",
"    ]. If prophylactic amnioinfusion were performed routinely in women with oligohydramnios to prevent FHR abnormalities, 80 percent of patients would be overtreated as only 20 percent of laboring term patients with oligohydramnios develop moderate or severe variable decelerations in the first stage of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that amnioinfusion has a higher success rate for alleviation of variable decelerations in patients with low pre-amnioinfusion amniotic fluid volume. In patients with a higher amniotic fluid volume (amniotic fluid index &gt;12 cm) and fetal variable heart rate decelerations, a nuchal cord or umbilical cord knot is a more likely cause of the variable pattern than reduced amniotic fluid so amnioinfusion is less likely to be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Meconium stained amniotic fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amnioinfusion has been advocated for women laboring with thick meconium to reduce the incidence of meconium aspiration and meconium below the vocal cords. It is not highly effective to prevent meconium aspiration because a significant proportion of infants with meconium-stained amniotic fluid have meconium within the trachea or bronchioles before meconium passage has been noted by the obstetrical provider and, in some cases, meconium aspiration may have predated labor [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of randomized trials of amnioinfusion for meconium stained amniotic fluid separately analyzed outcomes in settings where standard peripartum surveillance was available versus where it was limited (ie, inability to provide continuous electronic fetal monitoring) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/6\">",
"     6",
"    </a>",
"    ]. Where standard peripartum surveillance was available, amnioinfusion was not associated with a statistically significant reduction in the incidence of meconium aspiration syndrome (RR 0.52, 95% CI 0.26-1.06), perinatal death (RR 1.00, 95% CI 0.29-3.45), or the combined outcome perinatal death or severe morbidity (RR 1.13, 95% CI 0.88-1.47), although the incidence of meconium visualized below the vocal cords was significantly reduced (RR 0.31, 95% CI 0.18-0.53), as was neonatal ventilation or NICU admission (RR 0.45, 95% CI 0.23-0.90). However, in low resource settings with limited ability to diagnose fetal distress during labor and intervene effectively, amnioinfusion had a greater impact on reduction of meconium aspiration syndrome (RR 0.25, 95% CI 0.13 to 0.47) and perinatal mortality (RR 0.37, 95% CI 0.13-1.01).",
"   </p>",
"   <p>",
"    The authors concluded that amnioinfusion for meconium staining is associated with substantive improvements in perinatal outcome only in settings where facilities for perinatal surveillance are limited. In such settings, it is not clear whether the benefits are due to dilution of meconium or relief of oligohydramnios and subsequent cord compression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18648?source=see_link\">",
"     \"Prevention and management of meconium aspiration syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fetal survey in severe oligohydramnios",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic amnioinfusion (most often performed transabdominally) can facilitate sonographic fetal imaging and increase diagnostic precision in the setting of severe oligohydramnios. It is a reasonable option when the information obtained is likely to affect pregnancy management.",
"   </p>",
"   <p>",
"    In a review of patients with unexplained midtrimester oligohydramnios who underwent diagnostic antenatal amnioinfusion, the overall rate of adequate visualization of fetal structures improved from 51 to 77 percent after amnioinfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/7\">",
"     7",
"    </a>",
"    ]. In fetuses with preinfusion-identified obstructive uropathy, there was also an improvement (from 12 to 31 percent) in the identification of associated anomalies. Another study reported that information obtained at amnioinfusion led to a change of etiologic diagnosis in 13 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Failed external cephalic version",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transabdominal amnioinfusion has been used to facilitate external cephalic version. In one study, version after amnioinfusion was successful in a series of six patients who had previously failed the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/9\">",
"     9",
"    </a>",
"    ]. However, in another similar series, version after amnioinfusion was unsuccessful in all seven patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/10\">",
"     10",
"    </a>",
"    ]. Large randomized trials are needed to define the risks and true success rate of this procedure. We feel there are inadequate data to recommend amnioinfusion for this indication [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8281?source=see_link\">",
"     \"External cephalic version\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Preterm premature rupture of membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not perform prophylactic antepartum amnioinfusion in pregnancies with preterm premature rupture of membranes (PPROM). Although benefits such as reduction in pulmonary hypoplasia, prolongation of the latency period, and improved neonatal outcomes have been described, the available data are limited to a few small randomized trials of low quality &nbsp;and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5252/abstract/12\">",
"     12",
"    </a>",
"    ] . Furthermore, amnioinfusion is successful in maintaining adequate amniotic fluid in only about one-third of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amnioinfusion (instillation of fluid into the amniotic cavity via a catheter) is an effective method for eliminating repetitive variable decelerations in laboring patients. Therapeutic amnioinfusion performed in women with recurrent variable decelerations reduces the number of cesarean deliveries performed for fetal heart rate abnormalities. However, this benefit may not apply to centers that use stringent criteria for fetal decompensation, such as documentation of a low fetal pH, prior to proceeding to cesarean delivery.",
"      <br/>",
"      <br/>",
"      For women with recurrent intrapartum variable decelerations where there are no available ancillary measures to ascertain absence of fetal acidosis, we suggest amnioinfusion before resorting to cesarean delivery for a Category II fetal heart rate tracing that includes repetitive variable decelerations (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Repetitive variable decelerations'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For women with oligohydramnios, prophylactic amnioinfusion before fetal heart rate abnormalities occur confers no advantage over therapeutic amnioinfusion after the development of an abnormal fetal heart rate pattern. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Repetitive variable decelerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with meconium stained amniotic fluid who can be monitored with electronic fetal heart rate monitoring, amnioinfusion does not reduce the risk of meconium aspiration syndrome. Amnioinfusion is a reasonable option in low resource settings with limited facilities to diagnose fetal distress during labor and intervene effectively. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Meconium stained amniotic fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When severe oligohydramnios is present and a congenital anomaly is suspected, diagnostic amnioinfusion (most often performed transabdominally) can facilitate sonographic fetal imaging of congenital anomalies. Amnioinfusion is a reasonable option when the information is likely to affect pregnancy management (eg, pregnancy termination, referral to a tertiary center for delivery). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Fetal survey in severe oligohydramnios'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with failed external cephalic version, amnioinfusion does not facilitate success during a repeat procedure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Failed external cephalic version'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with preterm premature rupture of membranes (PPROM), prophylactic antepartum amnioinfusion does not clearly improve neonatal outcome. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Preterm premature rupture of membranes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/1\">",
"      Hofmeyr GJ, Lawrie TA. Amnioinfusion for potential or suspected umbilical cord compression in labour. Cochrane Database Syst Rev 2012; 1:CD000013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/2\">",
"      Novikova N, Hofmeyr GJ, Essilfie-Appiah G. Prophylactic versus therapeutic amnioinfusion for oligohydramnios in labour. Cochrane Database Syst Rev 2012; 9:CD000176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/3\">",
"      Ogundipe OA, Spong CY, Ross MG. Prophylactic amnioinfusion for oligohydramnios: a reevaluation. Obstet Gynecol 1994; 84:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/4\">",
"      Spong CY, McKindsey F, Ross MG. Amniotic fluid index predicts the relief of variable decelerations after amnioinfusion bolus. Am J Obstet Gynecol 1996; 175:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/5\">",
"      Ross MG. Meconium aspiration syndrome--more than intrapartum meconium. N Engl J Med 2005; 353:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/6\">",
"      Hofmeyr GJ, Xu H. Amnioinfusion for meconium-stained liquor in labour. Cochrane Database Syst Rev 2010; :CD000014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/7\">",
"      Pryde PG, Hallak M, Lauria MR, et al. Severe oligohydramnios with intact membranes: an indication for diagnostic amnioinfusion. Fetal Diagn Ther 2000; 15:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/8\">",
"      Fisk NM, Ronderos-Dumit D, Soliani A, et al. Diagnostic and therapeutic transabdominal amnioinfusion in oligohydramnios. Obstet Gynecol 1991; 78:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/9\">",
"      Benifla JL, Goffinet F, Darai E, Madelenat P. Antepartum transabdominal amnioinfusion to facilitate external cephalic version after initial failure. Obstet Gynecol 1994; 84:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/10\">",
"      Adama van Scheltema PN, Feitsma AH, Middeldorp JM, et al. Amnioinfusion to facilitate external cephalic version after initial failure. Obstet Gynecol 2006; 108:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/11\">",
"      Cluver C, Hofmeyr GJ, Gyte G, et al. Interventions for helping to turn term breech babies to head first presentation when using external cephalic version. Cochrane Database Syst Rev 2011; :CD000184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5252/abstract/12\">",
"      Porat S, Amsalem H, Shah PS, Murphy KE. Transabdominal amnioinfusion for preterm premature rupture of membranes: a systematic review and metaanalysis of randomized and observational studies. Am J Obstet Gynecol 2012; 207:393.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5394 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-6A12EA632A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5252=[""].join("\n");
var outline_f5_8_5252=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1509090\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      POTENTIAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Repetitive variable decelerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Meconium stained amniotic fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fetal survey in severe oligohydramnios",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Failed external cephalic version",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43203?source=related_link\">",
"      Amnioinfusion: Technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8281?source=related_link\">",
"      External cephalic version",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18648?source=related_link\">",
"      Prevention and management of meconium aspiration syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_8_5253="Frovatriptan: Patient drug information";
var content_f5_8_5253=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Frovatriptan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/55/9077?source=see_link\">",
"     see \"Frovatriptan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Frova&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6761883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Frova&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A very bad and sometimes deadly health problem called serotonin syndrome may happen. The risk may be greater if you take this drug with certain other drugs. Call your doctor right away if you have dizziness, very bad headache, agitation, hallucinations, fever, fast heartbeat, a heartbeat that does not feel normal, flushing, seizures, shakiness, sweating a lot, change in balance, change in thinking clearly and with logic, very bad upset stomach and throwing up, or very bad loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to frovatriptan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703469",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Chest pain or pressure, diseased arteries going to the legs, heart attack, heart disease, liver disease, poor bowel blood flow, stroke, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using this drug to stop you from getting migraine headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703844",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken almotriptan, eletriptan, naratriptan, rizatriptan, sumatriptan, or zolmitriptan in the last 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken ergotamine, methysergide, or dihydroergotamine in the last 24 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Agitation, twitching, sweating, or muscle stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache or if headache is not better after the first dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or bloody loose stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695908",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with liquids as early as you can after the attack has started.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695208",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your headache comes back after the first dose, 1 more dose may be taken 2 hours after the first one.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12500 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-06EB330AA9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5253=[""].join("\n");
var outline_f5_8_5253=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174639\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6761883\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020881\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020883\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020882\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020887\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020888\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020890\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020885\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020886\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020891\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020892\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/55/9077?source=related_link\">",
"      Frovatriptan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_8_5254="Fibrin sealant kit: Drug information";
var content_f5_8_5254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fibrin sealant kit: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16342178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Air/Gas Embolus Associated With Fibrin Sealant Spray - Canadian Product Labeling Updated",
"     </span>",
"     <span class=\"collapsible-date\">",
"      March 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has announced that manufacturers of fibrin sealant sprays will strengthen the product labeling to to ensure proper use of the devices. The announcement follows reports occurring outside of Canada of air/gas embolus (including 3 fatalities) with spray application of fibrin sealants. Risk of an air air/gas embolism increases when these products are sprayed too close to tissue or if the maximum recommended pressure is exceeded.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at the following website: file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26173a-eng.php",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Artiss;",
"     </li>",
"     <li>",
"      Evicel&trade;;",
"     </li>",
"     <li>",
"      TachoSil&reg;;",
"     </li>",
"     <li>",
"      Tisseel",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F136488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tisseel",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Blood Product Derivative;",
"     </li>",
"     <li>",
"      Hemostatic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adjunct to hemostasis:",
"     </b>",
"     Apply topically in an even, thin layer (do not inject intravascularly); actual dose is based on size of surface to be covered:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Evicel&trade;:",
"     </i>",
"     Spray or drop onto surface of bleeding tissue in short bursts (0.1-0.2 mL); if hemostatic effect is not complete, apply a second layer. To cover a layer of 1 mm thickness:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Maximum area to be sealed: 20 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Required size of Evicel&trade;: 2 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Maximum area to be sealed: 40 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Required size of Evicel&trade;: 4 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Maximum area to be sealed: 100 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Required size of Evicel&trade;: 10 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      TachoSil&reg;:",
"     </i>",
"     Apply patch to surface of bleeding tissue only. The number of patches applied is determined by the size of the bleeding area. Do not exceed the following maximums:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Patch size: 9.5 cm x 4.8 cm; maximum patches to be applied: 7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Patch size: 4.8 cm x 4.8 cm; maximum patches to be applied: 14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Patch size: 3.0 cm x 2.5 cm; maximum patches to be applied: 42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Tisseel:",
"     </i>",
"     Package size to be used is determined by the size of the surface to be covered. Apply in think layer to completely cover the application area.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum area to be sealed: 8 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Required package size of Tisseel: 2 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum area to be sealed: 16 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Required package size of Tisseel: 4 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum area to be sealed: 40 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Required package size of Tisseel: 10 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Autologous skin graft adherence:",
"     </b>",
"     <i>",
"      Artiss:",
"     </i>",
"     Apply by spraying topically in an even, thin layer over the wound bed immediately prior to applying graft (do not inject intravascularly); actual dose is based on size of surface to be covered:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Approximate graft fixation area: 100 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Required size of Artiss: 2 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Approximate graft fixation area: 200 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Required size of Artiss: 4 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Approximate graft fixation area: 500 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Required size of Artiss: 10 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Tissue flap adherence during facial rhytidectomy (facelift) surgery:",
"     </b>",
"     <i>",
"      Artiss:",
"     </i>",
"     Adults: Apply by spraying topically in an even, thin layer over the wound bed immediately prior to attaching the skin flap (do not inject intravascularly); actual dose is based on size of surface to be covered:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Approximate graft fixation area: 100 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Required size of Artiss: 2 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Approximate graft fixation area: 200 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Required size of Artiss: 4 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Approximate graft fixation area: 500 cm",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Required size of Artiss: 10 mL",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F136496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adjunct to hemostasis:",
"     </b>",
"     Topical (Evicel&trade;): Children &gt;6 months: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Autologous skin graft adherence:",
"     </b>",
"     Topical (Artiss): Children &ge;1 year: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Kit:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Artiss:  Solution, topical:  Fibrinogen 67-106 mg/mL and thrombin 2.5-6.5 units/mL (2 mL, 4 mL, 10 mL) [contains albumin (human), aprotinin, polysorbate 80; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Tisseel:  Powder for solution, topical: Fibrinogen 67-106 mg/mL and thrombin 400-625 units/mL (2 mL, 4 mL, 10 mL) [contains albumin (human), aprotinin, polysorbate 80; packaged with reconstituting solutions]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Tisseel:  Solution, topical: Fibrinogen 67-106 mg/mL and thrombin 400-625 units/mL (2 mL, 4 mL, 10 mL) [contains albumin (human), aprotinin, polysorbate 80; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Kit [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Evicel&trade;:  Solution, topical:  Fibrinogen 55-85 mg/mL and thrombin 800-1200 units/mL (2 mL, 4 mL, 10 mL) [contains albumin (human)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Patch, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     TachoSil&reg;:  Fibrinogen 3.6-7.4 mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     and thrombin 1.3-2.7 units/cm",
"     <sup>",
"      2",
"     </sup>",
"     (1s) [contains albumin (human), collagen (equine); 4.8 cm x 4.8 cm]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     TachoSil&reg;:  Fibrinogen 3.6-7.4 mg/cm",
"     <sup>",
"      2",
"     </sup>",
"     and thrombin 1.3-2.7 units/cm",
"     <sup>",
"      2",
"     </sup>",
"     (2s) [contains albumin (human), collagen (equine); 9.5 cm x 4.8 cm]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15804798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evarrest&trade; (fibrin sealant patch): FDA approved December 2012; limited distribution to select facilities expected in mid-December 2012 with full availability expected by the end of 2013. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Artiss: Apply using a painting motion in a thin layer to dry wound surface using Easyspray and Spray set (areas covered with fibrin sealant will appear to &ldquo;glisten&rdquo;). Immediately attach flap or skin graft; approximate time available for manipulation/positioning is 60 seconds. Hold graft in position with gentle compression for at least 3 minutes; full adherence is achieved in ~2 hours. To prevent sealant from adhering to gloves, wet them with saline prior to contact.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Evicel&trade;: Solution should be sprayed or dripped on the tissue to produce an even, thin layer. Application with provided device allows for the simultaneous application of both solutions. Apply spray with provided air tube; distance between nozzle and tissue surface should be 10-15 cm. Apply drops keeping applicator close to, but not touching tissue surface; do not inject directly into circulatory system.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     TachoSil&reg;: The outer aluminum foil pouch may be opened in a nonsterile environment; the inner sterile blister",
"     <b>",
"      must",
"     </b>",
"     be opened in a sterile environment. Apply the yellow, active side directly to the bleeding tissue either wet or dry. If applied wet, premoisten patch in NS for &le;1 minute, then apply immediately. After applying, hold in place with gentle compression through moistened gloves or moistened pad for at least 3 minutes. To prevent inactive side of patch from adhering to pad or gloves, moisten with saline solution. Once patch adheres, leave in place. Handle unattached patches with care to either reposition or remove.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tisseel: Apply in thin layers to avoid excess formation of granulation tissue and slow absorption of the sealant. Following application, hold the sealed parts in the desired position for 3-5 minutes. To prevent sealant from adhering to gloves or surgical instruments, wet them with saline prior to contact.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Artiss: Aid in adhering autologous skin grafts in burn patients or tissue flaps during facial rhytidectomy surgery (facelift) (not indicated for hemostasis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Evicel&trade;: Adjunct to hemostasis in surgery when control of bleeding by conventional surgical techniques is ineffective or impractical",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     TachoSil&reg;: Adjunct to hemostasis in cardiovascular surgery when control of bleeding by conventional surgical technique is ineffective or impractical",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tisseel: Adjunct to hemostasis in cardiopulmonary bypass surgery (including fully heparinized patients) and splenic injury (due to blunt or penetrating trauma to the abdomen) when the control of bleeding by conventional surgical techniques is ineffective or impractical; adjunctive sealant for closure of colostomies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F12807190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Serious and fatal air or gas embolisms have occurred during or after fibrin sealant application using air or gas pressurized spray devices, particularly when used improperly. Manufacturer directions should be followed closely to ensure safe use of spray devices.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be related to aprotinin contained in some products. Frequency may vary by product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Bradycardia (&le;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fever (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Hematoma/seroma (Artiss: Facial rhytidectomy: 1% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Skin graft failure (Artiss: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life threatening): Angioedema, bronchospasm, hypersensitivity (including anaphylactoid or anaphylactic reactions), cardiac arrest, chest discomfort, chills, D-Dimer levels increased, dermal cyst, dyspnea, edema, erythema, flushing, hemorrhage, hyper-/hypotension, hyperventilation, impaired healing, laryngeal edema, paralysis, paresthesia, pulmonary embolism (post procedural), renal failure, respiratory distress, seroma, shock, tachycardia, tachypnea, thromboembolic complications, urticaria, wheezing, wound abscess (facial rhytidectomy)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artiss: Hypersensitivity to aprotinin; direct intravascular injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Evicel&trade;: Anaphylactic or severe systemic reaction to human blood products; severe or brisk arterial bleeding; direct intravascular injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     TachoSil&reg;: Hypersensitivity to human blood products or horse protein; intravascular application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tisseel: Hypersensitivity to aprotinin; direct intravascular injection; severe or brisk arterial bleeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Cases of hypersensitivity or allergic/anaphylactoid reactions which may progress to severe anaphylaxis have been reported (rarely) with use; risk may increase with repetitive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alcohol, iodine, or heavy-metal ions: Exposure to any of these solutions may denature fibrinogen and thrombin proteins; if any were used, thoroughly rinse area before applying fibrin sealant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Artiss: May contain aprotinin (synthetic source). Product is not indicated for hemostasis and should not be used for that purpose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human plasma: Components of fibrin sealant are made from human plasma and theoretically may potentially transmit disease. Any infection suspected of being transmitted by this product should be reported to the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; TachoSil&reg; patch: May contain equine collagen; use contraindicated in patients with hypersensitivity to horse protein. Do not leave product in an infected or contaminated space due to potential for infection exacerbation. Do not over-pack when applying product in closed spaces or cavities; may compress underlying tissue. Do not use product in renal pelvis or ureter procedures (risk for calculus formation) or in the closure of skin incisions (may interfere with wound healing).  Not for use in the treatment of severe or brisk arterial bleeding or in neurosurgical procedures; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tisseel: May contain aprotinin (synthetic source). Do not use with oxycellulose-containing preparations; may decrease efficacy. Safety and efficacy in neurologic procedures (or other procedures within a confined space) have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For topical use only; do not inject or apply intravascularly; inadvertent intravascular administration may result in serious or life-threatening thromboembolic or allergic/anaphylactoid reaction. Use only the minimum amount necessary for hemostasis; excessive use may decrease efficacy and interfere with wound healing. Air or gas embolism has occurred when using spray devices with pressure regulators to apply fibrin sealants; risk of embolism appears to be related to using higher than recommended pressures or administering closer than the recommended distance from tissue surface.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7262223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16570843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if fibrin sealant is excreted into breast milk. The manufacturer recommends that caution be exercised when administering fibrin sealant to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Evicel External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mL (4 mL): $336.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mL (10 mL): $773.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Tisseel VH External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mL (1): $188.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mL (1): $312.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mL (1): $779.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch",
"     </b>",
"     (TachoSil External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.8 X 4.8 cm (2): $1041.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9.5 X 4.8 cm (1): $888.01",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F136481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tisseel Duo 500 (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Formation of a biodegradable adhesive is done by duplicating the last step of the coagulation cascade, the formation of fibrin from fibrinogen. Fibrinogen is the main component of the sealant solution. The solution also contains thrombin, which transforms fibrinogen from the sealer protein solution into fibrin, and fibrinolysis inhibitor (aprotinin), which prevents the premature degradation of fibrin. When mixed as directed, a viscous solution forms that sets into an elastic coagulum.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Artiss: Full adherence achieved: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Time to hemostasis: Evicel&trade;: 4-10 minutes; TachoSil&reg;: 6 minutes; Tisseel: 5 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Beierlein W, Scheule AM, Antoniadis G, et al, &ldquo;An Immediate, Allergic Skin Reaction to Aprotinin After Reexposure to Fibrin Sealant,&rdquo;",
"      <i>",
"       Transfusion",
"      </i>",
"      , 2000, 40 (3):302-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/8/5254/abstract-text/10738030/pubmed\" id=\"10738030\" target=\"_blank\">",
"        10738030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foster K, Greenhalgh D, Gamelli RL, et al, &ldquo;Efficacy and Safety of a Fibrin Sealant for Adherence of Autologous Skin Grafts to Burn Wounds: Results of a Phase 3 Clinical Study,&rdquo;",
"      <i>",
"       J Burn Care Res",
"      </i>",
"      , 2008, 29(2):293-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/8/5254/abstract-text/18354285/pubmed\" id=\"18354285\" target=\"_blank\">",
"        18354285",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shirai T, Shimota H, Chida K, et al, &ldquo;Anaphylaxis to Aprotinin in Fibrin Sealant,&rdquo;",
"      <i>",
"       Intern Med",
"      </i>",
"      , 2005, 44(10): 1088-9.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8941 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.81.197.98-FD66CD12EC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5254=[""].join("\n");
var outline_f5_8_5254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342178\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136487\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136488\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136500\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136490\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136496\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136491\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136473\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136462\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15804798\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136475\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136474\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807190\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136498\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136478\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136466\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299331\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136469\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136471\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136480\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7262223\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570843\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322998\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136481\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136465\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136477\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8941|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_8_5255="Trimethoprim: Pediatric drug information";
var content_f5_8_5255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trimethoprim: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"    see \"Trimethoprim: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/9/146?source=see_link\">",
"    see \"Trimethoprim: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Primsol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Trimethoprim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"      see \"Trimethoprim: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Otitis media, acute:",
"     </b>",
"     Infants &ge;6 months, Children, and Adolescents: Oral: 10 mg/kg/day in divided doses every 12 hours for 10 days; maximum daily dose: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection (uncomplicated), treatment:",
"     </b>",
"     Infants &ge;2 months, Children, and Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Monotherapy:  4-6 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Combination therapy: 6-12 mg/kg/day in 2 divided doses; in combination with sulfamethoxazole (AAP, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"      pneumonia (PCP); treatment:",
"     </b>",
"     Children and Adolescents: Oral: 15 mg/kg/day in 3 divided doses for 21 days; in combination with dapsone (CDC, 2009; CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Urinary tract infection (uncomplicated), treatment:",
"     </b>",
"     Oral: 100 mg every 12 hours or 200 mg every 24 hours for 10 days; alternative duration of 3 days has been recommended (Gupta, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Pneumocystis jirovecii",
"      </i>",
"      pneumonia (PCP); treatment:",
"     </b>",
"     Oral: 15 mg/kg/day in 3 divided doses for 21 days in combination with dapsone (CDC, 2009a)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Manufacturer&rsquo;s recommendation: Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-30 mL/minute: Administer 50% of recommended dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F231446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primsol&reg;: 50 mg/5 mL (473 mL) [dye free, ethanol free; contains propylene glycol, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F231432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer on an empty stomach; may administer with milk or food if GI upset occurs",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); protect from  light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from  light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of otitis media caused by susceptible",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     and",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     (oral solution: FDA approved in pediatric patients &ge;6 months); treatment of urinary tract infections caused by susceptible",
"     <i>",
"      Escherichia coli",
"     </i>",
"     ,",
"     <i>",
"      Proteus mirabilis",
"     </i>",
"     ,",
"     <i>",
"      Klebsiella pneumoniae",
"     </i>",
"     ,",
"     <i>",
"      Enterobacter",
"     </i>",
"     spp, and coagulase-negative",
"     <i>",
"      Staphylococcus",
"     </i>",
"     (including",
"     <i>",
"      S. saprophyticus",
"     </i>",
"     ) (FDA approved in adults). Has also been used in combination with other agents for treatment of",
"     <i>",
"      Pneumocystis jirovecii",
"     </i>",
"     pneumonia (PCP)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F231513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aseptic meningitis (rare), fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema multiforme (rare), exfoliative dermatitis (rare), maculopapular rash, phototoxic skin eruptions, pruritus (common), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Epigastric distress, glossitis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, megaloblastic anemia, methemoglobinemia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice (rare), liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Increased BUN and creatinine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to trimethoprim or any component; megaloblastic anemia due to folate deficiency",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal or hepatic function; decrease dose in patients with renal dysfunction. Use with caution in patients with potential folate deficiency (malnourished, chronic anticonvulsant therapy, or elderly). Due to resistance, should not be used for treatment of acute otitis media caused by",
"     <i>",
"      Moraxella catarrhalis",
"     </i>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause folate deficiencies with subsequent bone marrow suppression and blood dyscrasias; monitor patients for fever, sore throat, purpura, or pallor; obtain CBC if any of these symptoms occur; risk may be increased with high dose or prolonged use; discontinue trimethoprim if bone marrow depression occurs; leucovorin calcium may be needed to restore normal hematopoiesis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral solution contains propylene glycol and sodium benzoate. Benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.  In neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression. Avoid use of trimethoprim products containing sodium benzoate and propylene glycol in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2C9 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Trimethoprim may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amantadine: Trimethoprim may enhance the adverse/toxic effect of Amantadine. Specifically, the risk of myoclonus and/or delirium may be increased. Amantadine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Amantadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Trimethoprim may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Trimethoprim may decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: Trimethoprim may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): May increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Dapsone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Trimethoprim may enhance the adverse/toxic effect of Dapsone (Topical). More specifically, trimethoprim may increase the risk for hemolysis",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Trimethoprim may decrease the excretion of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Trimethoprim may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Trimethoprim may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: Trimethoprim may decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leucovorin Calcium-Levoleucovorin: May diminish the therapeutic effect of Trimethoprim. Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Memantine: Trimethoprim may enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Memantine may increase the serum concentration of Trimethoprim. Trimethoprim may increase the serum concentration of Memantine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mercaptopurine: Trimethoprim may enhance the myelosuppressive effect of Mercaptopurine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Trimethoprim may increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Trimethoprim may enhance the adverse/toxic effect of Methotrexate.  Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Trimethoprim may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Trimethoprim may increase the serum concentration of PRALAtrexate. More specifically, trimethoprim may decrease excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum level and/or possible toxicity with concomitant use of trimethoprim. Monitor for decreased pralatrexate levels with discontinuation of trimethoprim.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Procainamide: Trimethoprim may increase serum concentrations of the active metabolite(s) of Procainamide. Trimethoprim may increase the serum concentration of Procainamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Trimethoprim may decrease the metabolism of Repaglinide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: Trimethoprim may enhance the hyperkalemic effect of Spironolactone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varenicline: Trimethoprim may increase the serum concentration of Varenicline.  Management: Monitor for increased varenicline adverse effects with concomitant use of trimethoprim, particularly in patients with severe renal impairment. International product labeling recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause folic acid deficiency, supplements may be needed",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F231443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F231457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse effects have been observed in animals, trimethoprim is classified pregnancy category C. Trimethoprim crosses the placenta and can be detected in the fetal serum and amniotic fluid. Due to trimethoprim&rsquo;s potential effect on folic acid metabolism, TMP should only be used during pregnancy if the benefit justifies the potential risk. The use of dihydrofolate reductase inhibitors, including trimethoprim, during pregnancy may increase the risk of congenital anomalies including cardiovascular defects, oral clefts, urinary tract anomalies, and neural tube defects. Folic acid supplementation may decrease this risk. The majority of studies evaluating the effects of trimethoprim administration in pregnancy have been conducted with sulfamethoxazole/trimethoprim. Trimethoprim in combination with sulfamethoxazole is used in pregnancy for various indications (see the sulfamethoxazole/trimethoprim monograph for details).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, liver enzyme tests, bilirubin, serum potassium, serum creatinine and BUN",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1055906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak: 5-15 mg/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Trough: 2-8 mg/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to the enzyme dihydrofolate reductase in bacteria and inhibits conversion of dihydrofolic acid to tetrahydrofolate (functional form of folic acid). This results in depletion of folic acid, interference with bacterial biosynthesis of nucleic acids and protein production, and inhibition of microbial growth.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Readily and extensively absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Penetrates into middle ear fluid with a mean peak middle ear fluid concentration in children 1-12 years of 2 mcg/mL after a single 4 mg/kg dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Newborns: ~2.7 L/kg (range: 1.3-4.1 hours) (Springer, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants:1.5 L/kg (Hoppu, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 1-10 years: 0.86-1 L/kg (Hoppu, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: ~1.3 (Hoppu, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~44%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic (10% to 20%)  via demethylation, oxidation, and hydroxylation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Similar for tablets and solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: ~19 hours; range: 11-27 hours (Springer, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants 2 months to 1 year: ~4.6 hours; range: 3-6 hours  (Hoppu, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-10 years: 3.7-5.5 hours (Hoppu, 1987)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, normal renal function: 8-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Significantly excreted in urine (50% to 60%); 80% as unchanged drug via glomerular filtration and tubular secretion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/9/146?source=see_link\">",
"      see \"Trimethoprim: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report any skin rash, persistent or severe fatigue, fever, sore throat, or unusual bleeding or bruising; complete full course of therapy",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (10 mg/mL [dye free, ethanol free; contains propylene glycol, sodium benzoate; bubblegum flavor])",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 10 mg/mL oral suspension may be made with tablets. Crush ten 100 mg tablets in a mortar and reduce to a fine powder. Add 20 mL of a 1:1 mixture of Simple Syrup, NF, and Methylcellulose 1% and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     100 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 100 mL. Label \"shake well\" and \"refrigerate\". Stable for 91 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, &ldquo;Practice Parameter: The Diagnosis, Treatment, and Evaluation of the Initial Urinary Tract Infection in Febrile Infants and Young Children. American Academy of Pediatrics, Committee on Quality Improvement, Subcommittee on Urinary Tract Infection,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1999, 103(4 Pt 1):843-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/8/5255/abstract-text/10103321/pubmed\" id=\"10103321\" target=\"_blank\">",
"        10103321",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations From CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/8/5255/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(4):1-207.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta K, Hooton TM, Naber KG, et al, &ldquo;International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 52(5):e103-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/8/5255/abstract-text/21292654/pubmed\" id=\"21292654\" target=\"_blank\">",
"        21292654",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppu K, &ldquo;Age Differences in Trimethoprim Pharmacokinetics: Need for Revised Dosing in Children?&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1987, 41(3):336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/8/5255/abstract-text/3816021/pubmed\" id=\"3816021\" target=\"_blank\">",
"        3816021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppu K, \"Changes in Trimethoprim Pharmacokinetics After the Newborn Period,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1989, 64(3):343-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/8/5255/abstract-text/2705795/pubmed\" id=\"2705795\" target=\"_blank\">",
"        2705795",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Springer C, Eyal F, and Michel J, \"Pharmacology of Trimethoprim-Sulfamethoxazole in Newborn Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1982, 100(4):647-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/8/5255/abstract-text/7062219/pubmed\" id=\"7062219\" target=\"_blank\">",
"        7062219",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12865 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5255=[""].join("\n");
var outline_f5_8_5255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231470\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231471\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055903\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055895\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231446\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231432\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055908\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055899\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055907\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231513\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055911\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055894\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055893\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231504\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231441\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055914\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231443\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231457\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055902\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055906\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055892\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055910\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055901\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806706\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12865\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12865|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=related_link\">",
"      Trimethoprim: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/9/146?source=related_link\">",
"      Trimethoprim: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_8_5256="Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma";
var content_f5_8_5256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of enteropathy-associated T cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5256/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5256/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5256/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5256/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5256/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5256/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/8/5256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of generally aggressive neoplasms that constitute less than 15 percent of all non-Hodgkin lymphomas (NHLs) in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among these, in decreasing frequency of occurrence, are [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Peripheral T cell lymphoma, not otherwise specified",
"     </li>",
"     <li>",
"      Anaplastic large cell lymphoma, primary systemic type",
"     </li>",
"     <li>",
"      Angioimmunoblastic T cell lymphoma",
"     </li>",
"     <li>",
"      Extranodal",
"      <span class=\"nowrap\">",
"       NK/T",
"      </span>",
"      cell lymphoma, nasal type",
"     </li>",
"     <li>",
"      Subcutaneous panniculitis-like T cell lymphoma",
"     </li>",
"     <li>",
"      Enteropathy associated T cell lymphoma",
"     </li>",
"     <li>",
"      Hepatosplenic T cell lymphoma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enteropathy associated T cell lymphoma (EATL), also called enteropathy type T cell lymphoma, is a T cell lymphoma that arises in the gastrointestinal tract and is highly associated with celiac disease (gluten-sensitive enteropathy). This entity was originally mistakenly termed \"malignant histiocytosis of the intestine,\" due to the unusual immunophenotype of the tumor cells and initial recognition of a morphologic variant of the disease comprised of large \"histiocytic\" cells, but it is now clear that these tumors arise from intestinal intraepithelial cytotoxic T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation, pathologic features, and diagnosis of EATL will be reviewed here. The treatment of EATL and issues related to other PTCLs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Enteropathy-associated T cell intestinal lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link\">",
"     \"Initial treatment of peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EATL is a rare tumor that accounts for less than 5 percent of all gastrointestinal lymphomas and less than 1 percent of all non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/3\">",
"     3",
"    </a>",
"    ]. It is most commonly found in adults from geographic areas with a high incidence of celiac disease, such as the western part of Ireland, Italy, France [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/4\">",
"     4",
"    </a>",
"    ], and Northern Europe. In the Netherlands, for example, the incidence of EATL is approximately 0.10 per 100,000 person years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/5\">",
"     5",
"    </a>",
"    ]. The mean age at diagnosis is 60 to 65 years and 55 to 65 percent of cases are diagnosed in men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/3,6\">",
"     3,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Prevalence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A subset of patients with EATL has a monomorphic variant (type II EATL). This variant does not appear to be associated with celiac disease and therefore has a broader geographic distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Subclassification'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with untreated celiac disease have a substantially increased risk of developing EATL, especially among those diagnosed at an older age (ie, over age 33 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/8\">",
"     8",
"    </a>",
"    ]. Management of celiac disease with a gluten-free diet effectively prevents the development of EATL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/9\">",
"     9",
"    </a>",
"    ]. EATL only rarely develops in patients diagnosed with celiac disease early in life (presumably because of effective intervention) and patients with EATL rarely have a long clinical history of celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Similarly, patients with positive celiac disease serology and normal mucosa on biopsy (ie, latent celiac disease) do not appear to have an increased incidence of EATL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/12\">",
"     12",
"    </a>",
"    ]. The basis for the strong association of EATL with celiac disease is unknown; both antigen-driven T cell proliferation and less specific pro-proliferative effects of chronic inflammation are plausible possibilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients typically present with abdominal pain, often associated with intestinal (jejunal) obstruction, perforation, or bleeding. Less common presentations include symptoms of celiac disease or the clinical deterioration of celiac disease despite compliance with a gluten-free diet [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An international series of 62 patients with EATL reported the following clinical findings at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain &mdash; 88 percent",
"     </li>",
"     <li>",
"      Systemic B symptoms",
"      <span class=\"nowrap\">",
"       (fever/chills,",
"      </span>",
"      weight loss, night sweats) &mdash; 63 percent",
"     </li>",
"     <li>",
"      Fatigue &mdash; 38 percent",
"     </li>",
"     <li>",
"      Infection &mdash; 23 percent",
"     </li>",
"     <li>",
"      Adenopathy &mdash; 15 percent",
"     </li>",
"     <li>",
"      Hepatomegaly &mdash; 6 percent",
"     </li>",
"     <li>",
"      Splenomegaly &mdash; 6 percent",
"     </li>",
"     <li>",
"      Pruritus &mdash; 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority presented with stage IV disease (64 percent). Bone marrow involvement (3 percent) was unusual and most patients had serum levels of lactate dehydrogenase, calcium, and C-reactive protein that were within normal limits.",
"   </p>",
"   <p>",
"    Many patients are diagnosed with celiac disease at the time of presentation with EATL. A history of childhood onset celiac disease is uncommon. Signs and symptoms of celiac disease include steatorrhea, flatulence, stomach distension, weight loss, severe anemia, neurologic disorders, and osteopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of celiac disease in adults\", section on 'Nonresponders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EATL most commonly involves the proximal jejunum and less frequently involves the rest of the small intestine, stomach, or colon [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Less commonly, the tumor can involve the liver, spleen, lymph nodes, and other viscera such as the gallbladder. Involvement of the lung, skin, or soft tissues is rare.",
"   </p>",
"   <p>",
"    The international series described above of 62 patients with EATL reported the following sites of involvement at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small intestine &mdash; 90 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Mesenteric/intra-abdominal",
"      </span>",
"      lymph nodes &mdash; 35 percent",
"     </li>",
"     <li>",
"      Large intestine &mdash; 16 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Para-aortic/iliac",
"      </span>",
"      lymph nodes &mdash; 11 percent",
"     </li>",
"     <li>",
"      Stomach &mdash; 8 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Inguinal/femoral",
"      </span>",
"      lymph nodes &mdash; 6 percent",
"     </li>",
"     <li>",
"      Other sites were each involved in &le;5 percent of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;On gross examination of the intestine, multiple, circumferentially-oriented jejunal ulcers are typically present and are often associated with gut perforation. There may or may not be a mass [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tumor cells invade the intestinal wall and contain a variable admixture of small,",
"    <span class=\"nowrap\">",
"     medium/mixed,",
"    </span>",
"    and large or anaplastic tumor cells. The cells have a moderate to abundant amount of pale-staining cytoplasm with a round or angulated vesicular nucleus and prominent nucleoli [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/1\">",
"     1",
"    </a>",
"    ]. Early lesions may show mucosal ulceration with only scattered atypical cells and numerous reactive histiocytes, without formation of a large mass; these lesions are nonetheless clonal (",
"    <a class=\"graphic graphic_picture graphicRef64119 \" href=\"UTD.htm?27/48/28426\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76955 \" href=\"UTD.htm?29/23/30074\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Adjacent mucosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mucosa adjacent to the tumor often contains numerous intraepithelial T cells, histiocytes, and eosinophils. Mucosa uninvolved by tumor may or may not show signs of celiac disease including villous atrophy, crypt hyperplasia, an increased number of lymphocytes and plasma cells in the lamina propria, and intraepithelial lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/19\">",
"     19",
"    </a>",
"    ]. Pathologic evidence of celiac disease may depend on the segment analyzed, since in celiac disease, villous atrophy is most prominent in the proximal small intestine and may be absent in the distal jejunum or ileum.",
"   </p>",
"   <p>",
"    Intraepithelial lymphocytes in apparently non-neoplastic mucosa may be clonal, and may represent low-grade precursor lesions to the overt lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of celiac disease\", section on 'Small bowel biopsy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H14\">",
"     'Refractory celiac disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the typical case, tumor cells express pan-T antigens (surface CD7+) and the mucosal lymphoid antigen CD103 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Although CD3 can be detected intracellularly, these cells lack expression of the T cell receptor CD3 complex on the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/23\">",
"     23",
"    </a>",
"    ]. CD4 (11 percent), CD5 (17 percent), and CD8 (43 percent) are expressed in only a minority of cases, an immunophenotype that is identical to that of the intraepithelial lymphocytes, when present [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/6\">",
"     6",
"    </a>",
"    ]. Many cases express cytotoxic T cell-associated proteins (Granzyme B, TIA-1, perforin) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In many cases (37 percent), the large cell component of the tumor is CD30 positive (",
"    <a class=\"graphic graphic_picture graphicRef64119 \" href=\"UTD.htm?27/48/28426\">",
"     picture 1",
"    </a>",
"    ). While some cases demonstrate aberrant expression of cytolytic NK cell lineage receptors, these tumors have T cell receptor rearrangements and are clearly of T cell lineage.",
"   </p>",
"   <p>",
"    Patients with the less common type II EATL (monomorphic variant) express CD3 (95 percent), CD8 (63 percent), CD56 (73 percent), and T cell receptor beta, and do not usually express CD4 (5 percent) (",
"    <a class=\"graphic graphic_picture graphicRef76955 \" href=\"UTD.htm?29/23/30074\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Subclassification'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The T cell receptor beta and T cell receptor gamma genes are clonally rearranged [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. In addition, many patients have a DQA1*0501 or DQB1*0201 HLA haplotype that is commonly associated with celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link&amp;anchor=H7#H7\">",
"     \"Diagnosis of celiac disease\", section on 'Suggestive clinical features but negative serologic tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of EATL tumors have gene amplifications demonstrated by conventional cytogenetics or fluorescence in situ hybridization (FISH). Fifty to 60 percent have complex segmental amplifications of the 9q31.3-qter region [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/27\">",
"     27",
"    </a>",
"    ]. This genetic change is seen in both celiac disease-associated and type II EATL, and is rarely seen in other types of peripheral T cell lymphoma. FISH with probes specific for this region may be helpful in confirming the diagnosis, but the sensitivity and specificity of this genetic abnormality is unknown.",
"   </p>",
"   <p>",
"    Other recurrent chromosomal gains include 1q32 (26 percent), 5q35 (21 percent), 7q22 (31 percent), and 8q24 (18 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/3\">",
"     3",
"    </a>",
"    ]. Some patients will demonstrate a deletion in 16q12 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/1\">",
"     1",
"    </a>",
"    ]. The 1q and 5q abnormalities are more common in classical EATL, while 8q24 abnormalities involving MYC are more often associated with type II EATL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of EATL is most commonly made by the pathologic evaluation of a specimen of small bowel resected because of intestinal obstruction or perforation at the time of presentation (",
"    <a class=\"graphic graphic_table graphicRef55385 \" href=\"UTD.htm?5/61/6109\">",
"     table 1",
"    </a>",
"    ). The pathologic diagnosis is based on the combination of characteristic histologic and immunophenotypic findings cited above, often in the context of T cell clonality, and laboratory and clinical evidence of celiac disease.",
"   </p>",
"   <p>",
"    Since celiac disease is underdiagnosed in certain populations, it has been suggested that patients with a T cell lymphoma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a gut primary localization should be tested for underlying celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/28\">",
"     28",
"    </a>",
"    ]. Sometimes the underlying celiac disease is only appreciated when villous atrophy is observed in the resected intestine adjacent to the tumor, or with the detection of serum IgA EMA (endomysial antibodies), serum IgA tTG (anti-tissue transglutaminase), IgG DGP (deaminated gliadin peptide),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the typical HLA type (DQA1*0501, DQB1*0201) associated with celiac disease following the diagnosis of lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/17,29\">",
"     17,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link&amp;anchor=H17#H17\">",
"     \"Diagnosis of celiac disease\", section on 'Individuals with a moderate or high risk for celiac disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Subclassification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene analysis studies have suggested that there may be two distinct subtypes of EATL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I &mdash; Type I EATL accounts for 80 to 90 percent of cases and is strongly associated with celiac disease. The tumor cells are of variable size and morphology (",
"      <a class=\"graphic graphic_picture graphicRef64119 \" href=\"UTD.htm?27/48/28426\">",
"       picture 1",
"      </a>",
"      ). The adjacent \"normal\" mucosa may or may not demonstrate signs of celiac disease. The tumor cells typically express CD56 and do not express CD8.",
"     </li>",
"     <li>",
"      Type II &mdash; Type II EATL (also known as \"monomorphic\" EATL) accounts for 10 to 20 percent of cases and is less commonly associated with celiac disease. On histology, the tumor cells are monomorphic and small to medium in size with infiltration of the intestinal crypt epithelium (",
"      <a class=\"graphic graphic_picture graphicRef76955 \" href=\"UTD.htm?29/23/30074\">",
"       picture 2",
"      </a>",
"      ). The adjacent \"normal\" mucosa demonstrates villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis. There is no inflammatory background. Tumor cells generally express CD8 and CD56.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis includes refractory celiac disease and other types of T cell lymphomas that present in the gastrointestinal tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Refractory celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of EATL are preceded by a low-grade precursor lesion that clinically resembles refractory celiac disease (refractory sprue). Refractory celiac disease is clinically defined as the persistence of pathologic changes in the intestine consistent with celiac disease despite a strict gluten-free diet for more than 12 months. These pathologic changes include increased intraepithelial lymphocytes, villous atrophy, and crypt hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of celiac disease\", section on 'Small bowel biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of celiac disease in adults\", section on 'Refractory sprue'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cases of refractory celiac disease are commonly divided into two types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I refractory celiac disease &mdash; These lesions typically show no atypia in the intraepithelial lymphocytes, normal surface T cell receptor, CD3 and CD8 expression by intraepithelial T lymphocytes and a polyclonal pattern on T cell receptor gene rearrangement studies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type II refractory celiac disease &mdash; These lesions also have no atypia in the intraepithelial lymphocytes, but demonstrate a loss of surface T cell receptor, CD3, or CD8 expression and may have a monoclonal T cell receptor gene rearrangement [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/26,30\">",
"       26,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical significance of refractory celiac disease type is incompletely understood. While type I refractory celiac disease is unlikely to progress to EATL, type II may be an intermediate entity or precursor lesion to EATL. Imaging with computed tomography, positron emission tomography, and video capsule endoscopy may help to identify cases of refractory celiac disease that have progressed to EATL [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Extranodal NK/T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma is a lymphoma of natural killer (NK) or T cell lineage that most commonly presents with a facial mass. A small percentage of patients may present with gastrointestinal involvement. Because the morphology of the tumor cells is so variable, it is important to consider extranodal",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma in all cases of aggressive extranodal lymphoma associated with vascular invasion and necrosis.",
"   </p>",
"   <p>",
"    The key diagnostic features of",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell lymphoma are the demonstration of",
"    <span class=\"nowrap\">",
"     NK/T",
"    </span>",
"    cell markers (CD2, cytoplasmic CD3, CD56, and cytotoxic granule proteins) and Epstein-Barr virus (EBV), which is uniformly present. In contrast, EATL is not associated with EBV infection and infrequently expresses CD56. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gamma-delta T cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma-delta T cell lymphoma most commonly involves the liver and spleen (hepatosplenic gamma-delta T cell lymphoma), but less commonly involves other areas in the gastrointestinal tract. The diagnosis of gamma-delta T cell lymphoma is usually made based upon biopsy specimens demonstrating infiltrating atypical lymphocytes that express CD2, surface CD3, CD7, and CD16, and do not express CD4, CD5, CD8 or B cell surface markers (eg, CD20). The atypical lymphocytes express",
"    <span class=\"nowrap\">",
"     gamma/delta",
"    </span>",
"    T cell receptors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Like gamma-delta T cell lymphoma, EATLs express pan-T antigens (surface CD3+ CD7+) and do not express CD4, CD5, or CD8. In contrast to gamma-delta T cell lymphoma, EATLs typically express CD103 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The T cell receptor beta gene is clonally rearranged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Anaplastic large cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with anaplastic large cell lymphoma (ALCL) typically present with painless lymphadenopathy. On histology, the tumor is composed of large blastic cells with horseshoe-shaped nuclei, prominent nucleoli, with or without a prominent golgi complex (seen as a paranuclear clearing, or hof) in a cohesive growth pattern. On immunohistochemistry there is a homogeneous and strong expression of CD30 in a membrane and golgi pattern. There is also expression of T cell antigens or no lineage-specific antigens as in the case of the null cell type. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While a subset of patients with EATL may resemble ALCL histologically and express CD30, ALCL is not associated with celiac disease-type symptoms or the presence of the intraepithelial lymphocytic infiltrates in the adjacent \"normal\" mucosa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     B cell lymphomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common types of lymphoma involving the small intestine are of B cell origin, and include marginal B cell lymphoma, diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma, and occasionally, follicular lymphoma. Mantle cell lymphoma and follicular lymphoma often produce multiple polyp-like extensions of the mucosa (lymphomatoid polyposis), a gross appearance that is not seen in EATL. DLBCL and Burkitt lymphoma often produce large masses that may grossly resemble EATL, but are readily distinguishable (like other B cell lymphomas) by their morphologic and immunophenotypic characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of EATL is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Enteropathy-associated T cell intestinal lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=see_link&amp;anchor=H19#H19\">",
"     \"Initial treatment of peripheral T cell lymphoma\", section on 'Enteropathy-associated T cell lymphoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=see_link\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;EATL is an aggressive lymphoma with a poor prognosis. In one large series, the disease stage at presentation was IE, IIE, IIIE, and IV in 10, 21, 5, and 64 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/6\">",
"     6",
"    </a>",
"    ]. While some patients present with limited stage disease, dissemination to the liver, spleen, skin, and other organs is common as the disease progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/3\">",
"     3",
"    </a>",
"    ]. Many patients will die from complications of multifocal intestinal perforation due to refractory malignant ulcers. Occasional patients with localized disease are cured after surgical resection and there are reports of long term survival following hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of gastrointestinal lymphomas\", section on 'Enteropathy-associated T cell intestinal lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An international series of 62 patients with EATL with a median follow-up of 10.5 months reported a median overall survival of 10 months and a failure-free survival of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5256/abstract/6\">",
"     6",
"    </a>",
"    ]. Estimated rates of overall and failure-free survival at five years were 20 and 4 percent, respectively. The International Prognostic Index developed for B cell lymphomas was not a good predictor of prognosis in this population. In contrast, the Prognostic Index for PTCL, unspecified (PIT) could be used to divide the patients into four prognostic groups (",
"    <a class=\"graphic graphic_figure graphicRef53490 \" href=\"UTD.htm?15/25/15775\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Enteropathy associated T cell lymphoma (EATL) is an uncommon T cell lymphoma that arises in the gastrointestinal tract and is highly associated with celiac disease (gluten-sensitive enteropathy). EATL is most commonly diagnosed in adults from geographic areas with a high incidence of celiac disease, such as the western part of Ireland and Northern Europe. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients typically present with abdominal pain, often associated with intestinal (jejunal) obstruction, perforation, or bleeding. Less common presentations include symptoms of celiac disease or the clinical deterioration of celiac disease despite compliance with a gluten-free diet. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      EATL is usually diagnosed by the pathologic evaluation of resected small bowel (",
"      <a class=\"graphic graphic_table graphicRef55385 \" href=\"UTD.htm?5/61/6109\">",
"       table 1",
"      </a>",
"      ). On gross examination there are multiple, circumferentially-oriented jejunal ulcers, often associated with gut perforation. The tumor cells that invade the intestinal wall are variable in size and morphology. Most tumor cells express pan-T antigens (surface CD3+ CD7+) and CD103. CD4, CD5, and CD8 are usually negative. The T cell receptor beta gene is clonally rearranged. Adjacent mucosa may or may not show signs of celiac disease. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/2\">",
"      Isaacson PG, O'Connor NT, Spencer J, et al. Malignant histiocytosis of the intestine: a T-cell lymphoma. Lancet 1985; 2:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/3\">",
"      Zettl A, deLeeuw R, Haralambieva E, Mueller-Hermelink HK. Enteropathy-type T-cell lymphoma. Am J Clin Pathol 2007; 127:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/4\">",
"      Cellier C, Delabesse E, Helmer C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/5\">",
"      Gonzalez CL, Medeiros LJ, Braziel RM, Jaffe ES. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol 1991; 15:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/6\">",
"      Delabie J, Holte H, Vose JM, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood 2011; 118:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/7\">",
"      Deleeuw RJ, Zettl A, Klinker E, et al. Whole-genome analysis and HLA genotyping of enteropathy-type T-cell lymphoma reveals 2 distinct lymphoma subtypes. Gastroenterology 2007; 132:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/8\">",
"      Ekstr&ouml;m Smedby K, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008; 111:4029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/9\">",
"      Silano M, Volta U, Vincenzi AD, et al. Effect of a gluten-free diet on the risk of enteropathy-associated T-cell lymphoma in celiac disease. Dig Dis Sci 2008; 53:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/10\">",
"      Collin P, Reunala T, Pukkala E, et al. Coeliac disease--associated disorders and survival. Gut 1994; 35:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/11\">",
"      Egan LJ, Stevens FM, McCarthy CF. Celiac disease and T-cell lymphoma. N Engl J Med 1996; 335:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/12\">",
"      Elfstr&ouml;m P, Granath F, Ekstr&ouml;m Smedby K, et al. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. J Natl Cancer Inst 2011; 103:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/13\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1996. A 79-year-old woman with anorexia, weight loss, and diarrhea after treatment for celiac disease. N Engl J Med 1996; 334:1316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/14\">",
"      Mantovani G, Esu S, Astara G, et al. Primary T cell CD30-positive anaplastic large-cell lymphoma associated with adult-onset celiac disease and presenting with skin lesions. Acta Haematol 1995; 94:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/15\">",
"      Shiboski CH, Greenspan D, Dodd CL, Daniels TE. Oral T-cell lymphoma associated with celiac sprue. A case report. Oral Surg Oral Med Oral Pathol 1993; 76:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/16\">",
"      Tse E, Gill H, Loong F, et al. Type II enteropathy-associated T-cell lymphoma: a multicenter analysis from the Asia Lymphoma Study Group. Am J Hematol 2012; 87:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/17\">",
"      Gale J, Simmonds PD, Mead GM, et al. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000; 18:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/18\">",
"      Ashton-Key M, Diss TC, Pan L, et al. Molecular analysis of T-cell clonality in ulcerative jejunitis and enteropathy-associated T-cell lymphoma. Am J Pathol 1997; 151:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/19\">",
"      Chott A, Dragosics B, Radaszkiewicz T. Peripheral T-cell lymphomas of the intestine. Am J Pathol 1992; 141:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/20\">",
"      Murray A, Cuevas EC, Jones DB, Wright DH. Study of the immunohistochemistry and T cell clonality of enteropathy-associated T cell lymphoma. Am J Pathol 1995; 146:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/21\">",
"      Spencer J, Cerf-Bensussan N, Jarry A, et al. Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes. Am J Pathol 1988; 132:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/22\">",
"      Meresse B, Curran SA, Ciszewski C, et al. Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med 2006; 203:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/23\">",
"      Tjon JM, Verbeek WH, Kooy-Winkelaar YM, et al. Defective synthesis or association of T-cell receptor chains underlies loss of surface T-cell receptor-CD3 expression in enteropathy-associated T-cell lymphoma. Blood 2008; 112:5103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/24\">",
"      Daum S, Foss HD, Anagnostopoulos I, et al. Expression of cytotoxic molecules in intestinal T-cell lymphomas. The German Study Group on Intestinal Non-Hodgkin Lymphoma. J Pathol 1997; 182:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/25\">",
"      de Bruin PC, Connolly CE, Oudejans JJ, et al. Enteropathy-associated T-cell lymphomas have a cytotoxic T-cell phenotype. Histopathology 1997; 31:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/26\">",
"      Verbeek WH, Goerres MS, von Blomberg BM, et al. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease. Clin Immunol 2008; 126:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/27\">",
"      Zettl A, Ott G, Makulik A, et al. Chromosomal gains at 9q characterize enteropathy-type T-cell lymphoma. Am J Pathol 2002; 161:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/28\">",
"      Catassi C, Fabiani E, Corrao G, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA 2002; 287:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/29\">",
"      Howell WM, Leung ST, Jones DB, et al. HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Hum Immunol 1995; 43:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/30\">",
"      Carbonnel F, Grollet-Bioul L, Brouet JC, et al. Are complicated forms of celiac disease cryptic T-cell lymphomas? Blood 1998; 92:3879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/31\">",
"      Hadithi M, Mallant M, Oudejans J, et al. 18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease. J Nucl Med 2006; 47:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/32\">",
"      Mallant M, Hadithi M, Al-Toma AB, et al. Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J Gastroenterol 2007; 13:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5256/abstract/33\">",
"      Daum S, Wahnschaffe U, Glasenapp R, et al. Capsule endoscopy in refractory celiac disease. Endoscopy 2007; 39:455.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4704 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5256=[""].join("\n");
var outline_f5_8_5256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Tumor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Adjacent mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Subclassification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Refractory celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Extranodal NK/T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gamma-delta T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Anaplastic large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      B cell lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4704\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4704|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/25/15775\" title=\"figure 1\">",
"      PIT scores for EATL survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4704|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/48/28426\" title=\"picture 1\">",
"      Histology of EATL type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/23/30074\" title=\"picture 2\">",
"      Histology of EATL type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4704|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/61/6109\" title=\"table 1\">",
"      PTCL path",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4119?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of hepatosplenic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/36/35400?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33065?source=related_link\">",
"      Initial treatment of peripheral T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3930?source=related_link\">",
"      Management of gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_8_5257="Intellectual disability (mental retardation) in children: Evaluation";
var content_f5_8_5257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intellectual disability (mental retardation) in children: Evaluation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5257/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5257/contributors\">",
"     Penelope Pivalizza, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5257/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5257/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5257/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5257/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5257/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/8/5257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intellectual disability (ID) is a static encephalopathy with multiple etiologies that encompasses a broad spectrum of functioning, disability, and strengths. The term is synonymous with and is now preferred over the older term, mental retardation. The term global developmental delay is usually used to describe children younger than age five with significant cognitive deficits, because IQ testing is less reliable in this age group. A variety of other terms are used outside of the United States (",
"    <a class=\"graphic graphic_table graphicRef57206 \" href=\"UTD.htm?6/47/6908\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ID is an important public health issue because of its prevalence and the need for extensive support services. Its management requires early diagnosis and intervention, coupled with access to health care and educational resources.",
"   </p>",
"   <p>",
"    The evaluation of children with intellectual disability will be presented here. The definition, causes, diagnosis, management, and outcomes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40887?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Management; outcomes; and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental surveillance should be performed at every well child visit and targeted screening at periodic visits (9, 18, and 24 or 30 months). The goal is early identification of children with possible developmental delay or intellectual disability (ID) and prompt referral for further evaluation and early intervention services. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of standardized screening tools are available. These vary in their sensitivity and specificity. The following tests are some in common use. Details about these tests, including their accuracy in identifying infants or children with developmental delays, are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=see_link\">",
"     \"Developmental and behavioral screening tests in primary care\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ages and Stages Questionnaires (ASQ) &ndash; The ASQ provide age-specific questions about the child that are completed by the child&rsquo;s parent, and can be used to screen development in children from 4 to 60 months of age. These are used in clinical and research settings and applied in some screening and intervention programs [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bayley Infant Neurodevelopmental Screener (BINS) &ndash; The BINS can be used to screen development in children 3 to 25 months. It uses 10 to 13 directly elicited items per three- to six-month age range to screen neurologic processes (reflexes and tone), neurodevelopmental skills (fine motor, language), and cognitive processes.",
"     </li>",
"     <li>",
"      Brigance Screens-II &ndash; The Brigance Screens-II can be used to screen development in children from 0 to 90 months. It consists of nine separate forms, one for each 12-month age range, each of which takes 10 to 15 minutes to administer. It uses parent report (in the 0- to 24-month age range), direct observation, and elicitation to screen speech-language, motor skills, and general knowledge at younger ages and reading and math at older ages.",
"     </li>",
"     <li>",
"      Denver Developmental Screening Test-II (DDST-II) &ndash; The DDST-II is a directly administered tool that is designed to screen expressive and receptive language, gross motor, fine motor, and personal-social skills in children zero to six years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/2\">",
"       2",
"      </a>",
"      ]. It has limited sensitivity and specificity to detect language delay, mild ID, learning disabilities, and functional developmental delay [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/3\">",
"       3",
"      </a>",
"      ]. It is used to track developmental skills during longitudinal pediatric follow-up and to detect children who require further evaluation of delays.",
"     </li>",
"     <li>",
"      Infant-Toddler Checklist for Language and Communications &ndash; This tool can be used to screen language and communication development in children 6 to 24 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/4\">",
"       4",
"      </a>",
"      ]. Early language delay may be the first sign of atypical development in intellectual disability.",
"     </li>",
"     <li>",
"      Parents' Evaluation of Developmental Status (PEDS) &ndash; The PEDS can be used as a brief developmental screen in children from birth to eight years. In addition to functioning as a screening test, it provides longitudinal surveillance and helps to determine when referrals are necessary and when patient education, in-office counseling, watchful waiting, or additional screening is needed. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When a screening test suggests developmental delay, further evaluation is needed. Developmental evaluation of at least four subscales is recommended in order to provide a comprehensive estimate of functionality. A multidisciplinary approach is recommended. Throughout the evaluation, it is important to use skilled professional communication and allow sufficient time for the interview, to elicit parent concerns, provide genetic counseling, and convey sufficient information to enable optimal understanding and informed collaborative parent decision-making [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Referral to a developmental pediatrician or psychologist is usually needed to obtain a comprehensive developmental evaluation that includes cognitive-adaptive and behavioral assessment.",
"     </li>",
"     <li>",
"      Speech and language and adaptive functioning should be formally assessed.",
"     </li>",
"     <li>",
"      Evaluation by specialists in occupational and physical therapy will assist in assessing functional impairments and strengths.",
"     </li>",
"     <li>",
"      A social worker can assist in assessment of the family and provide counseling, including long-term planning.",
"     </li>",
"     <li>",
"      A geneticist can evaluate for suspected genetic disorders and provide genetic counseling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nature and timing of appropriate investigations are controversial, and there is no widely accepted standardized approach. The first step is a comprehensive history and physical examination. In three series, the history and physical examination identified the etiology of ID or developmental delay in 17 to 34 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive history should be obtained. This should include a detailed family history inquiring about any close family member with a neurodevelopmental or genetic disorder; and whether the mother has a history of miscarriage or",
"    <span class=\"nowrap\">",
"     stillbirth/neonatal",
"    </span>",
"    death. A specific inquiry should be made about whether there is any consanguinity. The prenatal, perinatal, and neonatal course should be reviewed, including an inquiry about alcohol intake during pregnancy, as well as a complete review of systems. The parents should be asked to provide a detailed developmental, behavioral, social, and educational history, as well as a record of medications.",
"   </p>",
"   <p>",
"    The results of any previous newborn metabolic and thyroid testing, neuroimaging, lead and iron screening, growth records, and vision and hearing surveillance should be reviewed. Results should be obtained from any prior developmental, psychological, and psychiatric evaluations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/9\">",
"     9",
"    </a>",
"    ]. A high index of suspicion for abuse and neglect is warranted, particularly in verbally inexpressive children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=see_link\">",
"     \"Child neglect and emotional abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sufficient time should be allocated for the evaluation. This should include an opportunity for the parents to communicate their concerns, perceptions, and misconceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A physical examination may help establish the etiology of ID and identify associated conditions. The examination should be comprehensive, with specific attention to the following (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=see_link&amp;anchor=H7#H7\">",
"     \"The pediatric physical examination: General principles and standard measurements\", section on 'Standard measurements'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurements of height, weight, and head circumference, including growth velocity.",
"     </li>",
"     <li>",
"      Dysmorphic features that may suggest genetic or syndromic etiologies to guide selection of genetic tests.",
"     </li>",
"     <li>",
"      Examination of the ears, nose, and throat, including hearing assessment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link\">",
"       \"The pediatric physical examination: HEENT\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Eye examination, including, visual acuity, visual fields, extra-ocular movements, strabismus, and evaluation of the fundi. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=see_link\">",
"       \"The pediatric physical examination: HEENT\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment of the heart, lungs, abdomen, genitourinary system, back, extremities, and skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=see_link\">",
"       \"The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=see_link\">",
"       \"The pediatric physical examination: Chest and abdomen\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=see_link\">",
"       \"The pediatric physical examination: The perineum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complete neurologic and neurodevelopmental assessment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=see_link\">",
"       \"Detailed neurologic assessment of infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Detailed observation of behavior, including attention, impulsivity, activity, affect, motor mannerisms, disordered social communication, and internalizing (eg, anxiety, depression) and externalizing behaviors (eg, oppositional and aggressive behavior).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Parent/family",
"      </span>",
"      interactions and behaviors may be observed for any features suggesting parental depression, parenting characteristics, or suspicion of child abuse. Parents may manifest features of genetically mediated disorders themselves, which would be relevant to their child's evaluation, diagnosis, and intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Sensory screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with global developmental delay",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ID appear to be at high risk for sensory impairments. Vision disorders affect 13 to 50 percent of patients with ID, and approximately 18 percent have hearing impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, assessment of vision and hearing is an essential part of the initial evaluation. This should include a complete ophthalmologic examination and audiometry, preferably using brainstem auditory evoked response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions about which laboratory studies should be performed are based upon clinical abnormalities identified during the history and physical examination and the diagnostic yield and availability of the specific tests [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The physician should consider whether a specific test is indicated in a child with ID based on clinical suspicion for a particular disorder in the child.",
"   </p>",
"   <p>",
"    If no specific disorder is clinically suggested or suspected, then testing for idiopathic or unexplained intellectual disability is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Evidence-based consensus is still developing for which tests should be routinely performed to evaluate a child with unexplained",
"    <span class=\"nowrap\">",
"     ID/global",
"    </span>",
"    developmental delay; tests may vary across clinical settings and among nations, especially where screening programs differ [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/12\">",
"     12",
"    </a>",
"    ]. Studies analyzing cost-benefit, cost-effectiveness and the evidence base for sequential or stepwise testing approaches are still needed.",
"   </p>",
"   <p>",
"    The results of the laboratory studies may identify a particular disorder that would allow the clinician to provide more information to the family about the associated prognosis, co-morbidities, anticipation of future needs, genetic counseling, and whether any specific treatment is available (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"     biotin",
"    </a>",
"    replacement). With the exception of metabolic disorders, which are rare, most causes of ID do not have specific treatments. Even if a specific diagnosis cannot be found, exclusion of certain disorders may be helpful for the parents and other family members.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENETIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the history and physical examination suggest a particular genetic disorder, specific genetic tests are recommended, individualized for a particular child. Where no specific disorder is clinically suggested or suspected, then genetic testing for idiopathic or unexplained intellectual disability is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The diagnostic yields of different tests or testing approaches are summarized in the tables (",
"    <a class=\"graphic graphic_table graphicRef72211 graphicRef51263 graphicRef62940 \" href=\"UTD.htm?37/44/38606\">",
"     table 2A-C",
"    </a>",
"    ); the reported diagnostic yields are estimated based on metaanalysis of different patient groups rather than representative population-based samples [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/13\">",
"     13",
"    </a>",
"    ]. In children with unexplained ID, the genetic test with the highest diagnostic yield is chromosomal microarray analysis (CMA). (See",
"    <a class=\"local\" href=\"#H18781219\">",
"     'Chromosomal microarray analysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18739238\">",
"    <span class=\"h2\">",
"     Genetic testing for a specific suspected or suggested disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with characteristics suggesting a particular syndrome should undergo specific genetic testing to confirm or rule out that disorder. Tests may be done on the parents as well as the child. Examples of suspected disorders for which specific genetic tests are recommended include specific chromosomal anomalies and fragile X DNA abnormalities. (See",
"    <a class=\"local\" href=\"#H18781219\">",
"     'Chromosomal microarray analysis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H31558952\">",
"     'Testing for fragile X syndrome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H31558975\">",
"     'Testing for Rett syndrome'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18781212\">",
"    <span class=\"h2\">",
"     Genetic tests for unexplained intellectual disability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic tests are recommended for unexplained ID because they can provide diagnostic and prognostic information and allow for informative genetic counseling of the parents and other family members. A test for chromosomal abnormalities has the highest diagnostic value if dysmorphic features or findings suggestive of a specific syndrome are present. Nonetheless, testing has diagnostic value even if such features are absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18781219\">",
"    <span class=\"h3\">",
"     Chromosomal microarray analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing evidence supports the use of chromosomal microarray analysis (CMA) as a first line genetic test for unexplained ID, instead of chromosomal karyotype analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/11,14-16\">",
"     11,14-16",
"    </a>",
"    ]. CMA is also known as molecular karyotyping, microarray-based genomic copy-number analysis or array-based comparative genomic hybridization (aCGH). The use of CMA leads to a genetic diagnosis in 15 to 20 percent of patients with unexplained ID, which is substantially higher than chromosomal karyotyping (",
"    <a class=\"graphic graphic_table graphicRef72211 \" href=\"UTD.htm?30/5/30812\">",
"     table 2A",
"    </a>",
"    ). The higher yield of CMA is primarily because of its higher sensitivity for submicroscopic deletions and duplications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/17\">",
"     17",
"    </a>",
"    ]. CMA provides much higher resolution than chromosomal karyotyping, identifying more genetic conditions, including single nucleotide polymorphisms (SNP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link&amp;anchor=H15538652#H15538652\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Array comparative genomic hybridization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a metaanalysis of 33 studies of patients with ID, autism spectrum disorders, or multiple congenital anomalies, the average diagnostic yield of CMA was 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/11\">",
"     11",
"    </a>",
"    ]. In another study of more than 35,000 patients with ID, CMA detected a pathogenic abnormality in nearly 19 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/18\">",
"     18",
"    </a>",
"    ]. CMA is not able to detect fully balanced rearrangements and low-level mosaicism, but these are relatively infrequent causes of abnormal phenotypes in this population (about 0.3 percent). CMA also does not detect point mutations responsible for single-gene disorders. Interpretation of a CMA result requires expert review to determine whether a copy-number variant is clinically significant. In many cases, testing of the patient&rsquo;s parents is necessary to fully assess the clinical significance of a result to enable appropriate genetic counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/11,19\">",
"     11,19",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Thus, we suggest chromosomal genetic testing with CMA rather than G-banded karyotyping in most patients with ID, especially where no specific cause is clinically suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/11\">",
"     11",
"    </a>",
"    ]. CMA testing is also appropriate if there is a family history of unexplained infant death, parental consanguinity or developmental regression or loss of milestones. A list of laboratories that perform CMA testing is available at the",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_lab_service_id/234754?db=genetests\">",
"     GeneTests website",
"    </a>",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_lab_service_id/234754?db=genetests\">",
"    </a>",
"    . Chromosomal karyotype analysis should be reserved for patients with obvious chromosomal syndromes such as Down syndrome, a family history of chromosomal rearrangement, a maternal history of multiple miscarriages or where CMA is unavailable [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link&amp;anchor=H15538624#H15538624\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Chromosomal analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further standardization of CMA technology, array design and content, and interpretation is needed; interpreting variants of uncertain clinical significance may be challenging. Because testing methods can vary, recommendations for CMA standards have been proposed; broadly-focused CMA testing is initially advised for unexplained ID, in preference to narrowly-focused tests [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/11\">",
"     11",
"    </a>",
"    ]. If the CMA testing result is normal or yields a known benign abnormality, then further evaluation using specific tests such as Fragile X testing may be considered, as recommended in a consensus statement [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31558952\">",
"    <span class=\"h3\">",
"     Testing for fragile X syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fragile X syndrome is caused by an abnormal expansion mutation of a CGG triplet repeat in the FMR1 gene and is the most prevalent form of inherited ID [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/20\">",
"     20",
"    </a>",
"    ]. Most affected males and approximately one-third of females have ID, which ranges from mild to severe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link\">",
"     \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Selection criteria for fragile X testing varies among authorities. Most experts recommend fragile X testing for all children in the following groups (",
"    <a class=\"graphic graphic_table graphicRef51263 \" href=\"UTD.htm?19/61/20445\">",
"     table 2B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/11,20\">",
"     11,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Males and females with ID and clinical features suggesting fragile X syndrome (eg, macrocephaly, large ears, enlarged testes, perseverative speech, and poor eye contact)",
"     </li>",
"     <li>",
"      Males and females with unexplained ID or developmental delay AND a family history of ID",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, many authorities suggest fragile X testing for all children with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Males and females with ID whose initial microarray testing is normal or benign [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Males and females with unexplained ID (because of a 1 to 3 percent diagnostic yield [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/13\">",
"       13",
"      </a>",
"      ])",
"     </li>",
"     <li>",
"      Males and females with unexplained autism [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Males and females with borderline ID [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31558968\">",
"    <span class=\"h3\">",
"     Subtelomeric chromosomal rearrangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtelomeric chromosomal rearrangements are identified in approximately 5 percent of children with ID [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/22\">",
"     22",
"    </a>",
"    ]. Abnormalities are more likely to be identified in severely affected children, intrauterine growth restriction, microcephaly or macrocephaly, short stature, or congenital malformations or a family history of ID [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, chromosomal microarray analysis (CMA) is the test of choice to detect these lesions, because it includes coverage of the telomeres and also broader coverage of the genome (",
"    <a class=\"graphic graphic_table graphicRef72211 \" href=\"UTD.htm?30/5/30812\">",
"     table 2A",
"    </a>",
"    ). Molecular screening using fluorescence in situ hybridization (FISH) of subtelomeric probes or microsatellite markers is a less comprehensive investigation, but may be substituted if array diagnosis is not available or if a specific telomeric disorder (eg, Cri-du-chat syndrome) is strongly suspected clinically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=see_link&amp;anchor=H15538631#H15538631\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\", section on 'Fluorescence in situ hybridization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31558975\">",
"    <span class=\"h3\">",
"     Testing for Rett syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the MECP2 gene causing Rett syndrome are an uncommon cause of ID in girls (1:10,000 female births) and are even more rare in boys. Testing for the MECP2 mutation should be performed in girls with unexplained moderate to severe ID who were normal during the first six months of life and experienced a period of regression or developmental stagnation usually beginning in the second year of life, especially if there are stereotypic hand movements [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=see_link\">",
"     \"Rett syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21442566\">",
"    <span class=\"h1\">",
"     OTHER TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Metabolic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;ID is a clinical feature of some inborn errors of metabolism. Most affected children have other manifestations of metabolic disease, such as episodic decompensation, developmental regression, or failure to thrive, or physical findings, such as dysmorphic features or hepatomegaly. In addition, screening programs in the United States identify many newborns with these conditions. Specific laboratory testing (including serum concentrations of amino acids, ammonia, and lactate, and urine organic acids) in ID occasionally identifies a metabolic disorder (",
"    <a class=\"graphic graphic_table graphicRef62940 \" href=\"UTD.htm?29/11/29884\">",
"     table 2C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/6,7,23\">",
"     6,7,23",
"    </a>",
"    ]. Some metabolic tests are helpful not only in diagnosing, but also in managing disorders (eg, calcium assays in DiGeorge syndrome, William syndrome). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=see_link\">",
"     \"Inborn errors of metabolism: Metabolic emergencies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=see_link\">",
"     \"Newborn screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The results of newborn screening for metabolic disorders should be reviewed as part of the initial evaluation. Additional testing should be performed if these results are not available, or in children with a positive family history of metabolic disorders, parental consanguinity, episodic decompensation, or developmental regression. The presence of these features increases the likelihood of identification of a disorder compared to nonselective screening, although the diagnostic yield is still low [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/7\">",
"     7",
"    </a>",
"    ]. To perform metabolic screening, concentrations of serum amino acids, urine organic and orotic acids, serum ammonia, and lactate are most often measured; very long chain fatty acids and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/11/22710?source=see_link\">",
"     carnitine",
"    </a>",
"    may also be measured on blood samples [13]. Electrolytes are measured to detect acidosis. If further metabolic testing is performed and guided by a specialist, the diagnostic yield increases to about 3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/13\">",
"     13",
"    </a>",
"    ]. Other possible tests include urine creatine and guanidinoacetate (for creatine synthesis and transport disorders), blood homocysteine and transferrin electrophoresis, urine glycosaminoglycans, and oligosaccharides [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=see_link&amp;anchor=H11#H11\">",
"     \"Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features\", section on 'Developmental delay'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following disorders may present with nonspecific findings, and should be considered in children presenting with otherwise unexplained ID: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Biotinidase deficiency",
"      </strong>",
"      &ndash; Clinical symptoms of biotinidase deficiency (",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/253260\">",
"       MIM #253260",
"      </a>",
"      ) may include seizures, hypotonia, ataxia, developmental delay, and cutaneous abnormalities (alopecia and rashes), although it may present with global developmental delay alone. Biotinidase deficiency is rare, but important to detect as it is readily treatable. Biotinidase deficiency is included in the newborn screen in all 50 U.S. states. This is also known as late-onset",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"       biotin",
"      </a>",
"      -responsive multiple carboxylase deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the hereditary ataxias\", section on 'Disorders of pyruvate and lactate metabolism'",
"      </a>",
"      .) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Duchenne muscular dystrophy",
"      </strong>",
"      &ndash; Boys with Duchenne muscular dystrophy may present with unexplained global developmental",
"      <span class=\"nowrap\">",
"       delay/ID",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/24\">",
"       24",
"      </a>",
"      ]. Early creatine kinase testing has been recommended in boys with unexplained global",
"      <span class=\"nowrap\">",
"       delay/ID",
"      </span>",
"      to enable early diagnosis and intervention, and to provide family counseling [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Creatine kinase testing should be readily considered in any child with ID if clinically suspected or suggested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thyroid screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;In countries without newborn screening programs, unrecognized congenital hypothyroidism can result in ID [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/26\">",
"     26",
"    </a>",
"    ]. In these countries, thyroid testing has been recommended for infants and children presenting with ID [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/12\">",
"     12",
"    </a>",
"    ]. In these cases, the majority of children have systemic signs of hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In countries in which newborn screening for hypothyroidism is routinely performed, thyroid testing is not indicated unless clinical features suggest dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lead screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lead is the most common environmental neurotoxin. Blood lead concentration greater than 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    has been associated with cognitive deficits and clinical symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efforts in the United States to reduce environmental exposure to lead had led to a decrease in average blood lead levels in children and fewer children with elevated values [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/27\">",
"     27",
"    </a>",
"    ]. Children should be screened at one to two years of age, particularly if they have risk factors for lead toxicity, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Living in a community in which more than 12 percent of children have blood lead levels of &gt;10",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Living in a house built before 1950",
"     </li>",
"     <li>",
"      Possible exposure to lead containing folk remedies",
"     </li>",
"     <li>",
"      Adoption or emigration from a country with a high prevalence of lead poisoning",
"     </li>",
"     <li>",
"      Iron deficiency",
"     </li>",
"     <li>",
"      Exposure to contaminated dust or soil",
"     </li>",
"     <li>",
"      Suspected abuse or neglect",
"     </li>",
"     <li>",
"      Parental vocational lead exposure",
"     </li>",
"     <li>",
"      Low socioeconomic status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although lead toxicity is unlikely to be the cause of ID in the United States, children with ID or developmental delay from other causes often have persistent mouthing behavior and are thus at increased risk for lead exposure. In one report, blood lead levels &gt;10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    occurred in a greater proportion of children with behavioral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    developmental problems than in controls (12 versus 0.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, pediatric lead exposure can harm cognitive function, even with blood lead concentrations less than 10",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, we recommend routine lead screening in children with developmental delay or ID, particularly if they fall into one of the high risk groups noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging sometimes detects an abnormality that can cause ID [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/6,7,31,32\">",
"     6,7,31,32",
"    </a>",
"    ]. As an example, in a retrospective study, magnetic resonance imaging (MRI) abnormalities were found in 109 of 224 (49 percent) of children with developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/32\">",
"     32",
"    </a>",
"    ]. The most common lesions identified were central nervous system malformations, white matter abnormalities, and cerebral atrophy. The yield is likely to be higher in children with specific physical features such as microcephaly or abnormal motor signs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of MRI appears to be greater than computed tomography (CT). This was illustrated by a series of children with moderate to severe developmental delay in which all patients had a CT scan and some also had an MRI. Abnormalities were found in 51 of 170 (30 percent) who had CT scanning and 19 of 28 (65 percent) who had MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the history or physical examination suggests CNS malformation or injury (such as microcephaly, seizures, or focal neurologic signs), we recommend neuroimaging in the evaluation of ID. MRI is preferred, although CT scanning may be acceptable if MRI is not available; potential radiation exposure and risk of sedation should be considered as part of informed decision-making. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=see_link\">",
"     \"Approach to neuroimaging in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Electroencephalogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine EEG evaluation contributes little to the diagnosis of ID. This is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 224 children with global developmental delay, EEGs performed in 60 did not contribute to determining the etiology [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, 10 of 120 children had abnormal EEGs associated with epileptic syndromes, although it is likely that they already had a recognized seizure disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/8,10\">",
"       8,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    routinely obtain an EEG in the evaluation of ID. An EEG may be helpful if epilepsy is present or an epileptic syndrome, neurodegenerative disorder, or speech regression is suspected (such as occurs in Landau-Kleffner syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal order or timing of tests to identify the etiology of intellectual disability (ID) is not certain. We usually follow the staged approach recommended by the practice parameter of the American Academy of Neurology and the Child Neurology Society for the evaluation of the child with global developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5257/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1286731\">",
"    <span class=\"h2\">",
"     All children with ID",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following assessments should be made in all children with ID (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Evaluation'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete history and physical examination",
"     </li>",
"     <li>",
"      Perform comprehensive developmental assessment",
"     </li>",
"     <li>",
"      Complete vision and auditory screening",
"     </li>",
"     <li>",
"      Review newborn screening results",
"     </li>",
"     <li>",
"      Perform a chromosomal microarray (CMA, also known as genomic microarray analysis) in all children with ID, unless a specific syndrome is suspected based on phenotypic characteristics and diagnosed by specific testing (",
"      <a class=\"graphic graphic_table graphicRef72211 \" href=\"UTD.htm?30/5/30812\">",
"       table 2A",
"      </a>",
"      ). If CMA is not available, then a G-banded karyotype is an appropriate substitute. (See",
"      <a class=\"local\" href=\"#H18781219\">",
"       'Chromosomal microarray analysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1286747\">",
"    <span class=\"h2\">",
"     Features requiring more comprehensive evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is parental consanguinity, prior unexplained infant death, multiple miscarriages, or loss or regression of developmental milestones, a comprehensive evaluation should be performed. In addition to the CMA or G banded karyotype described above, the comprehensive evaluation should include metabolic testing and genetics consultation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Metabolic testing'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1286754\">",
"    <span class=\"h2\">",
"     Features suggesting a specific test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with features that suggest a specific diagnosis, the following testing is recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the history or physical examination suggests Down, fragile X, or Rett syndrome or other genetic disorders, obtain specific tests for the disorder. (See",
"      <a class=\"local\" href=\"#H18739238\">",
"       'Genetic testing for a specific suspected or suggested disorder'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Since fragile X syndrome often presents with non-specific global developmental delay in young children, there should be a low threshold for fragile X testing. Fragile X testing is recommended for male and female children with clinical features suggesting fragile X syndrome, for those with unexplained ID and a family history of ID, and for those whose initial microarray testing is benign. In addition, many authorities recommend fragile X testing in all children with unexplained ID or autism. (See",
"      <a class=\"local\" href=\"#H31558952\">",
"       'Testing for fragile X syndrome'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Obtain metabolic studies (concentrations of serum amino acids, urine organic acids, serum ammonia, and lactate) and thyroid screen (T4, TSH) if results are not available from newborn screening or if the history or clinical signs suggest a metabolic disorder or hypothyroidism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Metabolic testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Thyroid screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some muscular dystrophies including Duchenne occasionally present with nonspecific developmental delay, and should be considered in children presenting with otherwise unexplained ID. (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Metabolic testing'",
"      </a>",
"      above) &nbsp;",
"     </li>",
"     <li>",
"      If the history or physical examination suggests a malformation or injury of the central nervous system (CNS), obtain neuroimaging, preferably magnetic resonance imaging (MRI). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the child has seizures or is suspected to have a syndrome that is associated with epilepsy, perform an electroencephalogram. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Electroencephalogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If risk factors are present for environmental exposure to lead, obtain a lead screen; testing for lead also should be considered in all mouthing, developmentally delayed children. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Lead screening'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20924429\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Geoffrey Miller, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/1\">",
"      Council on Children With Disabilities, Section on Developmental Behavioral Pediatrics, Bright Futures Steering Committee, Medical Home Initiatives for Children With Special Needs Project Advisory Committee. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. Pediatrics 2006; 118:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/2\">",
"      Frankenburg WK, Dodds J, Archer P, et al. The Denver II: a major revision and restandardization of the Denver Developmental Screening Test. Pediatrics 1992; 89:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/3\">",
"      Glascoe FP, Byrne KE, Ashford LG, et al. Accuracy of the Denver-II in developmental screening. Pediatrics 1992; 89:1221.",
"     </a>",
"    </li>",
"    <li>",
"     Glascoe FP. Collaborating with Parents. Ellsworth &amp; Vandermeer Press, Ltd, Nashville, TN 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/5\">",
"      Levetown M, American Academy of Pediatrics Committee on Bioethics. Communicating with children and families: from everyday interactions to skill in conveying distressing information. Pediatrics 2008; 121:e1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/6\">",
"      Majnemer A, Shevell MI. Diagnostic yield of the neurologic assessment of the developmentally delayed child. J Pediatr 1995; 127:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/7\">",
"      Shevell MI, Majnemer A, Rosenbaum P, Abrahamowicz M. Etiologic yield of subspecialists' evaluation of young children with global developmental delay. J Pediatr 2000; 136:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/8\">",
"      Battaglia A, Bianchini E, Carey JC. Diagnostic yield of the comprehensive assessment of developmental delay/mental retardation in an institute of child neuropsychiatry. Am J Med Genet 1999; 82:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/9\">",
"      Szymanski L, King BH. Practice parameters for the assessment and treatment of children, adolescents, and adults with mental retardation and comorbid mental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999; 38:5S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/10\">",
"      Shevell M, Ashwal S, Donley D, et al. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology 2003; 60:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/11\">",
"      Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/12\">",
"      McDonald L, Rennie A, Tolmie J, et al. Investigation of global developmental delay. Arch Dis Child 2006; 91:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/13\">",
"      Michelson DJ, Shevell MI, Sherr EH, et al. Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2011; 77:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/14\">",
"      Firth HV, Richards SM, Bevan AP, et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am J Hum Genet 2009; 84:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/15\">",
"      Sagoo GS, Butterworth AS, Sanderson S, et al. Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genet Med 2009; 11:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/16\">",
"      Moeschler JB. Medical genetics diagnostic evaluation of the child with global developmental delay or intellectual disability. Curr Opin Neurol 2008; 21:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/17\">",
"      Ropers HH. Genetics of intellectual disability. Curr Opin Genet Dev 2008; 18:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/18\">",
"      Hochstenbach R, van Binsbergen E, Engelen J, et al. Array analysis and karyotyping: workflow consequences based on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands. Eur J Med Genet 2009; 52:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/19\">",
"      Paciorkowski AR, Fang M. Chromosomal microarray interpretation: what is a child neurologist to do? Pediatr Neurol 2009; 41:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/20\">",
"      Hersh JH, Saul RA, Committee on Genetics. Health supervision for children with fragile X syndrome. Pediatrics 2011; 127:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/21\">",
"      Hall SS, Lightbody AA, Reiss AL. Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. Am J Ment Retard 2008; 113:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/22\">",
"      De Vries BB, Winter R, Schinzel A, van Ravenswaaij-Arts C. Telomeres: a diagnosis at the end of the chromosomes. J Med Genet 2003; 40:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/23\">",
"      Jaffe M, Borochowitz Z, Dar H. Diagnostic approach to the etiology of mental retardation. Isr J Med Sci 1984; 20:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/24\">",
"      Essex C, Roper H. Lesson of the week: late diagnosis of Duchenne's muscular dystrophy presenting as global developmental delay. BMJ 2001; 323:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/25\">",
"      Ciafaloni E, Fox DJ, Pandya S, et al. Delayed diagnosis in duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr 2009; 155:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/26\">",
"      al-Qudah AA. Screening for congenital hypothyroidism in cognitively delayed children. Ann Trop Paediatr 1998; 18:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/27\">",
"      Meyer PA, Pivetz T, Dignam TA, et al. Surveillance for elevated blood lead levels among children--United States, 1997-2001. MMWR Surveill Summ 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/28\">",
"      Screening for elevated blood lead levels. American Academy of Pediatrics Committee on Environmental Health. Pediatrics 1998; 101:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/29\">",
"      American Academy of Pediatrics Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. Pediatrics 2005; 116:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/30\">",
"      Lewendon G, Kinra S, Nelder R, Cronin T. Should children with developmental and behavioural problems be routinely screened for lead? Arch Dis Child 2001; 85:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/31\">",
"      Demaerel P, Kingsley DP, Kendall BE. Isolated neurodevelopmental delay in childhood: clinicoradiological correlation in 170 patients. Pediatr Radiol 1993; 23:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/32\">",
"      Bouhadiba Z, Dacher J, Monroc M, et al. [MRI of the brain in the evaluation of children with developmental delay]. J Radiol 2000; 81:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5257/abstract/33\">",
"      Moeschler JB, Shevell M, American Academy of Pediatrics Committee on Genetics. Clinical genetic evaluation of the child with mental retardation or developmental delays. Pediatrics 2006; 117:2304.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6189 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5257=[""].join("\n");
var outline_f5_8_5257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Sensory screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENETIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18739238\">",
"      Genetic testing for a specific suspected or suggested disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18781212\">",
"      Genetic tests for unexplained intellectual disability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18781219\">",
"      - Chromosomal microarray analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31558952\">",
"      - Testing for fragile X syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31558968\">",
"      - Subtelomeric chromosomal rearrangements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31558975\">",
"      - Testing for Rett syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21442566\">",
"      OTHER TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Metabolic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thyroid screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lead screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Electroencephalogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1286731\">",
"      All children with ID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1286747\">",
"      Features requiring more comprehensive evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1286754\">",
"      Features suggesting a specific test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20924429\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6189\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6189|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/47/6908\" title=\"table 1\">",
"      Intel disabil terms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/5/30812\" title=\"table 2A\">",
"      Diagnostic yield of screening for chromosomal anomalies in ID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/61/20445\" title=\"table 2B\">",
"      Diagnostic yield of screening for X linked disorders in ID",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/11/29884\" title=\"table 2C\">",
"      Yield of screening for inborn errors of metabolism in ID",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23178?source=related_link\">",
"      Approach to neuroimaging in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=related_link\">",
"      Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14618?source=related_link\">",
"      Detailed neurologic assessment of infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24489?source=related_link\">",
"      Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10250?source=related_link\">",
"      Inborn errors of metabolism: Metabolic emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40887?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Management; outcomes; and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2088?source=related_link\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=related_link\">",
"      Rett syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=related_link\">",
"      The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=related_link\">",
"      The pediatric physical examination: Chest and abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=related_link\">",
"      The pediatric physical examination: General principles and standard measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11194?source=related_link\">",
"      The pediatric physical examination: HEENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_8_5258="Onychomycosis";
var content_f5_8_5258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Onychomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5258/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5258/contributors\">",
"     Adam O Goldstein, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5258/contributors\">",
"     Beth G Goldstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5258/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5258/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5258/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5258/contributors\">",
"     Ted Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/8/5258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/8/5258/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/8/5258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onychomycosis refers to nail infections caused by any fungus, including yeasts and nondermatophyte molds. Dermatophytic onychomycosis (tinea unguium) occurs in three main forms: distal subungual, proximal subungual, and white superficial. One or several of the toenails or fingernails may be involved, seldom all. Most affected individuals have or have had tinea pedis as well. Most toenail onychomycosis is due to dermatophytes; however, many cases of fingernail onychomycosis are due to yeast.",
"   </p>",
"   <p>",
"    This topic will review the diagnosis and management of onychomycosis. Skin infections due to dermatophytes and yeast are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link\">",
"     \"Dermatophyte (tinea) infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=see_link\">",
"     \"Candidal intertrigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few large community-based studies looking at the epidemiology of onychomycosis. A study of 15,000 patients in Canada presenting to the offices of three dermatologists and one family physician found that 8 percent had onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients had only toenail involvement (7.6 percent); few had fingernail involvement alone (0.15 percent) or both toenail and fingernail involvement (0.27 percent).",
"   </p>",
"   <p>",
"    In small studies, the prevalence of onychomycosis varies from 4 to 18 percent depending upon the age and population studied [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Toenail onychomycosis is most commonly due to dermatophytes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]; fingernail onychomycosis is more likely than toenail onychomycosis to be due to yeast [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/1\">",
"     1",
"    </a>",
"    ], and some studies have found that yeast are the most common cause of fingernail onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Nondermatophyte molds appear to cause less than 10 percent of toenail onychomycosis and to be a very rare cause of fingernail onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Distal subungual onychomycosis is the most common presentation. As an example, a retrospective study from Italy found that among 4046 cases of onychomycosis, 90 percent were distal subungual onychomycosis, 7 percent were superficial white onychomycosis, and 3 percent were proximal subungual onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of distal subungual onychomycosis is due to",
"    <em>",
"     Trichophyton rubrum",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/5\">",
"     5",
"    </a>",
"    ]. Proximal subungual onychomycosis is generally due to the same organisms as distal subungual onychomycosis. White superficial onychomycosis is usually caused by",
"    <em>",
"     T. mentagrophytes",
"    </em>",
"    , although cases caused by",
"    <em>",
"     T. rubrum",
"    </em>",
"    have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/6\">",
"     6",
"    </a>",
"    ]. Yeast onychomycosis is most commonly due to",
"    <em>",
"     Candida albicans",
"    </em>",
"    and is often seen in those whose hands are frequently exposed to moisture (eg, bartenders, housekeepers) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are relatively few data on the risk factors for onychomycosis. Risk factors that have been associated with onychomycosis include older age, swimming, tinea pedis, psoriasis, diabetes, immunodeficiency, genetic predisposition, and living with family members who have onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. The association with tinea pedis raises the possibility of treating tinea pedis to prevent onychomycosis; however, it is possible that this simply reflects similar etiologies for fungal infections of the skin and nails.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although onychomycosis is usually a cosmetic concern to patients, it also causes physical discomfort for some, particularly with more severe or advanced disease. Additionally, in patients with diabetes or other immunocompromised states, onychomycosis may increase the risk of bacterial infections such as cellulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1346087\">",
"    <span class=\"h2\">",
"     Subtypes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Distal subungual onychomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The great toe is usually the first to be affected, but all nails are susceptible. The disease begins with a whitish, yellowish, or brownish discoloration of a distal corner of the nail, which gradually spreads to involve the entire width of the nail plate and extends slowly toward the cuticle. Keratinous debris collecting between the nail plate and its bed is the cause of the discoloration.",
"   </p>",
"   <p>",
"    The distal portion of the nail plate breaks away or is picked away by the patient, exposing the nail bed, which is in fact the site of the initial fungal infection (",
"    <a class=\"graphic graphic_picture graphicRef52455 graphicRef72013 \" href=\"UTD.htm?14/20/14664\">",
"     picture 1A-B",
"    </a>",
"    ). Portions of the plate that remain may be heaped up and irregular. The condition persists indefinitely if left untreated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Proximal subungual onychomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal subungual onychomycosis is a relatively uncommon form of onychomycosis that begins and progresses in a manner similar to distal subungual onychomycosis but, as the name implies, affects the proximal portion of the nail in the vicinity of the cuticle and extends distally (",
"    <a class=\"graphic graphic_picture graphicRef61687 graphicRef74473 \" href=\"UTD.htm?37/30/38376\">",
"     picture 2A-B",
"    </a>",
"    ). It usually occurs in individuals with a severely compromised immune system. It is often a marker for AIDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     White superficial onychomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;White superficial onychomycosis is usually caused by",
"    <em>",
"     T. mentagrophytes",
"    </em>",
"    , although cases caused by",
"    <em>",
"     T. rubrum",
"    </em>",
"    have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/6\">",
"     6",
"    </a>",
"    ]. It is characterized by the appearance of dull white spots on the surface of the nail plate of one or several nails. Untreated, the diseased areas spread centrifugally (",
"    <a class=\"graphic graphic_picture graphicRef66643 \" href=\"UTD.htm?5/48/5888\">",
"     picture 3",
"    </a>",
"    ). Eventually the whole of the plate may be involved. The white areas are soft and when scraped lightly with a dermal curette yield a chalky scale suitable for laboratory examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1346118\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to these three established variants, additional subtypes of onychomycosis have been proposed, including endonyx and totally dystrophic onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/14\">",
"     14",
"    </a>",
"    ]. Endonyx onychomycosis is defined as onychomycosis that involves only the interior of the nail plate, sparing involvement of the nail bed. Subungual hyperkeratosis is absent. The term totally dystrophic onychomycosis is used to describe complete destruction of the nail plate due to fungus that results in a thickened and ridged nail bed covered with keratotic debris. Totally dystrophic onychomycosis is most commonly a manifestation of end stage distal subungual or proximal subungual onychomycosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Yeast onychomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;While toenail onychomycosis is only rarely caused by yeast, yeast is a common cause of fingernail onychomycosis, particularly in previously damaged nails;",
"    <em>",
"     Candida albicans",
"    </em>",
"    is most often the causative organism. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology and microbiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients may have associated chronic paronychia or chronic mucocutaneous candidiasis associated with immunodeficiencies such as AIDS. Multiple nails may be involved with thickening, yellow or brown discoloration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    onycholysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mold onychomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of nondermatophyte molds in causing onychomycosis is uncertain. It is presumed that a small percentage of cases are caused by these molds (eg,",
"    <em>",
"     Aspergillus",
"    </em>",
"    and",
"    <em>",
"     Scopulariopsis",
"    </em>",
"    species) in patients in whom dermatophyte infection has been ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1183587\">",
"    <span class=\"h2\">",
"     Fungal melanonychia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal melanonychia is a term used to describe an uncommon form of onychomycosis caused by fungal species capable of producing melanin. When caused by dematiaceous fungi (pigment-producing molds), the term &ldquo;ungual phaeohyphomycosis&rdquo; is also used to refer to this condition. The most common molds isolated from affected nails are",
"    <em>",
"     Scytalidium dimidiatum",
"    </em>",
"    ,",
"    <em>",
"     Alternaria",
"    </em>",
"    species, and",
"    <em>",
"     Exophiala",
"    </em>",
"    species. Several non-dematiaceous fungi may also cause fungal melanonychia, including",
"    <em>",
"     Trichophyton rubrum",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brown to black discoloration of the nail plate is characteristic and may appear in a variety of patterns, including diffuse, linear, and localized pigmentation. Nail dystrophy may also be present. The possibility of other causes of nail pigmentation, such as racial longitudinal melanonychia, exogenous pigment deposition, and, most importantly, subungual melanoma, should be considered during patient evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail dystrophies, often clinically indistinguishable from onychomycosis, can occur with psoriasis, eczematous conditions, senile ischemia (onychogryphosis), trauma, lichen planus, iron deficiency, and other conditions. Most studies have found that onychomycosis is responsible for only 50 to 60 percent of abnormal appearing nails [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, it is important to establish the presence of the fungus before instituting antimycotic treatment. Insurance companies in the United States are increasingly requiring confirmation of the diagnosis before they will authorize reimbursement for medication.",
"   </p>",
"   <p>",
"    We suggest KOH examination of scrapings to diagnose distal subungual, white superficial, and totally dystrophic onychomycosis. Nail culture or histopathologic examination of nail plate clippings should be performed if the KOH examination is negative or if required by insurance companies for reimbursement of antifungal therapy. A biopsy of the nail plate or partial or full nail removal with culture is needed for the diagnosis of proximal subungual onychomycosis.",
"   </p>",
"   <p>",
"    Given the high prevalence of yeast in fingernail onychomycosis, infected fingernails should be cultured to establish the causative organism.",
"   </p>",
"   <p>",
"    Cultures will also occasionally demonstrate nondermatophyte molds, which may indicate a lower rate of successful treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     KOH examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;KOH examination of scrapings from the nail bed to demonstrate dermatophytic hyphae and arthrospores is the best means of confirming the diagnosis of proximal and distal subungual onychomycosis in patients with a suggestive clinical picture. The technique for obtaining the specimen is critical to the success of this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link&amp;anchor=H4044416#H4044416\">",
"     \"Dermatologic procedures\", section on 'Potassium hydroxide (KOH) prep'",
"    </a>",
"    .) In particular, it is important to remember that the most viable hyphae tend to be those in the region of the most proximal involvement of the nail. The specificity of KOH examination for the diagnosis of fungal involvement is high, but the sensitivity is variable, depending in part upon specimen adequacy and operator experience.",
"   </p>",
"   <p>",
"    In patients with white superficial onychomycosis, examination of scrapings from the white spots on the nail plate should also demonstrate dermatophytic hyphae and arthrospores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures (on Sabouraud's medium) are frequently helpful in patients who have a negative KOH examination. However, the sensitivity of culture may not be much better than KOH examination, and results are not available for four to six weeks. If negative, repeat culture is indicated in patients where there is a strong clinical suspicion of onychomycosis, since almost one-third of cultures may be falsely negative.",
"   </p>",
"   <p>",
"    Cultures occasionally demonstrate nondermatophyte molds, which may represent true infection or contamination of the culture in a patient with dermatophyte onychomycosis. One or more repeat cultures demonstrating the same nondermatophyte mold are required to establish a diagnosis of nondermatophyte mold onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dermatophyte test medium (DTM) culture may be an alternative to traditional fungal culture. DTM is cheaper than culture on Sabouraud's medium, can be performed in the physician's office, and results are available within three to seven days. Dermatophyte growth is indicated by a change in the color of DTM from yellow to red in response to alkaline metabolites that result from growth of dermatophytes. It is important to read such cultures in a timely fashion, since saprophytic organisms, which might grow over several weeks, can cause the same color change. DTM cannot identify the specific causative organism, but such identification is not necessary since all dermatophytes are susceptible to the therapies discussed below. In a study of 670 patients presenting to their primary care physician or podiatrist with clinical signs of toenail onychomycosis, DTM cultures had good positive and negative correlation with culture on Sabouraud's medium [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic examination of nail clippings with periodic acid-Schiff (PAS) stain is useful for the diagnosis of onychomycosis. The nail plate along with attached subungual debris is clipped just distal to its attachment to the nail bed and placed in 10 percent formalin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/19\">",
"     19",
"    </a>",
"    ]. This procedure is more costly than culture or KOH examination.",
"   </p>",
"   <p>",
"    Several studies have found that PAS staining of nail clippings is a sensitive test for the diagnosis of onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The largest study included 1146 nail samples from 851 patients with clinical findings suggestive of onychomycosis. Results from this study indicate that biopsy with PAS stain is a more sensitive test than culture or KOH examination; sensitivities of PAS stain, culture, and KOH examination were 82, 53, and 48 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/21\">",
"     21",
"    </a>",
"    ]. The superiority of PAS to culture was particularly evident among patients who had received any form of antimycotic treatment prior to the start of the study; sensitivities of PAS, culture, and KOH examination in this population were 88, 33, and 50 percent.",
"   </p>",
"   <p>",
"    A study that used a fluorescent stain for cellulose and chitin as a gold standard also concluded that this procedure was more sensitive than KOH preparation or culture (92 versus 80 and 59 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/22\">",
"     22",
"    </a>",
"    ]. The specificities were not significantly different (72, 72, and 82 percent, respectively). The Chicago Sky Blue stain, which provides a color contrast, has also been used for the diagnosis of onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1346147\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) testing may have value for the diagnosis of onychomycosis. In a study in which 550 nail specimens from patients with clinical findings suggestive of onychomycosis were subjected to PAS staining, PCR, KOH preparation, and culture, test results were positive in 54, 40, 37, and 21 percent of specimens, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/24\">",
"     24",
"    </a>",
"    ]. Additional studies are necessary to determine the role of PCR testing in onychomycosis. PCR is not widely available for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of most forms of onychomycosis is similar. Traditional topical therapies are generally ineffective for clearing the primary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/25\">",
"     25",
"    </a>",
"    ], and even oral therapy is associated with a high rate of initial treatment failure or recurrence. Nevertheless, treatment is often indicated in documented cases because of the morbidity associated with the infection and when there are specific comorbidities such as diabetes.",
"   </p>",
"   <p>",
"    When patients desire or need therapy, we suggest initial treatment of dermatophyte onychomycosis with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    since data suggest it has greater efficacy than the alternatives and fewer serious side effects. Other options may be preferable in some patients, however, based on local costs of therapy or the desire to treat with pulse therapy in patients who wish to limit the total intake of pills.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    appears to be a more effective initial agent for treatment of nondermatophyte mold onychomycosis and yeast onychomycosis. It is used in the same dose regimens as that used for dermatophyte onychomycosis. (See",
"    <a class=\"local\" href=\"#H3043729\">",
"     'Treatment of yeast and mold onychomycosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest treating onychomycosis in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of cellulitis, especially if repeated, of the lower extremity who have ipsilateral toenail onychomycosis.",
"     </li>",
"     <li>",
"      Patients with diabetes and toenail onychomycosis who have additional risk factors for cellulitis (ie, prior cellulitis, venous insufficiency, edema) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link&amp;anchor=H2#H2\">",
"       \"Cellulitis and erysipelas\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are experiencing",
"      <span class=\"nowrap\">",
"       discomfort/pain",
"      </span>",
"      associated with infected nails.",
"     </li>",
"     <li>",
"      Patients who desire treatment for cosmetic reasons.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Oral therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    appear to have higher rates of cure in head-to-head randomized trials than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. Although used more in the past, results with long-term oral griseofulvin treatment have been disappointing.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    , 150 to 300 mg once weekly has also been found to be effective in patients with onychomycosis and may be particularly useful in patients with complicated medication regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/30\">",
"     30",
"    </a>",
"    ]. However, head-to-head comparisons have not found once weekly fluconazole to be as effective or as cost-effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis found the following mycological cure rates for dermatophyte onychomycosis in randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"       Terbinafine",
"      </a>",
"      (76 &plusmn;3 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      pulse therapy (63 &plusmn;7 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"       Griseofulvin",
"      </a>",
"      (60 &plusmn;6 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      continuous therapy (59 &plusmn;5 percent)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      (48 &plusmn;5 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical cure rates are more difficult to assess across trials, since complete resolution of nail changes in a slow-growing toenail may require follow-up of more than 12 months, even when fungal infection has been eliminated. Trials have been of varying lengths and used varying definitions of cure. Reported mean clinical response rates for various oral therapies in published trials have been generally similar to mean mycological cure rates, however higher and lower rates have been found for individual agents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/34\">",
"     34",
"    </a>",
"    ]. One randomized trial with clear outcomes defined clinical cure as 100 percent toenail clearing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/35\">",
"     35",
"    </a>",
"    ]. This trial found that 60 percent of patients treated with 16 weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    had achieved clinical cure when assessed at 72 weeks, which is somewhat lower than the 76 percent mean mycological cure rate seen in the meta-analysis.",
"   </p>",
"   <p>",
"    Recurrence is common, particularly after treating toenails, and there is some evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    has higher recurrence rates and lower clinical cure rates than might be expected from the initial mycological cure rate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although continuous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    appear to have similar efficacy in short-term studies (up to one year) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], long-term cure rates appear to be better with terbinafine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], and terbinafine has fewer drug-drug interactions. A systematic review found that mycologic cure rates were better with terbinafine than itraconazole, but there was no adequate assessment of clinical cure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/40\">",
"     40",
"    </a>",
"    ]. A randomized, double-blind trial reported that terbinafine was more effective than itraconazole pulse therapy on measures of long-term clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/41\">",
"     41",
"    </a>",
"    ]. A randomized trial with 18 month follow-up also found that continuous terbinafine was more effective than pulse terbinafine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/42\">",
"     42",
"    </a>",
"    ]. There is some evidence that patients find continuous therapy easier and more convenient than pulse therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    , a newer oral broad spectrum antifungal agent, may be another effective treatment option for patients with onychomycosis. In a phase II randomized trial (n = 218), posaconazole oral suspension (100 mg, 200 mg, or 400 mg daily for 24 weeks or 400 mg once daily for 12 weeks) was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    (250 mg daily for 12 weeks) and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/44\">",
"     44",
"    </a>",
"    ]. At the 48-week assessment, all dose regimens of posaconazole were superior to placebo. The best results with posaconazole were obtained when patients were given 200 mg or 400 mg daily for 24 weeks (54 and 46 percent complete cured, respectively); the cure rates in these groups did not differ significantly from the terbinafine group (37 percent cured). Adverse event rates were similar among the groups.",
"   </p>",
"   <p>",
"    The high cost of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    favors the preferred use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    in patients with onychomycosis. However, posaconazole appears to be an emerging, additional treatment option.",
"   </p>",
"   <p>",
"    Patients should be advised that due to binding of the antimycotic drug to keratin in the nail and continued exposure of fungus to medication, improvement will continue after oral therapy has stopped; it may take 9 to 12 months to fully assess cure. Repeat courses of therapy can be tried if the patient experiences a recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;While dosage schedules have not yet been settled, the following schedules are commonly used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"       Terbinafine",
"      </a>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For fingernails &ndash; 250 mg daily by mouth for six weeks",
"     </li>",
"     <li>",
"      For toenails &ndash; 250 mg daily by mouth for 12 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fixed dosage",
"      <br/>",
"      <br/>",
"      For fingernails &ndash; 200 mg daily by mouth for six weeks",
"      <br/>",
"      For toenails &ndash; 200 mg daily by mouth for 12 weeks",
"     </li>",
"     <li>",
"      Pulse therapy",
"      <br/>",
"      <br/>",
"      For fingernails &ndash; 200 mg twice daily by mouth for one week per month for two months",
"      <br/>",
"      For toenails &ndash; 200 mg twice daily by mouth for one week per month for three months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pediatric dosing options include [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      one dose per week (12 to 16 weeks for fingernails; 18 to 26 weeks for toenails)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      daily for one week per month (two months therapy for fingernails; three months therapy for toenails):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Less than 20 kg: 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily",
"     </li>",
"     <li>",
"      20 to 40 kg: 100 mg daily",
"     </li>",
"     <li>",
"      40 to 50 kg: 200 mg daily",
"     </li>",
"     <li>",
"      More than 50 kg: 200 mg twice daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"       Terbinafine",
"      </a>",
"      (six weeks for fingernails; 12 weeks for toenails):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      10 to 20 kg: 62.5 mg daily",
"     </li>",
"     <li>",
"      20 to 40 kg: 125 mg daily",
"     </li>",
"     <li>",
"      Above 40 kg: 250 mg daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Safety and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     Terbinafine",
"    </a>",
"    is an allylamine and is primarily fungicidal. It is an inhibitor of CYP2D6, but this generally results in less important drug-drug interactions than inhibitors of CYP3A4.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    are triazoles that are primarily fungistatic. They are inhibitors of CYP3A4.",
"   </p>",
"   <p>",
"    Side effects requiring discontinuation of therapy are uncommon with all three medications and discontinuation is somewhat less frequent with pulse or intermittent therapy than with continuous therapy (",
"    <a class=\"graphic graphic_table graphicRef51566 \" href=\"UTD.htm?14/14/14573\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/46\">",
"     46",
"    </a>",
"    ]. It is important to review a patient's medication list before prescribing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    since a number of serious drug interactions have been reported.",
"   </p>",
"   <p>",
"    All three medications can cause hepatotoxicity, and have low but similar rates of aminotransferase elevations requiring discontinuation of therapy (",
"    <a class=\"graphic graphic_table graphicRef64340 \" href=\"UTD.htm?15/15/15613\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/46\">",
"     46",
"    </a>",
"    ]. Routine monitoring of liver function tests during therapy may not be necessary in patients without underlying liver disease, although many clinicians routinely obtain pretreatment values and check an additional set midway through treatment for patients taking the medications for longer periods of time.",
"   </p>",
"   <p>",
"    The manufacturer of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    recommends checking pretreatment serum aminotransferases and monitoring for potential symptoms of hepatotoxicity during treatment. Given the recommendation from the manufacturer, we suggest this monitoring in patients receiving oral terbinafine. We also suggest such monitoring in patients treated with continuous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . We do not suggest checking serum aminotransferases in patients without underlying liver disease who are treated with once weekly fluconazole or pulse itraconazole.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Topical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antifungal agents formulated as lacquers facilitate the local delivery of antifungal medication into the nail [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Two antifungal nail lacquers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    and amorolfine, have been utilized for treatment of onychomycosis. Topical antifungal creams are generally considered to be poorly effective for onychomycosis due to poor penetration of the nail plate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/47,49,50\">",
"     47,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Ciclopirox",
"    </span>",
"    &nbsp;&mdash;&nbsp;A topical antifungal nail lacquer containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    is available for the treatment of mild to moderate onychomycosis that does not involve the nail matrix (ie, spares the lunula) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combined results from two randomized, controlled trials suggest that complete resolution occurs in approximately 7 percent of treated patients compared with 0.4 percent using placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/52\">",
"     52",
"    </a>",
"    ]. Thus, only 1 of 15 patients who use the lacquer will have a favorable outcome despite prolonged use, and recurrence is common after stopping therapy.",
"   </p>",
"   <p>",
"    Randomized trials have also looked at the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    in combination with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. No greater clinical efficacy was found than with terbinafine alone. The studies reported higher rates of mycological cure with combination therapy; however, this was assessed while the patients were still being treated with topical ciclopirox, which may have affected the ability to detect persistent fungal infection.",
"   </p>",
"   <p>",
"    The lacquer is applied once daily to the affected nail, 5 mm of surrounding skin, and to the nail bed, hyponychium, and undersurface of the nail plate if possible. The nail is wiped clean with alcohol once weekly, and the unattached infected part of the nail is removed periodically. Treatment is continued until nail clearance or up to 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     Ciclopirox",
"    </a>",
"    is apparently safe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/17\">",
"     17",
"    </a>",
"    ], and can be prescribed for patients who are felt to be at high risk for complications of oral therapy. Due to the low likelihood of treatment success, we generally recommend not using topical ciclopirox for onychomycosis. Higher treatment success rates have been reported with topical amorolfine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Amorolfine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amorolfine is a topical antifungal agent with activity against dermatophytes, yeasts, dimorphic fungi, and a variety of filamentous and dematiaceous fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/55\">",
"     55",
"    </a>",
"    ]. The drug is not available in the United States.",
"   </p>",
"   <p>",
"    Amorolfine nail lacquer has been used as monotherapy for the treatment of onychomycosis sparing the nail matrix (ie, lunula). The drug is applied once weekly after the surface of the nail is filed with a disposable file and wiped with alcohol. In two randomized trials, once weekly application of amorolfine 5% nail lacquer for six months led to both clinical and mycological cure in 38 and 46 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Amorolfine has also been shown to increase cure rates when used in combination with oral antifungals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/58\">",
"     58",
"    </a>",
"    ]. In a randomized, open-label trial comparing terbinafine (250",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three months) plus amorolfine (once weekly for 12 months) versus terbinafine alone, patients who received combination therapy were more likely to achieve both clinical and mycologic cure (59 versus 45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, for patients with onychomycosis sparing the nail matrix who are not candidates for oral antifungal therapy, treatment with amorolfine is a reasonable alternative. The drug also appears to be useful as an adjunct to oral antifungals, although further studies are necessary to determine which patients should be treated with combination therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H600010\">",
"    <span class=\"h3\">",
"     Iontophoresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iontophoretic drug delivery, in which a low electrical current is used to enhance the absorption of topical medications, may have promise for improving the efficacy of topical antifungal treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. In a small, unblinded randomized trial that compared treatment of toenail onychomycosis with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    plus iontophoresis to topical terbinafine alone, combination therapy appeared to increase the likelihood for new healthy nail growth [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/60\">",
"     60",
"    </a>",
"    ]. Additional studies are necessary to determine the role of iontophoresis in the treatment of onychomycosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344806\">",
"    <span class=\"h3\">",
"     Medicated chest rub",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data on the efficacy of a medicated chest rub containing eucalyptus oil, camphor, menthol, thymol, oil of turpentine, oil of nutmeg, and oil of cedar leaf (Vicks",
"    <sup>",
"     &reg;",
"    </sup>",
"    VapoRub) in the treatment of onychomycosis. In a series of 18 patients who were instructed to apply Vicks",
"    <sup>",
"     &reg;",
"    </sup>",
"    VapoRub to affected nails daily for 48 weeks, four patients (22 percent) achieved both clinical and mycological cure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/63\">",
"     63",
"    </a>",
"    ]. Improvement in a minority of patients was also reported in a retrospective chart review; clinical clearance of onychomycosis was documented within 5 to 16 months in 32 out of 85 patients (38 percent) who agreed to apply a generic formulation of Vicks",
"    <sup>",
"     &reg;",
"    </sup>",
"    VapoRub to the nails daily [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although use of Vicks",
"    <sup>",
"     &reg;",
"    </sup>",
"    VapoRub and similar products is unlikely to be harmful, additional studies that support their efficacy in onychomycosis are necessary before treatment with these agents can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H783025\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efinaconazole 10% solution, a topical triazole antifungal agent, may be a future treatment option for onychomycosis. The efficacy of efinaconazole for onychomycosis was demonstrated in two phase III multicenter randomized trials (n = 870 and n = 785) in which patients with distal lateral subungual onychomycosis were randomized in a 3 to 1 ratio to treatment with efinaconazole or vehicle once daily for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/65\">",
"     65",
"    </a>",
"    ]. Four weeks after the end of treatment, complete cure (0 percent clinical involvement and mycologic cure) was achieved by 18 and 15 percent of patients treated with efinaconazole compared with only 3 and 6 percent of patients treated with vehicle. Efinaconazole solution is not yet commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical therapy involves removal of the nail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12758?source=see_link&amp;anchor=H6#H6\">",
"     \"Nail surgery\", section on 'Nail avulsion'",
"    </a>",
"    .) Surgery is generally only used to treat an isolated nail infection or in cases involving a dermatophytoma (a collection of dermatophytes in solid form under the nail).",
"   </p>",
"   <p>",
"    Recurrences are common in the absence of additional systemic or topical therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    , since the infection typically involves the nail matrix and bed in addition to the nail itself.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Laser/light therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An in vitro study reported successful inhibition of T. rubrum in nail clippings after exposure to a femtosecond infrared laser [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/66\">",
"     66",
"    </a>",
"    ], but there is little published data available on the in vivo efficacy of laser or other light-based therapies for onychomycosis. Improvement following the use of a near-infrared laser device (Noveon&reg;) has been reported in one small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/67\">",
"     67",
"    </a>",
"    ]. A multicenter trial investigating the efficacy of another device, the Pinpointe&trade; FootLaser&trade;, is currently underway [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Photodynamic therapy has also been studied for the treatment of onychomycosis. The procedure involves the application of a topical photosensitizer followed by irradiation of the treatment site with an appropriate light source. Successful treatment with this modality was reported in case reports and a small, open-label study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/69-71\">",
"     69-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies are required to determine the clinical role of laser and light therapy in the treatment of onychomycosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3043729\">",
"    <span class=\"h2\">",
"     Treatment of yeast and mold onychomycosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data on the comparative efficacy of therapies for onychomycosis caused by yeast (mainly",
"    <em>",
"     Candida albicans",
"    </em>",
"    ) or nondermatophyte molds.",
"   </p>",
"   <p>",
"    An observational study in 15 patients found some suggestion of broader response of various nondermatophyte molds to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study in 36 patients found that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (either continuous or pulse therapy) led to clinical cure in 15 of 17 patients with onychomycosis caused by a single nondermatophyte mold and in 16 of 19 patients with mixed onychomycosis (nondermatophyte mold plus at least one other dermatophyte or nondermatophyte mold) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    also appears to have efficacy against at least some nondermatophyte molds. A randomized trial found that 12 to 24 weeks of terbinafine cured three of seven patients with onychomycosis due to Aspergillus species but none of six patients with",
"    <em>",
"     Alternaria",
"    </em>",
"    species [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/74\">",
"     74",
"    </a>",
"    ]. No patients treated with placebo (four with",
"    <em>",
"     Aspergillus",
"    </em>",
"    sp.; six with",
"    <em>",
"     Alternaria",
"    </em>",
"    sp.) achieved cure.",
"   </p>",
"   <p>",
"    A randomized trial in 16 patients with",
"    <em>",
"     Candida",
"    </em>",
"    toenail onychomycosis found no target toenail cures with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial in 90 patients with",
"    <em>",
"     Candida",
"    </em>",
"    fingernail onychomycosis found high global cure rates with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    whether used alone (81 percent cure) or in combination with amorolfine lacquer (93 percent cure) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/76\">",
"     76",
"    </a>",
"    ]. There was no significant difference between the two arms of the trial. An uncontrolled trial of itraconazole in 44 patients with",
"    <em>",
"     Candida",
"    </em>",
"    fingernail",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    toenail onychomycosis found complete cure in 75 percent of patients, and in 11 of the 12 patients with fingernail onychomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The randomized trial discussed above found that 12 to 24 weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     terbinafine",
"    </a>",
"    cured 10 of 23 patients with",
"    <em>",
"     Candida",
"    </em>",
"    species; none of nine patients treated with placebo were cured [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/74\">",
"     74",
"    </a>",
"    ]. An uncontrolled trial of terbinafine in onychomycosis reported complete target toenail cure in 12 of 20 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these results, we prefer to treat onychomycosis caused by nondermatophyte molds or by",
"    <em>",
"     Candida",
"    </em>",
"    species with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . It is used in the same dose regimens as used for dermatophyte onychomycosis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"     Terbinafine",
"    </a>",
"    does also appear to have efficacy in some patients.",
"   </p>",
"   <p>",
"    The treatment of",
"    <em>",
"     Fusarium",
"    </em>",
"    onychomycosis in immunocompromised patients is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=see_link&amp;anchor=H346085011#H346085011\">",
"     \"Treatment and prevention of Fusarium infection\", section on 'Onychomycosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3043918\">",
"    <span class=\"h1\">",
"     NAIL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thick, dystrophic nails due to onychomycosis can make it difficult for patients to trim nails and may lead to pain during ambulation. The removal of hyperkeratotic nail debris may help to ameliorate these symptoms.",
"   </p>",
"   <p>",
"    Topical urea is a keratolytic agent that we have found useful for this purpose in patients who forgo antifungal treatment and as an adjunctive measure in those who proceed with treatment. For patients with very thick, dystrophic nails, we utilize the following nighttime regimen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apply a generous, protective layer of petrolatum to the periungual skin",
"     </li>",
"     <li>",
"      Apply a thick layer of urea 40% cream or ointment to the nail",
"     </li>",
"     <li>",
"      Occlude the nail with a bandage or tape and leave on overnight",
"     </li>",
"     <li>",
"      Wash the urea off with soap and water in the morning",
"     </li>",
"     <li>",
"      Repeat this procedure nightly until the nail softens and can be easily clipped or debrided",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Reapplication of urea without occlusion on an as-needed basis can be used to maintain improvement in these patients. Treatment without occlusion also is often sufficient for reducing nail hyperkeratosis in patients who present with less severe nail thickening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TREATMENT FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed in the preceding sections, all treatments for onychomycosis have relatively high rates of failure. Potential causes of treatment failure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inaccurate diagnosis (eg, disease is psoriasis rather than onychomycosis)",
"     </li>",
"     <li>",
"      Inadequate adherence to a full course of therapy",
"     </li>",
"     <li>",
"      Drug resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When a patient does not respond despite a confirmed diagnosis of onychomycosis, and treatment is still desired, we suggest switching to an alternative oral agent or referring the patient to a dermatologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported long-term recurrence rates of onychomycosis range from approximately 20 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/41,79,80\">",
"     41,79,80",
"    </a>",
"    ]. Methods that are sometimes tried in an attempt to prevent recurrence include intermittent oral antifungal therapy and the application of topical antifungal creams, powders, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    to affected nails after clinical cure is attained. There is little objective evidence to support these attempts at prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence supporting the use of amorolfine following successful treatment of onychomycosis. In a randomized trial (n = 52), more patients treated with amorolfine remained disease free three years after initial cure than patients who received no prophylactic therapy (70 versus 50 percent). However, a separate prospective study reported no significant difference in the rate of recurrence of onychomycosis with or without amorolfine prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/39\">",
"     39",
"    </a>",
"    ]. Amorolfine is not available in the United States. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Amorolfine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We typically do not prescribe prophylactic therapy after successful treatment of onychomycosis. However, we suggest that patients who develop tinea pedis after resolution of onychomycosis should be treated for this disorder in the hope that this might reduce the risk of recurrent onychomycosis.",
"   </p>",
"   <p>",
"    Patients who develop recurrent onychomycosis can generally be retreated with success rates similar to those seen for primary treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/8/5258/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/1/42001?source=see_link\">",
"       \"Patient information: Fungal nail infections (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onychomycosis refers to nail infections caused by any fungus, including yeasts and nondermatophyte molds. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dermatophytic onychomycosis (tinea unguium) occurs in three distinct forms: distal subungual; proximal subungual; and white superficial. Distal subungual onychomycosis is most common and is generally caused by Trichophyton rubrum. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to establish a diagnosis of onychomycosis prior to treatment. Nail dystrophies, often clinically indistinguishable from onychomycosis, can occur with psoriasis, eczematous conditions, senile ischemia (onychogryphosis), trauma, iron deficiency, and lichen planus. Most studies have found that onychomycosis is responsible for only 50 to 60 percent of abnormal appearing nails. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest potassium hydroxide (KOH) examination of scrapings of the nail bed to diagnose distal subungual onychomycosis and of the white spots on the nail plate to diagnose white superficial onychomycosis. Nail culture or pathologic examination of the nail plate with periodic acid-Schiff (PAS) staining should be performed if the KOH examination is negative and a diagnosis of onychomycosis is suspected. Pathologic examination of the nail plate is more sensitive and faster than nail culture, but is more costly. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A nail plate biopsy with PAS staining or partial or full nail removal with culture is needed for the diagnosis of proximal subungual onychomycosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who desire treatment should be warned that treatment failures and recurrences are common, particularly for toenail onychomycosis. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment failure'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Onychomycosis is most often treated to relieve pain from infected nails or for cosmetic reasons. We also suggest treating toenail onychomycosis in patients with a history of ipsilateral lower extremity cellulitis and in patients with diabetes who have additional risk factors for cellulitis (ie, prior cellulitis, venous insufficiency, edema) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who desire or need therapy for dermatophyte onychomycosis, or where the fungal species causing onychomycosis has not been identified, we suggest initial treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"       terbinafine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Fingernail onychomycosis is typically treated for six weeks and toenail onychomycosis for 12 weeks with terbinafine 250 mg daily. We suggest that patients who desire or need therapy for yeast onychomycosis or nondermatophyte mold onychomycosis be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest checking baseline serum aminotransferases before patients are treated with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33120?source=see_link\">",
"       terbinafine",
"      </a>",
"      or with continuous oral therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       itraconazole",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest NOT checking aminotransferases in patients receiving once weekly fluconazole or pulse itraconazole (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Safety and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient does not respond despite a confirmed diagnosis of onychomycosis, and treatment is still desired, we suggest switching to an alternative oral agent or referring the patient to a dermatologist (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Treatment failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/1\">",
"      Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter canadian survey of 15,000 patients. J Am Acad Dermatol 2000; 43:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/2\">",
"      Erbagci Z, Tuncel A, Zer Y, Balci I. A prospective epidemiologic survey on the prevalence of onychomycosis and dermatophytosis in male boarding school residents. Mycopathologia 2005; 159:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/3\">",
"      Sahin I, Kaya D, Parlak AH, et al. Dermatophytoses in forestry workers and farmers. Mycoses 2005; 48:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/4\">",
"      Romano C, Gianni C, Difonzo EM. Retrospective study of onychomycosis in Italy: 1985-2000. Mycoses 2005; 48:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/5\">",
"      Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol 2004; 50:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/6\">",
"      Ploysangam T, Lucky AW. Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. J Am Acad Dermatol 1997; 36:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/7\">",
"      Sigurgeirsson B, Steingr&iacute;msson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol 2004; 18:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/8\">",
"      Pi&eacute;rard GE, Pi&eacute;rard-Franchimont C. The nail under fungal siege in patients with type II diabetes mellitus. Mycoses 2005; 48:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/9\">",
"      Mu&ntilde;oz-P&eacute;rez MA, Rodriguez-Pichardo A, Camacho F, Colmenero MA. Dermatological findings correlated with CD4 lymphocyte counts in a prospective 3 year study of 1161 patients with human immunodeficiency virus disease predominantly acquired through intravenous drug abuse. Br J Dermatol 1998; 139:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/10\">",
"      Zaias N, Tosti A, Rebell G, et al. Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 1996; 34:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/11\">",
"      Faergemann J, Correia O, Nowicki R, Ro BI. Genetic predisposition--understanding underlying mechanisms of onychomycosis. J Eur Acad Dermatol Venereol 2005; 19 Suppl 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/12\">",
"      Roujeau JC, Sigurgeirsson B, Korting HC, et al. Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004; 209:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/13\">",
"      Bristow IR, Spruce MC. Fungal foot infection, cellulitis and diabetes: a review. Diabet Med 2009; 26:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/14\">",
"      Hay RJ, Baran R. Onychomycosis: a proposed revision of the clinical classification. J Am Acad Dermatol 2011; 65:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/15\">",
"      Finch J, Arenas R, Baran R. Fungal melanonychia. J Am Acad Dermatol 2012; 66:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/16\">",
"      Shemer A, Davidovici B, Grunwald MH, et al. New criteria for the laboratory diagnosis of nondermatophyte moulds in onychomycosis. Br J Dermatol 2009; 160:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/17\">",
"      Gupta AK. Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J Am Podiatr Med Assoc 2002; 92:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/18\">",
"      Elewski BE, Leyden J, Rinaldi MG, Atillasoy E. Office practice-based confirmation of onychomycosis: a US nationwide prospective survey. Arch Intern Med 2002; 162:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/19\">",
"      Lawry MA, Haneke E, Strobeck K, et al. Methods for diagnosing onychomycosis: a comparative study and review of the literature. Arch Dermatol 2000; 136:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/20\">",
"      Lilly KK, Koshnick RL, Grill JP, et al. Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests. J Am Acad Dermatol 2006; 55:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/21\">",
"      Wilsmann-Theis D, Sareika F, Bieber T, et al. New reasons for histopathological nail-clipping examination in the diagnosis of onychomycosis. J Eur Acad Dermatol Venereol 2011; 25:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/22\">",
"      Weinberg JM, Koestenblatt EK, Tutrone WD, et al. Comparison of diagnostic methods in the evaluation of onychomycosis. J Am Acad Dermatol 2003; 49:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/23\">",
"      Lim CS, Lim SL. New contrast stain for the rapid diagnosis of onychomycosis. Arch Dermatol 2011; 147:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/24\">",
"      Litz CE, Cavagnolo RZ. Polymerase chain reaction in the diagnosis of onychomycosis: a large, single-institute study. Br J Dermatol 2010; 163:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/25\">",
"      Crawford F. Athlete's foot and fungally infected toe nails. Clin Evid 2002; :1458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/26\">",
"      Arenas R, Fern&aacute;ndez G, Dom&iacute;nguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol 1991; 30:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/27\">",
"      Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol 1995; 32:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/28\">",
"      Hofmann H, Br&auml;utigam M, Weidinger G, Zaun H. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group. Arch Dermatol 1995; 131:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/29\">",
"      Scher RK. Onychomycosis: therapeutic update. J Am Acad Dermatol 1999; 40:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/30\">",
"      Scher RK, Breneman D, Rich P, et al. Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J Am Acad Dermatol 1998; 38:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/31\">",
"      Gupta AK. Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis. Pharmacoeconomics 1998; 13:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/32\">",
"      Havu V, Heikkil&auml; H, Kuokkanen K, et al. A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol 2000; 142:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/33\">",
"      Salo H, Pekurinen M. Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. Pharmacoeconomics 2002; 20:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/34\">",
"      Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. Br J Dermatol 2004; 150:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/35\">",
"      Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 1999; 318:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/36\">",
"      Kejda J. Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis. Postgrad Med 1999; Spec No:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/37\">",
"      Degreef H, del Palacio A, Mygind S, et al. Randomized double-blind comparison of short-term itraconazole and terbinafine therapy for toenail onychomycosis. Acta Derm Venereol 1999; 79:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/38\">",
"      De Cuyper C, Hindryckx PH. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol 1999; 141 Suppl 56:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/39\">",
"      Piraccini BM, Sisti A, Tosti A. Long-term follow-up of toenail onychomycosis caused by dermatophytes after successful treatment with systemic antifungal agents. J Am Acad Dermatol 2010; 62:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/40\">",
"      Crawford F, Young P, Godfrey C, et al. Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol 2002; 138:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/41\">",
"      Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/42\">",
"      Warshaw EM, Fett DD, Bloomfield HE, et al. Pulse versus continuous terbinafine for onychomycosis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2005; 53:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/43\">",
"      Warshaw EM, Bowman T, Bodman MA, et al. Satisfaction with onychomycosis treatment. Pulse versus continuous dosing. J Am Podiatr Med Assoc 2003; 93:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/44\">",
"      Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 2012; 166:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/45\">",
"      Gupta AK, Sibbald RG, Lynde CW, et al. Onychomycosis in children: prevalence and treatment strategies. J Am Acad Dermatol 1997; 36:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/46\">",
"      Chang CH, Young-Xu Y, Kurth T, et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am J Med 2007; 120:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/47\">",
"      Murdan S. Drug delivery to the nail following topical application. Int J Pharm 2002; 236:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/48\">",
"      Bohn M, Kraemer KT. Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis. J Am Acad Dermatol 2000; 43:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/49\">",
"      de Berker D. Clinical practice. Fungal nail disease. N Engl J Med 2009; 360:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/50\">",
"      Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008; 166:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/51\">",
"      Ciclopirox (Penlac) nail lacquer for onychomycosis. Med Lett Drugs Ther 2000; 42:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/52\">",
"      Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/53\">",
"      Gupta AK, Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 2005; 4:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/54\">",
"      Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. J Dermatolog Treat 2005; 16:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/55\">",
"      Welsh O, Vera-Cabrera L, Welsh E. Onychomycosis. Clin Dermatol 2010; 28:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/56\">",
"      Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17 Suppl 1:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/57\">",
"      Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly. Clin Exp Dermatol 1992; 17 Suppl 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/58\">",
"      Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol 2005; 19:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/59\">",
"      Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007; 157:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/60\">",
"      Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol 2010; 162:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/61\">",
"      Amichai B, Mosckovitz R, Trau H, et al. Iontophoretic terbinafine HCL 1.0% delivery across porcine and human nails. Mycopathologia 2010; 169:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/62\">",
"      Nair AB, Kim HD, Chakraborty B, et al. Ungual and trans-ungual iontophoretic delivery of terbinafine for the treatment of onychomycosis. J Pharm Sci 2009; 98:4130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/63\">",
"      Derby R, Rohal P, Jackson C, et al. Novel treatment of onychomycosis using over-the-counter mentholated ointment: a clinical case series. J Am Board Fam Med 2011; 24:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/64\">",
"      Ramsewak RS, Nair MG, Stommel M, Selanders L. In vitro antagonistic activity of monoterpenes and their mixtures against 'toe nail fungus' pathogens. Phytother Res 2003; 17:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/65\">",
"      Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 2013; 68:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/66\">",
"      Manevitch Z, Lev D, Hochberg M, et al. Direct antifungal effect of femtosecond laser on Trichophyton rubrum onychomycosis. Photochem Photobiol 2010; 86:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/67\">",
"      Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J Am Podiatr Med Assoc 2010; 100:166.",
"     </a>",
"    </li>",
"    <li>",
"     PinPointe FootLaser for the Treatment of Onychomycosis. file://clinicaltrials.gov/ct2/show/NCT00935649 (Accessed on June 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/69\">",
"      Watanabe D, Kawamura C, Masuda Y, et al. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008; 144:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/70\">",
"      Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 2008; 59:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/71\">",
"      Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial. Acta Derm Venereol 2010; 90:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/72\">",
"      Gupta AK, Gregurek-Novak T, Konnikov N, et al. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. J Cutan Med Surg 2001; 5:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/73\">",
"      De Doncker PR, Scher RK, Baran RL, et al. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients. J Am Acad Dermatol 1997; 36:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/74\">",
"      Lebwohl MG, Daniel CR, Leyden J, et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol 2001; 40:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/75\">",
"      Warshaw EM, Nelson D, Carver SM, et al. A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis. Int J Dermatol 2005; 44:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/76\">",
"      Rigopoulos D, Katoulis AC, Ioannides D, et al. A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol 2003; 149:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/77\">",
"      Gupta AK, De Doncker P, Haneke E. Itraconazole pulse therapy for the treatment of Candida onychomycosis. J Eur Acad Dermatol Venereol 2001; 15:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/78\">",
"      Segal R, Kritzman A, Cividalli L, et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/79\">",
"      Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/80\">",
"      Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 1998; 197:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/8/5258/abstract/81\">",
"      Warshaw EM, St Clair KR. Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. J Am Acad Dermatol 2005; 53:717.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4034 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5258=[""].join("\n");
var outline_f5_8_5258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1346087\">",
"      Subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Distal subungual onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Proximal subungual onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - White superficial onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1346118\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Yeast onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mold onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1183587\">",
"      Fungal melanonychia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      KOH examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1346147\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Safety and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Topical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Ciclopirox",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Amorolfine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H600010\">",
"      - Iontophoresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H344806\">",
"      - Medicated chest rub",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H783025\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Laser/light therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3043729\">",
"      Treatment of yeast and mold onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3043918\">",
"      NAIL CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TREATMENT FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4034|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/3/4148\" title=\"picture 1A\">",
"      Totally dystrophic onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/22/14690\" title=\"picture 1B\">",
"      Distal subungual onychomycosis - toenail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/10/44195\" title=\"picture 2A\">",
"      Proximal subungual onychomycosis - toenails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/24/38275\" title=\"picture 2B\">",
"      Proximal subungual onychomycosis - fingernails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/48/5888\" title=\"picture 3\">",
"      Superficial onychomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4034|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/14/14573\" title=\"table 1\">",
"      Onycho continuous safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/15/15613\" title=\"table 2\">",
"      Onycho tx discont",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30648?source=related_link\">",
"      Candidal intertrigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12758?source=related_link\">",
"      Nail surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/1/42001?source=related_link\">",
"      Patient information: Fungal nail infections (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_8_5259="Infant hypoall formula PI";
var content_f5_8_5259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Formula options for infants with dietary protein-induced conditions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Extensively hydrolyzed casein protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alimentum",
"       </td>",
"       <td>",
"        (Abbott)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutramigen LIPIL",
"       </td>",
"       <td>",
"        (Mead Johnson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregestimil",
"       </td>",
"       <td>",
"        (Mead Johnson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Amino acid-based",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elecare Infant",
"       </td>",
"       <td>",
"        (Abbot)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neocate Infant",
"       </td>",
"       <td>",
"        (Nutricia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Puramino (also known as Nutramigen AA)",
"       </td>",
"       <td>",
"        (Mead Johnson)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alan Lake, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5259=[""].join("\n");
var outline_f5_8_5259=null;
var title_f5_8_5260="Protocol for IV AAT replacement";
var content_f5_8_5260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52673&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous augmentation therapy with alpha-1-antiprotease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pre-procedure testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spirometry with DLCO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis profile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver function tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV titer*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Immunizations*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hepatitis B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        First dose at time of initial infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Repeat dose at 1 and 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anti-hepatitis B immunoglobulin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dose: 0.06 mL/kg IM once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Supportive therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cessation of smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoidance of respiratory irritants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Combination bronchodilators",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary rehabilitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxygen therapy (as needed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treatment of respiratory infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza and pneumococcal vaccinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Protocol for monthly augmentation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Product: Pooled plasma-derived alpha 1-antiprotease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interval: Weekly, biweekly, monthly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dose: ___ mg/kg, 60 mg/kg (weekly) or 250 mg/kg (monthly)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight: ___ kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infusion rate depends on specific products used. Consult package insert.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Variable practice.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5260=[""].join("\n");
var outline_f5_8_5260=null;
var title_f5_8_5261="Pruritus systemic therapy";
var content_f5_8_5261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Systemic therapies for pruritus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose range",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Antihistamines",
"        </strong>",
"       </td>",
"       <td>",
"        Variable depending on medication",
"       </td>",
"       <td>",
"        No direct effect on pruritus except in urticaria; sedating antihistamines may be useful through their soporific effects",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        SNRIs",
"       </td>",
"       <td>",
"        Mirtazapine 7.5 to 15 mg at night",
"       </td>",
"       <td>",
"        Useful in nocturnal pruritus, may cause increased weight and appetite",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        SSRIs",
"       </td>",
"       <td>",
"        Paroxetine 10 to 40 mg per day",
"       </td>",
"       <td>",
"        Consider in psychiatric patients with pruritus and paraneoplastic pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluvoxamine 25 to 150 mg per day",
"       </td>",
"       <td>",
"        Consider in psychiatric patients with pruritus and paraneoplastic pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertraline 75 to 100 mg per day",
"       </td>",
"       <td>",
"        Useful in cholestatic pruritus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         &micro;-opioid receptor antagonists",
"        </strong>",
"       </td>",
"       <td>",
"        Naltrexone 25 to 50 mg per day",
"       </td>",
"       <td>",
"        Useful in patients with cholestatic and CKD-associated pruritus; may cause nausea, vomiting and drowsiness; reverses analgesia and may precipitate acute withdrawal in patients receiving opioid analgesics",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         &kappa;-opioid receptor agonist/&micro;-opioid receptor antagonist",
"        </strong>",
"       </td>",
"       <td>",
"        Butorphanol 1 to 4 mg intranasally per day",
"       </td>",
"       <td>",
"        Useful in nocturnal and intractable pruritus; may cause nausea and vomiting as well as drowsiness; may precipitate acute withdrawal in patients receiving opioid analgesics; some potential for abuse due to concomitant weak &micro;-opioid receptor agonist activity",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Selective &kappa;-opioid receptor agonist",
"        </strong>",
"       </td>",
"       <td>",
"        Nalfurafine 2.5 to 5 micrograms per day",
"       </td>",
"       <td>",
"        Useful in CKD-associated pruritus; may cause insomnia; approved in Japan only",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Anticonvulsants",
"        </strong>",
"       </td>",
"       <td>",
"        Gabapentin 100 to 3600 mg per day",
"       </td>",
"       <td rowspan=\"2\">",
"        Applies to both: useful in neuropathic pruritus, may cause drowsiness and weight gain; usually given in two to three divided daily doses; dose alteration for renal insufficiency may be needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregabalin 150 to 300 mg per day",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Substance P antagonist",
"        </strong>",
"       </td>",
"       <td>",
"        Aprepitant 80 mg per day",
"       </td>",
"       <td>",
"        Beneficial in pruritus associated with the S&eacute;zary syndrome; expensive",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CKD: chronic kidney disease; SNRI: selective neuroepinephrine reuptake inhibitor; SSRI: selective serotonin reuptake inhibitor.",
"     <br>",
"      * Immunosuppressive agents such as cyclosporine, azathioprine, and mycophenolate mofetil may be beneficial for pruritus in severe atopic dermatitis (see \"Management of severe refractory atopic dermatitis\").",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       All doses are for adult patients, oral administration, unless noted otherwise.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother 2010; 11:1673. Copyright &copy; 2010 Informa Healthcare. Adapted with permission of Informa Healthcare.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5261=[""].join("\n");
var outline_f5_8_5261=null;
var title_f5_8_5262="State driving restrictions A";
var content_f5_8_5262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Driving and epilepsy: regulations and practices of US states in 2001",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        State",
"       </td>",
"       <td class=\"subtitle1\">",
"        Seizure-free restriction, months*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rare exceptions to seizure-free interval considered based on mitigating factors&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Required MVA medical review, interval in y",
"       </td>",
"       <td class=\"subtitle1\">",
"        Physician liable for driving recommendation&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alabama",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Annually for 5 y from last seizure",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alaska",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arizona",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Nocturnal, aura, and AED revision",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arkansas",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        California",
"       </td>",
"       <td>",
"        3, 6, or 12",
"       </td>",
"       <td>",
"        Nocturnal, breakthrough, and AED revision",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colorado",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Connecticut",
"       </td>",
"       <td>",
"        3*",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        District of Columbia",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        Nocturnal, AED revision, and solitary seizure",
"       </td>",
"       <td>",
"        1 (until seizure- free for 5 y)",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delaware",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Florida",
"       </td>",
"       <td>",
"        24*",
"       </td>",
"       <td>",
"        Nocturnal (must supply EEG)",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Georgia",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        First seizure and nocturnal",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hawaii",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idaho",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        MD recommendation",
"       </td>",
"       <td>",
"        1 (or semiannually)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Illinois",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indiana",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iowa",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Nocturnal",
"       </td>",
"       <td>",
"        6 mo, then at every renewal",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kansas",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Nocturnal and solitary seizure",
"       </td>",
"       <td>",
"        1 (until 3 y seizure-free)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kentucky",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        1",
"        <br/>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Louisiana",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        AED revision",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maine",
"       </td>",
"       <td>",
"        3*",
"       </td>",
"       <td>",
"        Seizure \"breakthrough\"",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maryland",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        AED revision",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massachusetts",
"       </td>",
"       <td>",
"        6*",
"       </td>",
"       <td>",
"        MAB recommendation",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Michigan",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        AED revision",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minnesota",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        Acute illness, AED revision, and first seizure",
"       </td>",
"       <td>",
"        Every 6 mo (until 1 y seizure-free)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mississippi",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Missouri",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        MD recommendation",
"       </td>",
"       <td>",
"        Individual",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Montana",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        No (MVA may require)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MVA: motor vehicle agency; AED: antiepileptic drugs; MAB: medical advisory board.",
"     <br>",
"      * Seizure-free restriction frequently adjusted by MVA MAB and treating physicians.",
"      <br>",
"       &bull; Mitigating factors considered in permitting some patients to drive despite less than minimum seizure-free period: auras, nocturnal seizures only, seizure breakthrough during physician-directed AED change, and solitary or first seizure.",
"       <br>",
"        &Delta; No: physicians legally immune or indemnified; yes: physician possibly liable for driving recommendation.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Krauss GL, Ampaw LA, Krumholz A. Individual state driving restrictions for people with epilepsy in the US. Neurology 2001; 57:1780. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5262=[""].join("\n");
var outline_f5_8_5262=null;
var title_f5_8_5263="Rickets bow-legs 2";
var content_f5_8_5263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bow-legs in rickets",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 207px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADPAPwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDtuc1YAJPBwagHf1qZCMAHv0NJgSqTng1Q8R6mmi6DfapK6qtrEXGf4mPCj8TV9QB0rzj41X7SW2jaBGeb2b7RMB/cToPxNRKXKm2OMXJqKOO8F2csQWe4BM0zGVyf7zHJ/U12njC+/s3wdfXIb5xFsT/ebgfzpNKsESCNAvbisz4t77fwSibQoedQfw5rxqUvbV436s9ur+5oSt0R5HDJEsaKc/KOo71cguE3ALnJ65FZiNjH0q5CcYJ6V9YqEWfIyx8462NmKSMgDKgjpVpCjKBvFZMR3dP0qyq8cCr+pp7MxebNPWJoADBGc+9QSrt6nI9qgKgA8j8KrSOQ2Qx4qJYKUdma081hJ6xsSsfnAYcd69i+DHibU7HQpbPT5Yordrls5QFs4Hc14k1xIvIwfrXrnwXi83SWbIMjTM7+x4H9K87HqdGk5Hr4GpSxFRRWp2vjiW4vrFnu5pJjt6scj8B2ra+Ds3mfDvTQTkxvNEfbbIwrJ1+PzkkhAJyKl+DjvbWmt6W/Btbrz4/9yQZP65ryMBUbm1J7no5hTtBWWx6IDznI5FU9avodK0jUNSuCPs9nbvcOPUKpNW+D0JrnPiP4fm8WeCNY0S1naC6uIt0RQ43svzBD7EjB+teweMj5K1nXNT8Xumo67dPc3TvvVT92JM8Ki9hUsLsMMFZQOOO1YWlXTwiISxshII2kdcHBx68it2yutxYDBU9Qa26GtuhaEzE8gMDznNWraUFgGB47DvVKHAd9qZHtS2j4BJRhg9KloXQ1ZJkPZwfQmmiWMJxuGTTCyyoAOMepquHVP4h+dSkIdLNuBCg49PWq4z5gDDinvKu3hlx6DjFNaVY4yzFTxnrVIonsdSfSdZsNQhyXtJ0mwOCQpyR+NfUVjewalYW1/ahxb3cSzx7hhtrDIzXyDEupaxcLbaPYXNy0jbVaOM4POOvSvrjSLFNK0bT9ORtwtLeODd6lVAzSkiJItAnHTI6CmNuBPzdqeevfNMY9v1qGSmRMc/gMVE5564qRuuSMU05qRp3MNR19alUnGD6dqgHTNWIz8nT2psskU4X1rxnxxP8Aa/i00Z5S0toolBPQkbj/ADr2YHnFeEXUv2r4p+IpOoS6MYP+6AP6Vz4p2pM6MIr1Uej6auSuO38q4z416gi6TaWJGXeTzOvQCu209wltu6MOCM14z8W9TW98U+QjHbbIEP1NedllPnrpvoejmdTkw7Xc5KFtx5zmraVnIxZuDwKuwsRxX1sGfF1Il6J9vTOaspcH+I1Vi5FSqAeQK6ItnFNJ7lgS54Aps7qFPvTGIQ8A1UubgrIoP3TVSlZakwp8z0JS+RxXrnwRmxY3Gcf6/Az/ALoNeQBcgEV2Pwt1r7NrT6YzLtkHnLn+8OK8vNIueGkkexk0lDFRPoC98tsttxnkVj+E7k2nxK8pTiK/s3Vh2JQ5H8zWhDJ5tsC3XvWBpjbfiboIAxlpVP0218hgnJYiJ9ni4p0JHrIk46EDPeqOv3Mdn4f1e6mWVooLOaRhD9/AQn5T61aBOa4T456yukfC3Wf3zxXN8FsrcR4DO7nkfTbnNfTI+aWpyXwp8D6X4m+G3h9PE1hb3NnHGwju7clJYd7FgGI5749K0dV/Z2TypJdF12SCTf8Au47lBIhX3Yc1i/Cy61zR9Lt20iZXKRhXtM/IwA9DXtngzxhY6ldfZLnOn35HNnL91m9UJ6fSlCtGWkWXKFSm7SPmzxF8L/E3h52a/sXuYB/y8WrExkf0/Guek0u7hBIhuABzhG3A191OMKQuP909K5688OeHr793qOjWYY9D5YH5MMGqbl0C6W58YfYZsnYl8nr+73Zpq2lyvyMkzA/349pr7Al+HHhJfmGmNyei3EuP/Qq07Hwf4d09A9po9qrDncyb2/Nsmi8+ocyufI2g+BfE3iKRV0Xw7cSR9Tc3BEMX4M3X6CvS/C/wHuIbpLvxhewzWsXzfYNPVmMpH8LMe30r6KhUJCIo12KOAFGNo/pVHWL+00qxZpruG1IXIeVunvjvVXE5HnurabFpskDzWkNqrssNtCoC+XH0HTvkjir7kbuv41xvizxtpJDPawTandxSF1uJ2KRrjkdOTzzgYFdFol4L7RbC72gefAsvtkj+VJtPYyimty2GPJxzTWIwfX60bieQRmmsct/OpZQxsE8dKaSM8tStz+NRFjk8jr3oGjEUHPNSrkg4PNRJ97BJqbOD/Kg0JomAbex+VRub8K+f/BDNqut6lqOM/aruSX82NexeNr7+zfB2uXgbDR2jhf8AeYYH6mvL/hZaeVpkBxzt3HiuHMJctK3c7svjzVL9jtdcvV0rRbq5IB8mIuR6nHH6184T3M17dS3E7F5JWLsT6mvX/ilrkVnoNxCMmS4xEB2HNeQxoSuBzWmU0rQcrGOb1feULk0JVVqeM9DUMUe3JNSqQTjBxXuRPnZasvQt/tD8aniO/PzdKppwm7AFSwP8wwa3izlnHdoeXG4A4/Oq1+N0Z7HFS3GFbdwP60xirrzyMd6UtdBw0akira3RFu687h0xW7D4gCjwrM1jHb3GmvJbT3ES4E8btlC/+0CW5+lc2LaZJy0YGPc1qRalPBoesae1vHJBfxIDkZKPG25WU9scj8a5asXUg4yPRw840qqlGx9NaHd+bGFOW3DIPrWdakr8TfD7c/651P8A3zXO/CjVm1Pw5YzuxMipsY+44robhvJ8ceHJ+ii9UZPuCK+Opx5MUl5n2VR89Btdj1evnr9o7Vmv/HOieH42Pk6dD9plXqDK/TPuB/OvodE3zLH6ttr5G8T3p1n40eJLpiWUXZiXPZU+Ufyr360uWDZ4OGjzVEj1bwDH5KRnntXol9pthrduI76MiQD5J4ztkQ9iD/SuD8KYCoFxkV2kMu07euOetfORqyjPmR9BKEZx5ZIitPEuteC7mK21hm1DSeiXhPzBfQ+4+v516Z4e1zTPENh9p0y4W4hJwQRgqfQivObq9DxPDMokhZeQ4yDXn0Osf8IX4ot72yuJINOuJFiuE6hMnhsema9vDYtVPdluePicI6XvQ2PpKW2hUdXTP901Tuks7aPfNLKT1ALnn8qybTxPE8RFw0fmrwcHgnsR7GvLvG3jGbWtUfTNHm2QRnbPcd29VHoP513SairtnmxvOVoI6rV/iZulex8O2rTXbNsUkZ/EDv8AjWCdAudQma68SXck0pORArZAPuf6D86b4ZgttOj/ANHH71vvynqf8K12uCw4bPvXjYnHNu0D2sNgFH3qmrOE8X20UERhgiEceMYUfz9a1/hLfG68FCCQlnsriS3JJ7Z3L+hFUvFjiSFyTz3qr8FrgbfEUCkbUuI5R7ZUD+lPL5tzd9R5hTSgmj0bODx0pGbB5PX15o7Gmk8455r12eONkYen5VGXwcDH41IxyD14qFjkkkCkMxx1JGPpipFPNQjsR2qRcdR+NJFnH/Gi5S3+GmqBmw07RxKPUlx/Suc8AxyRaMm4Avt4Bpnx6uzNL4c0UH/WytdSD2HA/maveGXWJ4YCQCRyD24rzcxd7RPUy5W5pHPXtvZ6/qWm+HLh1abUb5pLzacSW8cYIRQTwNxZvyFZviX4X6rperXNtoRGrW8YzujyGX1U57iovFFqZviJOttJjMSEsDgqRnnI716f4W8daz4cjQeIbX7fp2Qv2pQC6jtk9/xxXfhqsYxUYvXscWLoObc5K6PA7q3uLJ/Lvbaa3ccETIV/nQoXg7cZHbvX2naS+HfG+lo81raajayAhSyjKn0PcEe9chd/AjwvfTSPZtd2rMx+RZMqp9B6V6MK66njTw9/hPmKJFZDhsn0p3lJyQ4FfQjfs/abvdIvEF1ayj/lnPED+vcVWP7PShufFsKr2xbZP/oVaqvCxzvDVL6HgmF3cuDjqMU35OQua+i7X9nXT2Ki48R3Mh7+VCq5+nNW9W+E3w48H2iXPiK7u5+DtSSb5pCOwUUnXiOOFn1PmaPMkoijBklY8IgLMfwFen/DvwIbTVdN13xg0On6ZHMvl21ycSXJPH3f7vNdppd7Ndl4/h34YstB00DnUbiMPK30JyAfpuPuK5rxVpElpDc397e3F9fAb2mmYknHOBnJArhxGYU6fut6/ienhssnL3jI8L7/AAp438QeF7ngwXjPDjoUbkY/AivRNaYG60WdSd/22Lb7815z4nuTrXx4eV08qIWsItwv8UYjGCfXqa73xFIbNLZ9oJtpEnU/QivBxkYxxMZeaPocLJyw7i+zPZdwiujIx4iZnP0GTXxT4TmN54n1O7Y5M9zJJk98sTX2ZeyLNY3k0R/1lpLImPeMkfzr4t+HnE82Thi5/nXpYv8AhM83BL96e56HNsCjOAB1966M3p2534Ld81xumSlVGOc9+1abTkoSelfOvc95bGrcah+7AJ+uTXI3dk3ijXrTRYyyi5Y+bIvJjjH3n/CnanqHkQvuYcDJyK7v4X6E+naS2q3qj7fqShwCOYoeqr+PU/WvRwNJzlfscONq+zj5lGTwhrWh+B9TttN1uTUdQtLaVrGWWLEm0DKoT3IGcH6V5F8NdWE9grSMWnYnzC3Xf3r6gSTY6uOdp6djXyz4u0v/AIQf4q6npsHFjekXtrjsr5OPwOR+FepiouUGkeZhWlPU9asb8LGFUcdWGeavC9/duY2x7HrXDaffF41Jb5T1rWjnJAIOATzzXzctz6COweIpzIhLHA9qi+C741zxLH1BjhbP/AmqhrdwTAzHGKs/A4GXWPEs5HyiOFPxyTXpZcvfuefj/wCGesnnGOKafTml74prHueK9hnjIa5ZQCDzUWTUhI79Ov1qI9egpDMZfanocrUQbGODUic/Smizx34pp53xZ0ePO7NmmF9OTWxf3FvZ+LbG2C4byMtg/ewfSsb4lLJp3xg0a/kANvcQIsZbpkHBFLrt2LDxcdcu0jLWZJWN03JLxwpx2rz8TDnqWfY9XBO1L5mZZ2//ABW+rSNkky5HsMDFeqaM2yFlKBoyMFSMg/hXlOkahJqurXGpyQxwvdSGQxR/dT0Uewr0HSro+UAxrza7tP0O+mlyWK2rWF94ZuzrXhF5IoEw9xYhsrgdSB3HX6V7V8OfF1p4u003doPLljws0RPKN9P615d9sCk5PGOlcra6lN4I8YW+q6bI8Wm3BKXCDkDPUf1H4162CxTqe5Pc8jHYRR/eQPriVYbiEedGrgeo6VTm062bGxFwfWuRTxZv8todssMqLIkkfKlSAc5/Gm6h4nEbJHFtd2OAueK9A8ltsn8beJ7DwPoNxeg+fdt8sEX/AD0kPQD+teJ6RpVxrmoPrvjCSa4uZm8yO1kPyp9fTtxWb4r12XxJ4+xdt/oenErEnRSw6n8/5Vvx3uSp3V5+OxLp+5Dc9PAYdS9+R38FyrW6RoFWNVwqqMAVw/jOMS2kyjnKkc1ah1N0yFIwfU9KxdfvfNjcBsk18+7uVz3dFGxw+t+dpmn+DvH0eJorc/2Vexk/MGjztP4rn8hXo19eRa5BpkyTKYb2Itg9SNuQPrXDyXtofgZ4ssL07pBqcYs4wfmaVyCMD2wc+1XPAdlqFrb3uk3ht5V0+ASoZCQ0RYZAH0zivZxVNThGXU87CtqcodD3vwfJ9p8PaOZujW6xNn0GUP8AKvkSwt20XxlrGmP8pt7ySP8ADccfpX15pUX2XSbGIDaUgQEdMHAJ/Umvmb46WA0b4v3FzEu2LUoY7rj+9jDfqP1rsrQcqTTODDzUa11sdjozCSMbTxitGb5cjOPauc8NTEwqemB3Na11djpn73Ga+cktT30Y2qRmeWK27TSrFj/eOK+imCpIUQAKvygeg7V8/wBkyv4i0Ynlft0O70++K99f775PGa9zLl+7Z4uYu80g4AOa+ff2nY/K8U+D7wcNJDLGT/usMf8AoVe/Fjjrg968D/abcS+JPBdup+dI5nI9i64/lXbU+FnHS+NGfocjNAmT9Aa6ODLqd/A/nXK6azRIinjHeuisrgYPJzXzFTc+ljsU/EEwSN88V1XwOtGi8M6jfuMfbbxthPdUAX+YNee+L7t9pSJd0jnaq9yT2r3Pw5pS6F4d07S1IItoVRz6v1Y/nmvVy6GjkeZmM9FE0n68dfSmlhg8ZHfNMbr14zTc4PODXqM8oCelMZjn5c4+lIzEMc0zJPOcUgMfJI4p4ddwGTz2xxxUUfQDn3qRTwccDNIsw/HPhe28WaL9lmbybmE+Za3A6xv7+3rXDa/pmoeHNGnvNb8i6tbaBIvtUJyZWbgZQ/qa9ZU8H2rlfihEs3w519DztgEg+qtmlKnGe5pTrSpfCeReF2Ij4GO4HpXfWEjLGM5BxXnPhJtyR5I6A/pXoME37kA14GIXvs96i7xTLzTYGXY1n3FsdavLbS0BzcSAE4+6ByW/AA0/77f5Nbfw+tg/iC8nIBMEAVc9ix/+tWuDjzVEY4uXLTbOi0DwlaaLapb217qMirnG+XC/guOK0xpMe2Ty7u5RihVDhSYz/eHHP41fXr/M09eO/WvePBPAfHfhyfwTq2j3Yvpb63vd8Ukzpt2yA55GT1B/nWnp1/5oU7+RXafG20in+GOrvLjfavFcQt3Dhwv8mNeR6RPIkUbSfxKDXmZhC9pHp4CejiegiViM55NZmoSBY28zLDp8pwabp115ijDZqj4hmxA5GcdMYryYL3j1W9DmEuLT+1NLjsllXWW1ETQXE5/cRxqOQU/ibOK9U+HWlXF9f3c15mWW6mDXMrcYRTyCOxJ7U/4V+ENC1fwjpOtahZeZqKNPGkocjbluCB/eHY16jptrb2MAhtYViTqdo5Y9yx7mvdVDmUb7I8aWJUFKK3ZoO2ST6nOB/Kvnv9qaIx654VuQpG6CaMt64YY/nX0CxBwexrxj9qGzEvhTRL9VBe2vjEW/2XUn+YFdTWljhpu0k2c14Um3aWCmCwWnvdtJLtxg5x9KyPB85W32MrZA7CtkQiGQyPjJ5r5upC0mfSRndJll18i1juAcNHIrg98gg19ASMrvuByD8wrw/wANWja34h0+xKfulcXE/p5ackH69Pxr2x2DMT0zXr5fFxptvqeRmEk5pLoOZiST2Ar52+Ncx1D402loSRHZWEagHsxBJ/mK+hGPpyDXgPxvszpfxV0nWXGLbVLURFvSRPlP/stdNa7g0jloP31cpXa+R0PA5zVjS7rfKNp3etMknFxHsOMkYqG0Iso3Mi7W7Gvn1HufRKSLGjRjU/iToVoy5RLgTOvqE+b+le9yHlvfmvEvg5B9t8fX9+4+SytGwx7M52/yJr2stzg9+K9zCQ5KSR4eMnzVX5EZxkcEmo2GFOD0p5OTx0qJ2zx0yexrpOTURsYxj6UzdilZsnJpvFIDETj69alQ8Hj3quh/lUgJ6DNCLLCkd6w/Hds934G16CEEu1o5AHfHNa6HnGTn0qHVT/xJtSBH/LtLnH+6aYmfNvhS5CiLaxyQOK7cXrROUZfl9cVwvhO3WaGFgSJFA5FehWiRSRYb74714mJSU2e7h23BGjaHzBuP5113w5h/c6leYOJZVjU46hR/9euIl8xUjhtyDLO4iXPGCeK9Y0eyj0uxhsofuRLgk9WbuT9TW+X09XM58fUtFQ6mkp7mpAeahVqkB5r1DyTmvinZyaj8OPEMEClpPs4lUDqdjBj+gNeJ6aovNIt5oSeUFfSasqn51DoRhlPcHgg186T6d/wjvjnXNCjP+iwy+ZAM9EfkD8K48bC8OZdDuwU1GfK+oWE9wlysZGzJ+91qbxDPthaMyBiR2rQSFR8zJ9aw9eihtoZpfmZ9pxk968qFnI9Vu0dD2j4MxvD8NNKDg5d5XUexau5RufpXO+B4PsfgzQrfGCtohI9zya31ICjmvfjpFHz03eTZOHIA/lXln7SO7/hXEAGPm1KPP5GvT8jHvXmf7Q67vhwX6+XfQv8ATnFMlbo8y8Gyt9jUlf3m3H1rp4LGSVWe4JJ9PSsrwHCJIfug+ldXfRssLYzzxxXhVn7zPeh8JsfCpYm1TXJFwZI4ooh6gE5P8q9EOeOQMd68k+F7m18ZXEYztu7VgR7qQf6V6wG3ZBr18K17JWPIxN/au5ISc/LmvIf2llU+EdCn/wCW8eqKqeuCjE/qBXrbHHPP4V4l+0RdPc654V0hCdipLdyL79FP6GtZu0W2Z01eSSMixt2urWKWFwG29D606cN5Tx3KcgYz60eGo5UCIWOAeRWtq8AFtI5XPGc14aaue3rY0fgZgyeJ5FGEWSGIYHXgmvUWfjg84rzf4HRlNE1yUfx3oH5LXoTHpXuU17qPFq6zYrP2qMmjIpjH04qrGYFjg1GeTyf1o3cdaZvxwaQjGHPWpQcHnFQ8ml3HNBZZQg46ZNFwhktbiIAEvC68+6mo0IyMkcVYjcB0zyO49qYmfNngyAnMY6oSp/AkV6Ha23lLkDkdQK46O2Oi+OtXsXUgR3LOgPdH+Yfzr0GAKyKTjJHFeNilabPaw0r01YwNaMmyM2/yyxMJVYdcjmvYdGvl1LSrW9BGZ4w7Y7N3/UGvN54FKtkc4wM11Hw4mz4feBs5t7h4wPY4I/nXRgam8Tnx0NFI69Tjg5PpT1PQ5qLccYFPH+cV6J5pMrIpLSkCJAXc+ijk/oK+bYZ7nXNev9ekO6S9uXcZPRAcKPyFe5ePL7+z/BGvXWQrLZSRr9X+Qf8AoVeS+E7Xbo1rGV5CKPrxXFjanLBLudmDgnJvsb1nAZLflQT7VzniGyMjQWwy0k8yRgHuWYD+tdvFELe0DYAH15rF0iA658Q9MhUloLVjcSH0CjjP/AiK87Dx5ppHpVZKMGz2iFBDHFEoAWNFQD0wMVMp9uaiDkkk8808Nk+v1r3T58kJPHOPxrjvjDYtqnwz16FcF4ohcr/2zYMf0BrryR0qO4giuoJbefmCdGif6MMH+dAHz98L7hZYE25G5Q2a7++Tfbt2PXivKfBaTaLrV9pNwds9lO0Dc9cHivU3m3QAk8HkV4mIhyzZ7dGXNBGf4JP/ABcCxGMYimwf+AGvWlOO3SvJvB3yfES1JPWCbH/fJr1VW6HI+leng/4SPOxf8QezcY5rwb4zzb/i/YIxJWPS48D0yTXu7HOR+tfPfxYl+0/GedVz/o9lDCceuM/1rSv8DM6Hxo1dEXBZscGrviWYw6dt6DHWo9MiYpGORwM1m+LJJLzZZW5JnuHWCMe7HFePCPNKx7E5WVzv/hNZ/Y/A9vIww15K9z+BOB/KuuJyM96is7RNP0+1soVxHbRLEv4D/Gn5Oeua91aaHhOV3caTyMelMYkdzTiDxx+VRucHGOKBDXOD0J71HuJp3rzxUROTxn8DSAxxMnBBNL5yZ65rMB9F/KpFwP4fxqVI0aNNZ4+oz+YqUXCkHgkfhWWnTOKnjHHQU7iPOfjHYm31LTvENsjBGxa3RGOO6Mf1H5Vf0C8F1bRrvGduc+tdfq+mwavpd1YXozBcoUP+yezfUHBryjwzLc6NqNzo+oDbdWr7CT/GvZh7EVx4unzR5jtwdWzcGd3dKMHPGBipvh3diC/1W0Yj5wkyAn6g/wBKgC+bFkHj2rGtrpdL8R2l0zEQs3ky/Ru/4HFcWFqclRXOzE03Om7HrMdwmOcZ+tPE6HqwB685/wAKyzhSQfwNKrFjtGa9m54tjlvjVqKjwlBp0TqZNQvEjIGeUXLN29dtZOgR+XaKD2AxWR4wvV8QeN1it28yz0pPJDDoZScvj6YA/CulsYFitgzHCgdMV5WOnzSUex6mChaPM+o/VboW+nbwfmbge1XvhRYm3srrVp8ebetsjyORGpOT+J/lXOXFlLrmqwadG7At80h7Rx9z/SvT7aGO3gigt12QRIERR2AHFaYOm0uZkY2r9hGmLngkY/KnCcev6VQUZP3uKeM8fMa71Jnmmh5/Hynr/s0faBs5JGPRf/r1QBYDg07c2OtFwseOfF2xbSvH9jrUI22+qxCOU4wBMgx+q4NdFpcourGNeSwGc1u+PvD3/CT+F7vT0YLeIftFq57Sr0H49K8/8AaqLu0MMwKXcZMcsZ4KOOCD+tcOMg7cyPQwU/sm5pkz2PjfR5yMB5GhyP8AaUj+tem/aDjvx715d4itZWjiubP/AF1u4lQk9GU5Fdro2rwaxYC5t/lbpNEesbelVgqt4cvUnG02pc3Q3ftDllALckDivnvVpDqfxe8T3QJKLcCMHP8AdAH9K9r1PVLfRNKutWvX2W1qhlOf4iPuqPcnArw/wDZTzpdajdKyy3czTOT15Oa1xM+WDM8LT5pnbwSCC2du+MCoPA9mdU8WG+kG6304bhxwZWyFH4DJ/Kk1l1trLJG8n5UUHqx4ArtPCmknRNDitmANy+Zp29XPUfgMD8K5cHC75ux1YyfLHl6s2mmkIyTUZkf6fjTDuIwKiJOMA4r0dTyx5lfFRNK/OW5+lIc+vNRsDjnOaGx2FaSTs3FRGRsnDUY6gnmmFc0rjKQXFLj8qpNrWlKfm1C2BH+3TB4g0YnB1G3z9aEmUzSX0HTrxU6DIBPTrWMPEGjc41GD36/4VKPEWjBQW1GLPoA3+FOzJNlcdu/Ncp468MSa0kV/phWPWLUYjJ4Ey/3G/pWkfE+iKQDfA/8AbNv8KSXxToiD5rwkeojb/Cjl5lYabTujlfC+sx3KNBcBobyI7JYJBhkPetTULGC+gZcZUjn1rlviXqujzxw6zo07DV7dgrhYmUTRd9309au+GNae+EZ6hlDZHpXk4rDOn70T18NiFUVpbnYeF7+SRH0+7bdc26ja5/jj9/cVR+Ievz6XZ2umaY+zVdTyquOsMQ6v9T0FQzA206ajbJunt8sy5xvXuPxrmvDH2nUtQudc1GMSX10+QM5EMf8ACi+2K3hi/wBzzPdHPPC/vtNjZ8OaFDploigEjqSepPqTWhqVy0apbW6mS4lO2OFOpPr9KTULtoYuMAY5rE8JeJrTTry/vb+Ga4upG8qIpjEcY64yepNcmGouvO8jrr1VRh7qPQ/DOjrpNowkcS3kp3Tye/8AdHsK2lPoeDXEt8QtPDYj0+6YcZyyjGfxpp+IKcrHpLlz93dLj+le0o2VkeI25O7O7GTjnge1Pw3UNya4NfiBwM6Vjjkedzn8qk/4T8ZIXTMED/ntn+lLlFY7nkHrQckcnjtXDP8AECRSNumIRjnM3/1qjb4g3GMnS4fQnzj/AIUJBY7s59e+a8i+KFmPDniew8QWI2w6nIYLtAMDzAMh/qRn8q23+IN6MlbC1xnH3zXK/EDxRfeIfDU2nTWtorKwuEkXO4OnIx9VyPxolDmVmVTk4SUkdZpt2t5bp0KkZp9lINK162mUbYLhhBNjpz0J+hri/BmovcaTA5baGHFdLeXiSR+XJg7/AJSf5GvDV6NW6Pdko1abXcyfHN1L4s8bS6Gj40rR2AdQeJpiOSf93p+frXQ6fbRWVqADiNfQVyvg62i0qG6WVjJPLcOzyE5Lc9Sa6K+vAYGCsAgHCgVeKqSqVLLYjD0lShbqWPCkCax4jmuWIa303G1TzulPQ/gK71y3OQSTXh+ja/qelteLps4ijnm3sVUEkgY6mrzeKtdkc/8AE0nAH90KOSfpXrUYKMEkeTiJOVRnr3zA4Cn8BR5TnnY2PpXj669rRUb9UujzxyP8Kb/bmtNw+q3TDPADgf0rWxjZnsJhYfwtn6VBLGVyTgfU4ryM6tqrEmTUrvd1+/1qrJJNLu82aeXcc8yHmk0Vys9f2EcnAGM5LDFMyh582LnkfvB/jXj5LbVHmTMo6DzCcfrUciKT95gOw34xSsgsyt5aMgJIZjng+lCwFRkheasPGSFC7Rj3709UKOFC4PXPr6/0p3KsQJBHknhkXvjGaYEVySgIx2x2q/5YXBdANvGFP50hO7KnO4DkjFLmDlKDRyRhmwQvp1qpMrLk5fB646fjW1t2jHzKe+ajMCo2crhuuDT5g5Tn707IS7Lu3DYq4zuJ4Art/Amjy2NhbQyoVZB85Pc9f8/SqfhHTbfUtfUXBwlrCZ1QDl2HQV3SW0zLF5b4csuVVeeQSfrjFebj6zf7tHo4OlpzlTxGJI9HvZLbb53lMF+pFSeGNK+x6XAjEExoASfXFO1mBpLeDYQ/nyqp52jrWh9kuSGSULGkbhQqPkZxnJFefry2O/2bb5rGLrlrI8Eyqh+ZCAfevOI7WRAUKhWUkHJ9q9imUJCTdkJC8Rb5m2kY7j1rzSYh7maRkOWLFT7Y6134CbV1bQ8/GwVkymkXz/OcMP0q6FUFc5yMde/epFixvBIBAJB9R61OojyA3VRnce3y4r0eZs4ErFdY3DHCdwMfrUqBkl2kfKBg8+2TU0cY2kE7y2QWxjHIH9aYEJVTtGWPqemeeKlsQ1Sp5YqQcAknBx1NI/UB8YPDEjmptxeMDjbnuOeT/gKRy0mFCYHr2z6flRewWKMkUhXIwvcnHesy/SdUCiRWllOxMjpkHJ/LFbzKSSItu0DBJ7dzUWnwW/8Abli9yitEJPm3cKCR1PsCRRKbjFtF04KUkmSeHdCktbOKAMPLUYJrrL3TkXTFdAGVe/qab9j32kUkcgYSiSUuvIZl4Cj2q7ZaZdRhrQwo0Yh87ZJIOM9/rXiS5pPme57kYNKyOQ8PwfaJpDywLMoz2GTWhqVtJDvTBZcdKvaVaiwspLwQTOEkLb1Hy9TxTwkrTM9xICrNtJUdMjjipk3zXGo2WpwBsZIpnQqwJO4HPGDUi25yNpUH610fiG2SytoHkI+0mUxFeodfX2rLt0JUgbRnjJFezh6rnTTZ42JpqFRojjjYtgEkg53UuxzuCFeRgEenrVgMwQYBYDPfih0LRhYvr8vGa2u2YFYIVfackEdPSgI5YccZ4PrVjym2AEbT7dSfem4UZ3AN6/8A1h2ouBVZcEKSc56dgaAsp6LjHB+WrGzLB0wVHVccio2MZOeSTyeKLjKLgklTJtJ7fjTlJaTYsm7LcAfn/iKThRhlxkfezkmprdACE2H5uPof6c4/OgZKmVjKygFm/iHXj2+lJtQj1HQkdc+/6VN5UitgpuJGeaHUqoUoduex/wA+1ICAnDYOevQHOajlQHK8E9sdv8mrT4JAKtnO3Hv/APrxTDGo5wBk4Oex6jj8KAK8atA++BnR9p/eLkMB1wPrW3c6/qslpJGs6pu2hZVjxIu3HQ57jrWckTRyupKggkZc+5qWNlZArINx4+U/n/IVEoKW6NIVZw+F2H6xqV5raxRXThIo2U7YBsywIwx96g02a+sbmS7gu7jz5U8pmdt25enT+tTBcDAC7j2P0z/SlSPErlGyFJGCevJ5pciStYbrTbu3qJPJcXMcLXUkk4iXbGZDkrx0FR7Nwfdt5B6euP51KjEKQW3uRzt7daFPyfIp2AHJz32mmklojNtvVirDt3rkry2OPf8AlUh3bvnxucE/L0xkChj5ed75GSADyOtLHIrcklfmzyOnP/1qZIRHLBpCFQ4PB5Pf+lO8sjOxsrt6n6D/ABpApEpKqhUDr+Bp7YZfm3LGSQuOO+P6UAMML7toGQBxg89h1/GkG6SBgR1Y5APQ9Bj8M045yNynaoyWU8knJppU5wrAn3OMe/60ADJkYOPLIz/u/X9KaYyWz8uSoALce/8AMiptiGIRuwDk5GxuPx/ACmhVDJlhjucdO/8AUUAhsMjWbo1pO8RUHBVsqAeDx75qmIHWYtHJcGSQbS/nE8dhV10UOwHUDjIx14z/AFp6KAVJAA69e3/6sUrIvnltcrWMup2Gn/YbXUJY7UkMUYbtvOePWtoa7fyljMtp5jlWDJHhl2j0rPbgk8c5OAf5foKTaTJ94b+x7A561MqcJO7RpHEVIqykxtxL592087tI7nJbHQ/0pHiDHCjq3+c/pSIpUsgjJcsMA+n+eaeD5RIAyWHGB096taaGLbbuyNSEUMNoPKnuCaXIWRmXHPPy/wBaNzBgokHPGRxio1OVbf8AIQew4NUIkkBIU5UueDjsKjdwACuFOMEgZz9aWNTIpU/NHnjcetM3sqsQMA9ABwDQAjOhO5UwmeSOuKgdxuwDle2amDuyEkZU89MYNRqYcfOHBNAGWQqyDaNq9MZ4+n9Kvwg7gVX5OhYnj6/qtQLMSCyBdvUqRnnv+uanjZGJKnagHRRyf85/Sm0BKxbcTu3AYwSCPfipAv8ACCTg9FGOPXP0xTY59rR/Nleo3D8f6U5RyRu2qM5A/pUjGsuJmDFgqnh/fHX8cU1yoADFn+bOMf1ppZ2G5iQuemf8+9SI6vGvdh8oXHHTvTATySyFnPPQ/l3/ABFAJfYqAgA9x9Dn9alSdYpiHX9PfP8AWnj5m2rxkHPt1HH5UgBQFRFkzuZsYU9e2f1pVUBgVwFxjIHfg/1pjMpf5V+VG4z9RShwVOCflHYfMMKB9KQARh+Dgj5cjuMkU0bnyg5wvUDgfKeKkeQ71XIO7BOR/tVCzlcxhvlwSFAx2NAiYHl/MQE54Y/7x6UqtmP7zHAHU47NxSmUDbzgE4/8eNMcblwWODyCfp/9egCYHcwG19ueRt4AyOvrRHImwrgtgHGecHr/AFp2d5YqQMEEk5OR3/lS4bLFcBl+XIHbp/SgBI40ZAMAADkZwT0/oDSr86hWdQvLDPHbOP0pI2wgBVdwyVI7g5/xpxdSxUqp4DYP1H/16AGPG6LtfPBx93gdufXpTgqKpYjpnooI5/ytJNIGIkUndnHzdM4/xzT5XCqyqBjHzKOB/ngUAQsikqDJgklTjt2z+tCyHO4oCVXA7EjP/wCqo2lWJGVTxgjOOp/yaV3DbWUkc/wn8aYEpkDD5MEZzjpg+34/ypytmFWIyhBGcdfrUYI4xnIyMD0z6/g350ITvK8NHnIz2NADwHWTJxgEDpTyhDvhsZOQQDk0xfv7cgjHLMKaWPGS2G9Ow/zigBJWJIUpkE5Kgf1qJy4kkdvmU8YAxUkxRJlUOwPc9xUBdQRklsjHPamBJMCsh+QE8bNtSxriMscDnoTjmqqllDpuJUHhvb/P86sRSvbkyKf3gGAcZznigQlwwZypcAHjPYVFFHC6ZkdUbJ4yaFfbjzN208Z/+tVZ1yxOePUjmgZ//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bilateral, symmetric bowing of the femurs and tibias.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Phillips, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_8_5263=[""].join("\n");
var outline_f5_8_5263=null;
